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List of abbreviations 
Values are expressed following the International System Units. Amino acids are referred in the 
text using their IUPAC three-letter codes. Nucleic acids are referred using their one-letter IUPAC 
codes. Atoms are referred in the text using their element symbols.  
Aβ: Amyloid-β 
ACN: acetonitrile 
AD: Alzheimer’s Disease 
AFM: Atomic Force Microscopy 
Bpy: 2,2’-bipyridine 
CV: Cyclic Voltammetry 
DNA: Deoxyribonucleic acid 
DOSY: Diffusion Spectroscopy 
Ee : enantiomeric excess 
Er : enantiomeric ratio 
EPR: Electron Paramagnetic Resonance 
ESI-MS: Electrospray Ionization Mass Spectrometry 
IAPP: Islet Amyloid Polypeptide 
IB: Inclusion bodies 
LC-MS: Liquid Chromatography-Mass Spectrometry 
MLCT: Metal to ligand charge transfer 
NMR: Nuclear Magnetic Resonance 
PB: Phosphate Buffer 
PDB: Protein Data Bank 
Phen: 1,10-phenanthroline 
Salophen: N,N'-bis(3,5-di-tert-butylsalicylidene)-1,2-diaminobenzene  
SDS-PAGE: Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
STD: Saturation Transfer Difference 
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TEM: Transmission Electron Microscopy 
Th-S: Thioflavin-S 
Th-T: Thioflavin-T 
TON: turnover number 
Tpy: 2,2’:6’,2’’-terpyridine 
UV-Vis: UV-Visible spectrophotometry 
WT: wild-type 
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General introduction 
It is announced, XXIst century will be that of ecology. For Chemistry, this is reflected by the 
Green Chemistry Principles, aiming at developing environmentally friendly alternatives to existing 
chemical processes. This comes with the use of catalysts, which can be used in small amounts to 
convert efficiently high amounts of substrates. But even employed in small amounts, catalysts can 
represent important source of pollution, especially when using heavy metals or ligands requiring 
multi-step syntheses. Research efforts thus tend to promote the development of new generations of 
catalysts.  
Among the different possible approaches, one consists in seeking inspiration from enzymes. 
This gave rise to various elaboration strategies including the development of biomimetic coordination 
complexes, directed evolution of enzymes, or the development of artificial metalloenzymes. These 
systems aim at combining the efficiency of natural enzymes with the wide scope of reactivities and 
substrates of coordination catalysts, the overall system being fully biocompatible. Presence of a 
biomolecule (either nucleic acids or proteins) is also expected to confer rate enhancement, selectivity, 
and specificity, as observed in naturally occurring enzymes.   
In this context, decided to focus on Amyloid fibres as a support biomolecule for our hybrid 
catalysts. These protein aggregates have unique properties, including robustness, stiffness, heat and 
solvent resistance that make them good candidates for catalytic applications. Because they are 
insoluble, they could also be easily recycled.  
This thesis focuses on the elaboration of bioinorganic hybrid catalysts made of incorporation of 
coordination complexes into Amyloid fibres. To this view, a new expression and purification 
procedure was developed for Amyloid-β in Escherichia coli, enabling the rapid production of reliable 
peptide samples (see Chapter II).   
A series of organic ligands was designed, inspired by reported amyloid-incorporating 
molecules. Corresponding Cu(II), Fe(II) and Ru(II) coordination complexes were synthesized and 
fully characterized, using various spectroscopic techniques, including NMR, EPR, cyclic voltammetry, 
UV-Visible and fluorescence spectrophotometry (see Chapter III).  
These complexes were subsequently tested for their interaction with Amyloid fibres. UV-
Visible and fluorescence measurements allowed to highlight candidates displaying good intercalation 
into fibres. Further investigations using UV-Visible and NMR afforded insights on the nature of 
binding sites and the interaction pattern of coordination complexes. These results were supported by 
docking studies (see Chapter IV).  
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Finally, the catalytic activity of our systems was assessed on styrene epoxidation reaction. All 
these results prompted us to draw outlooks for the evolution of our hybrid systems, both in terms of 
interaction with fibres and in terms of catalytic efficiency (see Chapter V).  
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Chapter I. Context of the project 
Introduction 
This project lies in the context of the development of artificial metalloenzymes, aiming at 
combining the strengths of chemistry and biology to develop innovative hybrid catalysts. Among the 
different existing methodologies, we got interested in the non-covalent incorporation of coordination 
complexes into biomolecules, which constitutes a straightforward and versatile alternative to 
bioconjugation strategies.  
We propose to apply this strategy to amyloid fibres. These highly ordered protein assemblies 
have numerous occurrences in Nature, and share a characteristic cross β-sheet structure which might 
suits non-covalent intercalation. They are also very stable and resistant, which has prompted their use 
for various nanotechnology applications. 
 In the frame of this thesis, we chose to focus on Amyloid-β peptide. Because of its implication 
in Alzheimer’s Disease, this peptide has been extensively studied for its interaction with a wide set of 
molecules.  
In a first part, this chapter portrays the field of artificial metalloenzymes, focusing on the 
approach consisting in incorporation of a metal complex into biomolecules, taking advantage of this 
sophisticated surrounding.  
In a second part, an overview of amyloid proteins is proposed, going from their natural 
occurrences to their applications in nanotechnology.   
Finally, focus is made on amyloid-β peptide, which was selected for this project. A precise 
description of its features is given, laying the foundations for the rest of the study.  
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I.  Context of the study: artificial metalloenzymes 
This chapter is adapted from: Hoarau, M., Hureau, C., Gras, E., and Faller, P. (2016). Coordination 
complexes and biomolecules: A wise wedding for catalysis upgrade. Coordination Chemistry Reviews 308, 445–
459. Original article is in Annex III. 
I.1. Role and importance of artificial metalloenzymes in catalysis 
“Chemistry without catalysis would be a sword without a handle, a light without brilliance, a 
bell without sound.” As nicely stated by Alwin Mittasch, catalysis plays an essential role in modern 
chemistry. Over the last 15 years, three Nobel Prizes were awarded for works on metal-based 
catalysis, reinforcing the importance of coordination complexes in organic synthesis.  
From a general view, coordination catalysis utilises a large selection of metal ions, ligands and 
substrates to achieve a large set of reactivities. The reactivity of a coordination complex is mainly 
based on the tuning of its redox properties, substrate accessibility and/or Lewis acidity of its metallic 
centre. This is achieved by modulating the donor/acceptor character of the ligands and by controlling 
their geometry, arrangement and bulkiness around the metallic centre. For instance, steric hindrance 
can be used to induce substrate selectivity. Chemists excel at developing very sophisticated ligands 
that confer to complexes the desired properties. However, this has several limitations, among which 
the multi-step synthesis of the ligands and the use of rare metal ions, which represent significant 
economical and ecological concerns. An alternative would be to go towards “greener” processes 
inspired from Nature.  
In Nature, enzymes are in charge of catalytic reactions, displaying extremely high rates, 
selectivity and specificity, optimised by evolution. By observing metalloenzymes, it appears that the 
first, second and outer coordination spheres play a crucial role in tuning the reactivity of the metallic 
centre. Indeed within enzymes the reactivity is not only driven by steric control of the metal site by the 
ligands but also via remote interactions (H bonding, electrostatic, stacking etc.) that guide the substrate 
into the active site, position it to ease the reaction, and help the release of the products. In other words, 
the strength of enzymes resides in the combination of inner and outer sphere effects, which confers 
rate enhancement, specificity and selectivity. Moreover the mobility, dynamics and/or conformational 
changes of the protein chain can help to adopt the most suitable geometry for the active site. All of this 
makes enzymes very powerful catalysts, but only considering a single reactivity and a limited series of 
substrates.  
Chemists thus developed synthetic analogues of enzyme active sites, to better understand the 
structure-properties relationships. The ultimate goal would be to identify and select the crucial 
parameters for powerful catalysis, getting rid of the less pertinent ones. Among others, such mimics 
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(structural, functional or both) were proposed for hydrogenases [1–4], superoxide dismutases [5–8], 
photosynthetic system [9,10] or oxygenases [11]. These systems go from the simplest, using very 
usual metallic ions and ligands [12] to the most sophisticated ones [13–15]. Even though models of 
metalloenzymes are very helpful for investigation purposes, they are often poor catalysts.  
Different alternatives emerged to develop bioinorganic hybrid systems whose catalytic activity 
could compete with enzymes, often termed as “Artificial Metalloenzymes” [16–25]. Some of them 
proposed to modify natural enzymes or proteins to confer them non-native reactivity, while some other 
proposed to create new metalloproteins with fully controlled topology (Section I.2). In the context of 
this thesis, this chapter will focus on the approach consisting in incorporating coordination complexes 
into various biomolecules to form hybrid catalysts (Section I.3).  
I.2. Different approaches for artificial metalloenzymes elaboration 
I.2.a. Replacing the native metal ion of an enzyme 
The replacement of the native metallic ion of an enzyme represents a first strategy, relatively 
easy to develop. It consists in replacing the native metallic ion of an enzyme by another, modifying its 
reactivity. Kaiser and co-workers first exemplified this approach in 1976. By changing Zn(II) with 
Cu(II) in carboxypeptidase A, they showed that the native activity was completely inhibited, and 
substituted by oxidizing properties [26].  
Subsequent studies from Soumillion and colleagues showed that substituting Zn(II) by Mn(II) in 
carbonic anhydrase gave rise to an epoxidase activity [27]. In parallel, Kazlauskas et al. showed that 
the same Mn(II) carbonic anhydrase also displays peroxidase activity [28]. Figure 1 shows the X-ray 
structure of the active site of a Mn(II)-substituted human carbonic anhydrase II. It appears that the 
same amino acids are involved in the coordination of Zn(II) and of Mn(II) (i.e. His 94, His 96, and His 
119), showing that the overall organization of the active site is not distorted by the substitution of the 
metallic ion. Some mutagenesis studies showed that several other amino acids within the catalytic 
pocket influence catalysis, further confirming the crucial importance of the whole environment. 
Another step forward was the replacement of Zn(II) with a metallic ion of low natural 
abundance. This was achieved by incorporating Rh(I) into human carbonic anhydrase II. This system 
catalysed olefin hydrogenation and styrene hydroformylation with moderate to good yields and 
selectivities [29,30]. 
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Carbonic anhydrase constitutes a typical illustration of how a simple swap of metallic ion in an 
enzyme can dramatically modify its reactivity. Unfortunately, this strategy can only be applied to a 
few, rather exceptional, enzymes, and in most cases more significant modifications are required. 
I.2.b. Operating mutations in enzyme active site 
Metalloenzymes are very sophisticated systems, in which both the inner and outer coordination 
spheres have strong impact on enzymatic activity. In the active site, the nature and geometry of 
coordinating amino acids allow the fine-tuning of the redox potential and Lewis acidity of metal ions, 
which dictates enzyme specificity. Apart from the active site, residues can play a role in substrate 
selectivity, facilitating their conveyance to the catalytic pocket. Another strategy for the development 
of new enzyme-like systems thus consists in mutating amino acids of metalloenzymes. This can be 
achieved by random mutagenesis, screening a wide library of mutants for a specific activity, or by 
site-directed mutagenesis with support of molecular modelling. 
A representative example is the engineering of cytochrome P450, an iron hemoprotein which 
catalyses mono-oxygenation of substrates by molecular dioxygen. By performing some mutations on 
its active site, either site-directed or random, it is possible to enlarge the set of substrates of 
cytochrome P450 while keeping its good oxidizing properties [31]. The Cys apical ligand of the heme 
centre of cytochrome P450 was replaced by Ser, removing the “thiolate push”, and thus preventing the 
native monooxygenase activity (i.e. C-O bond formation). Combination with other mutations was also 
needed to reach specific reactivities, such as intramolecular amination (C-N bond formation) [32,33] 
and carbene transfer to olefins [34,35] with good yields and selectivities.  
Figure 1: X-ray crystal structure of Mn(II) replacing Zn(II) in human carbonic anhydrase II. Residues affecting catalysis 
efficiency and selectivity are circled in white. 
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Another interesting example was proposed by Lu and co-workers, who gave WT-myoglobin 
(Figure 2A) a nitric oxide reductase activity, by mutating three residues of the natural active site and 
thus inducing the coordination of a second Fe ion (Figure 2B) [36]. Similarly, WT-myoglobin was 
implemented to coordinate Cu ion, thus displaying a 4-electrons dioxygen reductase activity [37,38].  
I.2.c. De novo design of artificial metalloenzymes 
De novo protein design constitutes an original alternative for artificial metalloenzymes 
elaboration. It consists in the rational design of new proteins, which fold into well-controlled 3D 
structures. A typical example is the triple helix bundle developed by the Pecoraro’s group, formed by 
hydrophobic interactions between amphiphilic helices (Figure 3). These systems, first developed to 
study the binding of toxic heavy metals [37], have required huge effort to control the geometry of the 
binding site [39]. These systems were then transposed for Cu [40,41] and Zn coordination [42,43] 
showing promising catalytic activities [44–46] such as nitrite reductase [41], hydrolase [43] and 
hydratase [42]. 
 
A     B 
Figure 3: The three stranded coiled coils developed by Pecoraro group. A: General view of the protein scaffold. B: Detail 
of Zn(II) coordination sphere. 
Figure 2: Myoglobin-based artificial metalloenzyme. A: Native active site of myoglobin (PDB1JP6), B: Engineered active 
site of myoglobin. Native residues appear in grey, mutated residues appear in pink, Fe centres appear in red. 
A B 
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I.3. An original approach: incorporation of metal complexes into biomolecules 
I.3.a. Concept 
In parallel to these strategies, an alternative approach was proposed, at the frontier of biology 
and inorganic chemistry. It consists in incorporating a coordination complex displaying catalytic 
activity inside a biomolecule. The complex, which only possesses first coordination sphere effects 
from its ligands, could thus also benefit from second and outer sphere effects due to the biomolecule. 
In other words, biomolecules are proposed to bring what coordination complexes are missing 
compared with enzymes: outer sphere effects. 
One of the strength of this approach is the huge variety of biomolecules, complexes and 
catalytic reactions that can be considered. It is also strongly supported by directed evolution together 
with chemical optimization, enabling to fully optimise the system. 
Different strategies were proposed in literature to bind a coordination complex to a biomolecule. 
Three main possibilities have been investigated:  
• Non-covalent anchoring, taking advantage of weak additive interactions between the 
biomolecule and the coordination complex (electrostatic, hydrophobic, H-bonding…). 
This method is very convenient, but the localisation of the complex can lack specificity. 
• Covalent attachment of the coordination complex to a biomolecule. This strategy is 
more time demanding and consists in the bioconjugation of the complex either with an 
amino acid (natural or not) or with a nucleotide. This strategy enables a more precise 
positioning of the complex. 
• Functionalization of a native guest of a protein with a coordination complex, taking 
advantage of natural interactions. The bioconjugation step is thus facilitated by the 
limited size of the cofactor. In the case of proteins, this approach ensures the burying of 
the complex inside the protein pocket.  
These strategies were successfully applied to various biomolecules, including DNA, proteins, 
enzymes or peptides. Representative examples are depicted in the next sections. 
I.3.b. Incorporation of metal complexes into DNA 
With their structure in double helix, nucleic acids are one of the most elegant natural examples 
of chirality. The DNA double helix constitutes a rare example of switch from central molecular 
chirality to helical supramolecular chirality. Nature uses RNA for metal-driven catalysis in ribozymes, 
but its low stability so far prevented its use for catalytic applications. DNA was thus logically a 
privileged scaffold for asymmetric catalysis.  
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• Intercalation of coordination complexes into natural double-strand DNA 
In their seminal paper, Roelfes and Feringa presented the first example of a direct transfer of 
chirality from natural DNA to a Cu(II) complex involved in Diels–Alder reaction [47]. It was 
promoted by stacking interactions between DNA and a Cu(II) complexes linked to a DNA-
intercalating moiety. When tested for catalytic Diels-Alder reaction, these systems showed a strong 
predominance for the expected endo product. The enantiomeric composition was dependent on linker 
length and when the linker becomes too long, ee’s dropped dramatically. Subsequently, the same 
authors showed that direct interaction of Cu(II) complexes within DNA via stacking with aromatic 
ligands displayed better activity in cyclopropanation reaction [48]. This anchoring approach was thus 
used in subsequent studies, where these Cu(II) complexes afforded ee’s up to 99% when involved in 
Diels–Alder reaction, Friedel–Crafts, syn-Hydratation of enones or Michael additions [49–51]. 
Interestingly, they showed that in the Friedel–Crafts and Diels–Alder reactions, the replacement of a 
bipyridine by a terpyridine causes a swap of enantiopreference [51]. The Cu(II) to ligand ratio was 
also investigated with respect to the cyclopropanation reaction and increasing the Cu(II):L ratio from 
1:2 to 1:1 leads to an improvement in the ee values. In the meantime, Wang et al. showed the crucial 
role of the helix chirality by studying L- and D-DNA interacting with a Cu(II) bipyridine complex 
[52]. The L- and D-hybrid systems, tested on Friedel–Crafts and Michael addition, showed “mirror” 
selectivities, the switch from one to the other inducing a switch of chiral induction. This highlights the 
fundamental importance of both the biomolecule and the metal complex, both of them influencing 
selectivity. 
Lastly, Park and colleagues demonstrated the dramatic influence of the oligonucleotide 
sequence: the ee values strongly depend on the nucleotide GC or TA content and whether the A, T or 
G, C bases are alternated. The oligonucleotide length is also significant [53]. They also propose a 
model for the binding of the catalyst in the DNA helix (Figure 4) [54,55].  
• Covalently-functionalized oligonucleotides  
A very different strategy proposed by Roelfes’ group consists in covalently functionalizing an 
oligonucleotide with a ligand. Upon hybridization with a DNA template and coordination with Cu(II), 
a DNA helix is formed with the coordination complex in its vicinity. This approach is convenient in 
terms of screening, allowing variations in nucleotides, linkers and ligands. It also ensures a better 
preservation of the whole structure. When tested for Diels-Alder cycloaddition, the different systems 
displayed ee’s up to 93%. Expectedly, this effect is substantially dependent on the nucleotides 
surrounding the anchoring position [56]. Similar studies were conducted on synthetic DNA 
functionalized with a diene–Ir(I) complex. The resulting catalysts yielded 28% ee in kinetic resolution 
of phenyl allyl acetate [57]. Finally, Sugiyama and colleagues proposed to graft DNA strands on two 
points of a bipyridine. Upon metallation and hybridization, the resulting catalyst showed 86% ee for 
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Friedel–Crafts alkylation [53]. Despite the variable efficiency of these catalysts, they constitute the 
first examples of covalently functionalized DNA operating catalysis. The wholeness of this kind of 
hybrid systems should be more easily preserved than those where the coordination catalyst is bound to 
DNA by non-covalent interactions.  
I.3.c. Incorporation of metal complexes into proteins 
Virtually any of the 35,000 known proteins might exhibit some level of interaction with a 
coordination complex, thus becoming a potential catalyst. Nevertheless, to obtain a significant impact 
of the protein environment on catalysis, the coordination complex and the protein chain have to be in 
close proximity. Because of this requirement, a first criterion for selection of an appropriate host 
candidate is the presence of a large enough vacant space buried inside the protein. In this way, the 
coordination complex would be surrounded by protein and take fully advantage of this interaction. 
This reaction pocket could also contribute to confer selectivity and even specificity to substrates.  
(a) Incorporation of a coordination complex into an apo-protein  
A straightforward strategy for the elaboration of hybrid catalysts is the insertion of a synthetic 
catalyst into a protein from which the native metallic cofactor has been removed, thus taking 
advantage of the cavity left vacant.  
• Case of planar coordination complexes  
The first example is the incorporation of coordination complexes into apo-myoglobin, which 
naturally hosts an iron porphyrin. Because of their planar structure and their high catalytic efficiency, 
Schiff base complexes were considered as good candidates to replace the hemic group. The first 
approach was envisaged by Carey et al. consisting in the covalent dual anchoring of functionalized 
Mn(III) or Cr(III) salen complexes into the hydrophobic pocket of apo-myoglobin. To do so, a 
Figure 4: A binding model for intercalation of a coordination complex into double-helix DNA. 
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covalent link was made by the creation of two disulfide bridges using methane thiosulfonate salen 
derivatives and Cys mutations, the positions of which were determined by molecular modelling. The 
corresponding Cys mutants were expressed, produced and purified, then bioconjugated to the Schiff 
base complex. Modelling studies showed that the complex was positioned in the active site exactly at 
the same place as the hemic group in the wild type myoglobin, as depicted in Figure 5.  
The interest of the double anchoring of the coordination catalyst has been established by 
comparison with a single-point attached counterpart in the sulfoxidation of thioanisole: both the ee 
values and the rate were improved. This is fully consistent with a better immobilisation of the complex 
inside the cavity, taking thus full advantage of a better-defined environment [58]. These systems could 
now be further improved by directed evolution, or applied to a wider set of reactivities, but the overall 
process might represent a rather time-consuming approach.  
Another possibility, potentially easier but also probably less topologically defined, consists in 
direct incorporation of Schiff base complexes into apo-myoglobin mutants [59]. The crystal structures 
obtained showed that the complexes were positioned in pertinent mutants at the exact same place as 
the hemic group in the wild-type myoglobin. Even if the rate was improved by optimising the ligand, 
the ee obtained for thioanisole sulfoxidation did not exceed 33%.  
Comparison with the previous example leads to three general remarks: (i) Imposing a fixed 
position using covalent anchorage may preclude the most suitable location of the catalysts for catalytic 
enhancement, whereas more freedom is given to the system in non-covalent anchoring, (ii) in contrast, 
regarding the ee values, a much more dynamic interaction leads to a loss of influence of the proteic 
environment and thus to a lower chiral induction, (iii) combining the two approaches, i.e. mutations to 
covalently anchor the catalyst and to optimize the binding pocket could be more appropriate.  
In this context, Lewis and co-workers found a good compromise: allowing the complex to 
choose its best position, and then covalently grafting it in situ [60]. To do so, they functionalized their 
Mn-terpyridine complex with a maleimide group. The resulting coordination complex was incubated 
Figure 5: Myoglobin active centre modified with Mn(salen)-type complex. Complex is covalently attached on the two L72C 
and Y103C mutated positions. The position of the hemic group in wild-type myoglobin is shown in blue showing the correct 
positioning of the coordination complex. 
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with Cys mutants of nitrobindin. Once the complex is set at its most suitable place inside the protein, 
the formation of a carbon-sulfur covalent bond allows the immobilization of the complex. The mutants 
displaying the most efficient bioconjugation were considered as the most appropriate, and were tested 
for several catalytic oxidation reactions. In the best case, the product was obtained with 99% yield. 
Yet the ee’s obtained remain low (7%) indicating that the most suitable positioning of the metallic 
complex in the protein may not efficiently transfer the chiral information from the environment to the 
reaction product. The topology of the edifice still needs to be improved for example allowing the 
metallic cofactor to choose its most favourable position inside the protein. The reactivity of the 
maleimide allows its permanent binding at the right position, limiting dynamic exchanges; but the 
precise positioning into a chiral pocket might require a thorough screening to allow a significant chiral 
induction to be achieved.  
• Case of non-planar coordination complexes 
Non-planar coordination complexes were inserted into proteins involved in the transport of 
metallic complexes. They have the advantage to exist natively in the apo-form and are able to bind 
coordination complexes easily. Thus, Fe(II) complexes of the diamino-pyridine BPMEN and BPMCN 
ligands were incorporated into the apo-form of the periplasmic nickel-binding protein NikA (where 
NikA binds Ni(II) in form of a coordination complex). The resulting hybrid displays sulfoxidation 
activity with good to moderate yields. In that case, suitable substrates were determined by docking 
studies [61]. To illustrate this, Figure 6 shows the crystal structure obtained for the incorporation of an 
analogous Fe(II) complex into NikA, which was involved in arene dihydroxylation of the ligand itself 
[62]. 
 
Figure 6: Crystal structure of the Fe coordination complex incorporated into periplasmic nickel-binding protein (NikA) 
and electron density map of FeL. 
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The other example is FhuA that incorporates the Hoveyda–Grubbs catalyst. This system showed 
efficient polymerization with a preference for the cis form [63]. This was assigned to the cavity effect 
of FhuA, which has a β-barrel structure and hence a confined space. Similar results were also reported 
for another hybrid system namely the β-barrel protein aponitrobindin functionalized with CpRh(I). 
These examples nicely illustrate the fundamental effect of the confinement to force the reaction even 
to its less favoured stereochemical outcome. 
• A specific case: Ferritin 
An even more pronounced confinement can be obtained with apo-ferritin, a hollow protein with 
several relatively small access-channels. A Rh(I)-norbornadiene complex was inserted in the cavity of 
apo-ferritin, where it reacted to form a covalent bond with a cysteine. The Rh complex catalyses the 
polymerization of phenyl acetylene with restricted molecular weight and a narrow molecular weight 
distribution due to the cavity effect [64].  
(b) Incorporation of a coordination complex into an hollow protein  
A more chancy strategy is to consider proteins which do not natively host metallic complex but 
possess cavities, for instance for the transport of organic molecules. Even though these cavities are not 
naturally used for catalysis, they remain an asymmetric environment, allowing stereoselectivity to be 
expected. When the cavity is sufficiently small, using of non-covalent anchoring approach was 
preferred.  
• The host cavity is made by a monomeric protein  
A very simple strategy to form hybrid catalyst was introduced by Ward and co-workers, who 
incorporated vanadium oxide [65] or osmium oxide [66] into streptavidin. The resulting systems 
displayed selectivities up to 95% ee for olefins dihydroxylation. Subsequently, an elegant biomimetic 
oxidation system was developed by incorporating a corrole metallic complex into albumins. The 
complex was buried inside the protein via interaction with the sulfonato and pentafluorophenyl groups 
that decorated the corrole central group. This system was tested for thioanisole sulfoxidation using 
hydrogen peroxide, showing efficient reactivity and promising ee’s [67]. Another example, using the 
same strategy, was the incorporation of Mn(III) complexes into xylanase, a protein displaying affinity 
for synthetic Fe(II) porphyrins. When tested for styrene oxidation, the system displayed moderate 
yields, but good selectivities (up to 80%) [68]. 
• The host cavity is made by supramolecular interaction of proteins  
In a recent study, Roelfes and co-workers showed that the hydrophobic interface formed upon 
dimerization of proteins could also be used as an active site. Copper complexes grafted onto dimerized 
Lactococcal multidrug resistance regulator were used to catalyse Diels–Alder cycloaddition with 
excellent efficiency and selectivity [69]. Similarly, Hilvert developed a system based on a small heat 
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shock protein, able to form spherical capsids, functionalized with Grubbs–Hoveyda catalyst. This 
system demonstrated good properties for olefin metathesis [70].  
• Grafting of coordination complex outside a cavity  
An hybrid system was developed by Inaba et al., in which Sc(III) bipyridine complex is 
covalently grafted onto the surface of proteins. The hybrid exhibits moderate results both in terms of 
conversion and ee values for ring-opening reaction [71].  
I.3.d. Functionalization of a natural cofactor of a protein  
• Biotin/(Strept)avidin system  
In an effort to simplify the elaboration of hybrid catalysts, some groups proposed to attach the 
coordination complex onto natural cofactors of proteins, taking advantage of the strong host–guest 
interaction to incorporate the complex at a precise place in the protein. The most common example is 
the biotin-(strept)avidin couple, in which the interaction is very strong (KD ≈ 10−15 M) and fast 
(binding rate constant of biotin-streptavidin is in a range of 3.0 × 106 - 4.5 × 107 M−1 s−1 ) [72]. 
Conjugation of catalysts onto biotin, followed by interaction with avidin or streptavidin, affords highly 
reliable systems [73]. This also permits one to get rid of the complicated step of bioconjugation with a 
protein.  
In 2003, Ward and co-workers developed a phosphine functionalized biotin which upon 
metallation with Rh(I) and incorporation into avidin and streptavidin was able to catalyse asymmetric 
hydrogenation with 96% ee after 15 h. Interestingly, avidin and streptavidin offered opposite 
enantiopreference [74]. Much effort was made in subsequent studies to improve this system, 
considering different optimization parameters. Different anchoring positions, metallic ions and ligands 
were tested, as well as different mutants of the host protein. Finally, a library of substrates was tested. 
This “chemogenetic” optimization allowed determination of a system with high selectivity. After the 
chemogenetic selection, a careful study of crystal structures allowed to point out other mutations of 
interest, further improving the catalysts [75]. This constitutes a very elegant example of combined 
chemical and genetic optimization, showing the full potential of this yet simple system.  
In subsequent studies, Ward and colleagues showed that a unique mutated position (112 or 121) 
into His allowed a dual anchoring, both by biotin/streptavidin interaction and by Rh coordination by 
His, as shown in Figure 7. This appeared highly beneficial to the system: conversion increased from 
60 to 100%, and ee values from 0 to 79% for transfer hydrogenation of a prochiral imine compared 
with the wild type protein [76]. This study only considered the transfer hydrogenation, but other 
reactivities were also demonstrated. As such, biotinylated Rh(III) complexes were efficient for C-H 
activation [77] and imine reduction [78,79]. In a very comprehensive study, the same group 
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investigated several parameters with respect to the hydrogen transfer reaction, including the nature of 
the coordination complex and the influence of the mutants at position 112. Interestingly, the nature of 
the complex impacted strongly the transfer of chirality, with the two enantiomers being detected 
depending on the catalysts used. Also, with a given catalyst, the two enantiomers can be obtained 
depending on the nature of the mutants at position 112 [80]. More recently, Cp-Ir(III) complexes were 
also successfully used for NAD+ reduction [81].  
Mn salen complexes were also tested for asymmetric sulfoxidation, displaying somewhat low 
yields and selectivities, therefore illustrating that this strategy cannot be systematically generalized, 
and requires cautious optimization [82].  
• Other host-guest systems 
Still within this context, an original example is the use of a natural protein inhibitor to constitute 
hybrid catalysts proposed by Matsuo and co-workers. They functionalized an inhibitor of 
chymotrypsin with a linker and a catalytic entity. The inhibitor goes into the active site of the enzyme 
and the coordination complex is thus positioned inside the hydrophobic pocket, and can intercept the 
incoming substrates. In the present case, the functionalized Grubbs–Hoveyda complex was able to 
catalyze ring-closing metathesis with good rates [83]. Finally, Mahy and co-workers used 
neocarzinostatin, a cytotoxic protein known to recognize specifically enediyne derivatives. Since these 
compounds are of limited stability, the authors used a formerly established mutant that binds tightly 
testosterone. An iron–porphyrin complex was then decorated with a testosterone moiety and inserted 
into the cavity. The resulting system was subsequently tested for thioanisole sulfoxidation, but showed 
only low enantioselectivity [84].  
I.4. Incorporation of metal complexes into antibodies 
An original strategy is the use of the antibody–antigen recognition. The presence of exogeneous 
species in a body leads to the production of antibodies directed against it, forming a very stable 
duplex. In the case of an exogeneous metallic complex, the association with an antibody would modify 
Figure 7: Docking studies of Rh-functionalized biotin into WT-streptavidin (left), S112H (middle) and K121H 
streptavidin (right). The double anchoring of the coordination complex improves the catalytic properties of the system. 
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the environment of the metallic centre in an asymmetric manner, and could display interesting 
catalytic properties.  
As such, Mahy’s group aimed at developing cytochrome P450 mimics by raising antibodies 
against natural or synthetic porphyrins [85]. In this case, the protein environment also serves as a 
protection against heme oxidative degradation. The resulting Fe(III)-porphyrin-antibody complex 
showed good peroxidase activity with a large scope of peroxide sources and substrates [86]. Looking 
for a system bearing an apical ligand on the metallic centre, antibodies were then directed against 
Microperoxidase 8. The resulting scaffold was tested for peroxidase activity [87], nitration of phenol 
[88] and thioanisole sulfoxidation [89]. Even though the catalytic performance of these systems is yet 
limited, this study constitutes a proof of concept for the use of antibody–metal complex system as 
hydrid catalysts. Subsequently, an attempt was made using the so-called “Trojan horse strategy”. The 
porphyrin group was attached to an estradiol molecule, which allowed binding to an anti-estradiol 
antibody. The catalytic rates were thus improved, but the ee’s remained low, witnessing the low 
influence of the protein environment [90]. This strategy could find applications with diverse metal 
complexes. 
I.5. Incorporation of metal complexes into peptides 
With their shorter length and their possible chemical synthesis, peptides were proposed as an 
interesting alternative for proteins. Their handling is also less sensitive, and their functionalization is 
easier. However, their high flexibility also makes the rationalization of their quaternary structure more 
difficult.  
In a first trial to design a catalyst-peptide hybrid, Lewis et al. developed tetrapeptides bearing 
Pd or Ir metallacycle on their N-terminal end (Figure 8). These constructions conserved the reactivity 
of the free complexes, but unfortunately no selectivity was observed. The authors proposed that in its 
favoured conformation, the peptide scaffold is too far from the metallic centre to influence its 
reactivity [91].  
To get a stronger influence, the coordination complex was grafted along the peptide chain, using 
a non-natural amino acid as the anchor. Christensen and colleagues proposed to incorporate 
phosphine-modified amino acids either in one or two points of the peptide backbone (Figure 8). In this 
way, peptidic environment surrounds the coordination complexes. This first attempt displayed high 
yields but mild selectivities [92]. Importantly, the doubly coordinated complex showed better yields 
and selectivity than its single-point attachment analogue. This is consistent with an increasing burying 
of the catalytic centre in the peptidic scaffold. In a subsequent work, a second generation of ligands 
enabled the remarkable improvement of selectivity. They also demonstrated that inverting the 
stereochemistry of the amino acids induces an inversion of the stereochemistry of the products [93].  
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The use of three-dimensionally ordered peptides was also proposed, in order to reduce the 
dynamic of the system. As such, Gilbertson group developed a library of β-turn peptides decorated 
with phosphine ligands. The resulting hybrid catalysts are efficient for Michael addition, with ee’s up 
to 85% [94].  
These different examples establish peptides as promising hosts for metal complexes. Compared 
with proteins, the issues are opposite: here, there is no risk of steric hindrance, contrariwise it seems 
that the peptide backbone should surround the catalytic moiety as much as possible. The somewhat 
easy development of peptide libraries should strongly help to solve this problem. 
I.6. Outlooks 
All these examples highlight the wide diversity of applications that can arise from this area of 
hybrid catalysts prepared from coordination complexes host in biomolecules: chiral scaffolds can be 
constituted from a large scope of biomolecules and used to target a wide range of reactivities. At this 
point, none of these systems can compete with naturally occurring enzymes in terms of speed rates (all 
the processes presented above being complete in a few hours to a few days). However, they clearly 
establish that the catalytic properties of a coordination complex can be highly enriched by the 
stereochemical induction brought by biomolecules. Compared with standard coordination catalysts 
they offer interesting alternative as they can induce enantioselectivity without requiring time-
consuming production of sophisticated ligands, which is also expensive and generates waste.  
Finally, it appears that many biomolecules are still to be explored. Some promising examples 
involving auto-assembling proteins, including fibres, needles, disc and rod structures obtained with 
amphiphilic proteins and peptides recently appeared in literature, showing interesting extension of this 
research field to heterogeneous catalysis [95,96]. Within this context, this thesis proposes the use of 
amyloid fibres as a support for the elaboration of hybrid catalysts.  
  
Figure 8: Schematic representations and molecular models of peptide-based systems. Coordination complexes can be 
attached on the N-terminal end (a), in the middle (b,d), or on two points of the peptides (c,e). 
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II.  Amyloid fibres: a bio-nanomaterial as a support for catalysis 
II.1. Definition of amyloids 
The definition of amyloids is foremost structural. It concerns polypeptides that, additionally to 
their native folding can adopt a second, very stable and ordered structuration.  
Under their amyloid form, these polypeptides display a common cross β-sheet structure that 
consists of ordered arrays of β-sheets, whose side-chains interdigitate to form a hydrophobic interface 
(Scheme 1.A). β-sheets are composed of β-strands that bind together by H bonds between backbone 
amides (Scheme 1.B). When under amyloid forms, proteins form insoluble aggregates with unique 
physical properties (see II.2.d). 
 
II.2.  Natural occurrences of amyloids 
II.2.a.  Role in disease 
Amyloid aggregates were first discovered in the context of human diseases in the 1850s. Today, 
23 amyloidogenic proteins are related to human diseases, targeting various organs including brain, 
nervous system, kidney, or heart. Some amyloid diseases are global health issues whereas other only 
concern a limited number of patients. Their causes can be genetic, sporadic or even infectious. The 
formation pathway of amyloid aggregates is often part of a very complex process and thus scarcely 
understood.  
Here are three typical examples of amyloid diseases, aiming at showing the diversity in terms of 
mechanisms and toxicity.  
• Alzheimer’s disease (AD) is perhaps the most famous “amyloid disease”. It is 
characterized by the presence of amyloid plaques in the brain (Figure 9A) that adsorb 
Scheme 1: Representation of amyloid structuration. A: Cross β-sheet structure. β-sheets appear in purple, side-chains 
appear in yellow. B: Face and side views of a β-sheet (purple) composed of two β-strands (green arrows) interacting 
through H bonds between amides. 
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onto neuronal and glial cells and interfere with neurotransmission [97]. According to 
the so-called amyloid cascade hypothesis, monomeric amyloid-β peptide (Aβ) first 
assembles into oligomers, which are then reorganized to form fibres, the three species 
being in dynamic equilibrium [98]. Although the overall mechanism of the disease is 
poorly understood, it is widely acknowledged that the major toxicity arises from 
amyloid-β oligomers, which mediate inflammation and harm neurons [99]. However 
fibres are also toxic, causing membrane deformation, and promoting the formation of 
aggregation-prone species [100]. Different therapeutic approaches are proposed, either 
decreasing Aβ production, inhibiting its aggregation, or improving its clearance [101]. 
• Amyloid deposits are also found on pancreas of patients suffering from Type II 
diabetes. They result from the dysregulated production of Islet Amyloid Polypeptide 
(IAPP), which forms deposits on the surface of pancreas (Figure 9B). They have a dual 
toxicity, accelerating cellular apoptosis of pancreatic cells and decreasing insulin 
secretion. As for Aβ, studies showed that only the aggregated forms of IAPP were 
toxic, probably due to their interaction with cell membranes [102]. Therapeutic 
approaches consist in limiting production and aggregation of IAPP [103]. 
• A mediatised example of amyloid-related disease is spongiform encephalopathies, also 
known as Prion diseases. These rare neurodegenerative pathologies are due to Prion 
proteins, naturally present in the brain and the spine under a safe conformation. But 
Prion can adopt an alternative folding, becoming insoluble and hydrophobic, and thus 
toxic for the brain. A misfolded protein can catalyse the conversion of normally folded 
ones, promoting the accumulation of amyloid deposits in cells (Figure 9C). Prion 
proteins are infectious agents, and can be spread between individuals (animals and/or 
humans) by inoculation of infected tissues or fluids. Yet, most cases remain sporadic or 
familial [104].  
Figure 9: Micrographs of amyloid deposits. A: Amyloid-β plaques in the brain of Alzheimer’s disease patient. B: Islet 
Amyloid Polypeptide in the pancreas of type II diabetes patient. C: Prion protein in the brain of variant Creutzfeldt-Jakob 
patient. 
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II.2.b. Functional amyloids 
First discovered in the context of diseases, it took about one century to find out that amyloid 
fibres also play salutary role in organisms. Examples of so-called “functional amyloids” imply all 
types of organisms, from bacteria to mammals.  
High content of amyloids is found in bacterial biofilms. In E. coli and Salmonella, amyloid 
fibres are formed by Curli proteins. They self-assemble into β-sheet rich fibres on the surface of 
bacteria, ensuring their adherence on any type of surface, and promoting their interaction. Their role is 
thus crucial for biofilm formation. They also protect bacteria against external attacks [105].  
In fungi, hydrophobins were found to display amyloid character. Once secreted, hydrophobins 
self-assemble into amphiphilic monolayers at the air/growth medium interface. This results in a 
decrease of the surface tension, enabling the growth of fungi in aerial conditions. Hydrophobin coating 
also contribute to maintain water and gaz exchanges between fungi and its environment. Finally, 
hydrophobins also coat fungi spores, preventing immune response in hosts and helping spores 
dispersion in environment. At the molecular scale, hydrophobins display rodlets structure, stabilized 
by four disulphide bridges [106].  
In insects and fish, amyloid fibres are present in high amounts in eggs envelope as chorion 
proteins. Their role is to protect embryo against environmental aggressions, such as temperature or 
pressure variations, or microorganisms. Chorion proteins contain a central domain with repeating 
glycine residues, which was shown to aggregate into characteristic β-sheet structure in vitro [107].  
In mammals, amyloid fibres are implied in the biosynthesis of melanin. Upon proteolytic 
cleavage, 80-kDa fragments of glycoprotein Pmel17 are released and auto-assemble in melanosomes 
to form fibres. Those fibres play a dual role, both promoting synthesis of melanin by template effect, 
and preventing the release of toxic synthetic precursors. A careful control of the secretion pathway 
together with fast aggregation kinetics prevent the propagation of toxic amyloid species in the 
organism [108]. A partial repeat sequence rich in Pro, Ser and Thr was shown to be crucial for auto-
assembly [109].  
These examples illustrate the diversity of functional amyloids, both in nature (size, origin, AA 
content…) and role (protective, functional, structural, catalytic…). This diversity is likely to further 
extend with discovery of new amyloids.  
II.2.c. A characteristic quaternary structure or a highly stable energetic state? 
Under physiological conditions, amyloid is considered as a quaternary structure that only 
concerns a limited number of proteins, even though this number tends to increase over the years. 
However, some examples show that proteins displaying no apparent amyloidogenic character could 
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acquire it upon denaturation. This was reported when bringing proteins into organic solvents [110] or 
at non-physiological pH [111] or upon heating [112]. Similar effect was reported with overexpression 
of insoluble proteins in E. coli, leading to formation of inclusion bodies with amyloid character. This 
prompted people to hypothesize amyloid as a particular energetic state, which can be reached by any 
protein provided high concentration and sufficient denaturation. When looking closely to all proposed 
structures of amyloid fibres, we see that the intermolecular interactions at the root of amyloids consist 
in H-bonding between the amide groups of the main chains. From a strictly conformational point of 
view, almost any protein or peptide could actually adopt an amyloid state. Thus, the question is not 
anymore « what makes a protein form amyloid? » but rather « what makes some proteins stable in 
their amyloid state in physiological conditions? ».  
II.2.d. Common characteristics of amyloids 
The amyloid-forming proteins are very diverse, both in size, shape and function, and finding 
sequence homologies between them is often deceptive. Yet, the propensity to form fibres can often be 
attributed to a short core sequence (<10 AA). Although amyloids are broadly hydrophobic, a high 
content in hydrophobic residues in this central core is not the key to for forming amyloids. 
Contrariwise, it seems that the presence of specific molecular interactions among the side chains is 
required, which can involve various types of amino acids. As such, a high content of Gln, Asn, and 
Val was reported in the core of various disease-related proteins [113]. But aromatic amino acids are 
also frequent, probably driving the formation of fibres. 
Whatever their length, origin or sequence, amyloid proteins share in common to auto-assemble 
along a major axis to form fibres of 6-12 nm diameter and few μm long, with a characteristic cross-β 
structure. Amyloid fibres thus display very characteristic X-rays diffraction patterns. The formation 
conditions of fibres are highly variable, going from physiologically relevant to extreme conditions. 
Interestingly, it appears that structural amyloid fibres display isomorphic structure, whereas disease 
related amyloids have polymorphic structures.  
In fibres, two types of interactions are observed. In the one hand, β-sheet formation is promoted 
by H-bonds involving peptide backbones. These intermolecular H-bonds run parallel to the fibre axis. 
In the other hand, specific interactions between peptide side-chains are observed (hydrophobic 
interactions, π-stacking, saline bridges…). These interactions run perpendicularly to the fibre axis, and 
can either be intramolecular or intermolecular (in the case of “staggering”, or of interaction between 
filaments, see III.2.d). They result in stabilization of the cross-β folding [114].  
Mechanical studies demonstrated that their tensile strength was comparable to steel and their 
stiffness to silk [115]. They are also highly insoluble, and resistant to heat, organic solvents and 
proteases. The classification of a protein as an amyloid often arises from its specific binding to 
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amyloid-specific dyes, including Congo Red (displaying apple green birefringence upon binding 
amyloids) or Thioflavin-T (displaying a shift of its emission wavelength upon binding amyloids) [116] 
(see Section III.2.a).  
II.3. Amyloid fibres as nanomaterials 
Amyloid fibres have exceptional physical properties: they are very strong and stable, they are 
resistant to heat, organic solvents, denaturing agents and proteolysis. This contrasts with the image of 
proteins as delicate and sensitive and paves the way to new biotechnological applications. 
II.3.a. Amyloid fibres as a template for nanostructure formation 
In 2003, Lindquist and colleagues proposed to use amyloid fibres as template for the formation 
of gold and silver nanotubes [117]. To this goal, a mutant of yeast Prion was prepared, displaying 
cysteine residues on the surface of fibres. By an electrodeposition procedure, gold and silver were 
deposited onto the fibre surface. The resulting nanotubes were found to display good conductivity and 
low resistance, with dimensions suitable for microelectronic applications. The same year, Gazit et al. 
demonstrated that peptides fibres could be used as molds for nanowires synthesis [118]. They showed 
that the Aβ derived Phe-Phe dipeptide was forming hollow fibres with a central pore, filled with 
aqueous medium. When heating in the presence of silver ions together with citric acid, metallic 
nanowires are formed within the fibres. A final proteolytic digestion of the peptide scaffold allows the 
release of nanowires. Finally, Lynn’s group showed that sophisticated superstructures could be 
obtained from the KLVFFAE segment peptides of Aβ [119]. Fibres can switch from disorganized 
flexible nanotubes to highly ordered laminar superstructure by simple addition of sulfate ions. All 
these nanomaterials could find applications in nanodevices. 
II.3.b. Amyloid fibres as a grafting support 
Several studies showed that it is possible to operate some amino acid substitutions in 
amyloidogenic proteins without altering their aggregative properties. Starting from there, several 
groups proposed to graft functional entities on amyloid fibres, as it is already widely done with other 
nanomaterials. As such, Wickner’s group proposed to fuse different enzymes or fluorescent proteins 
with a yeast prion protein [120]. They showed that fibre formation was not impacted by the presence 
of fusion proteins, and that their native folding and activity was maintained upon aggregation. This 
constitutes the first example of enzymes supported on amyloid fibres, and could be of interest for 
enzyme immobilization. Subsequently, Baldwin et al. fused a cytochrome b to the SH3 aggregation-
prone domain [121]. Upon auto-assembly, cytochrome b is able to stoichimetrically bind 
metalloporphyrins, and the resulting scaffold displays a high surface density of porphyrins. It thus 
constitutes a good model system for long-distance electron transfers. 
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II.3.c. Amyloid-based hydrogels 
Another use of amyloid peptides is the formation of hydrogels. Xu’s group showed that Fmoc-
protected dipeptides were able to form two-dimensional gels when heated in acidic conditions [122]. 
Dipeptides are then able to switch from hydrogel state to solution state upon interaction with a specific 
biological ligand. Hydrogels display physical properties similar to amyloid fibres, and could find 
applications for drug delivery or tissue repair. 
II.3.d. …catalysis? 
Until now, only a few preliminary examples of amyloid fibres as a support for catalysis were 
reported. Yet, some natural amyloids display intrinsic catalytic properties, mostly when coordinating 
metal ions. As such, Alzheimer’s related amyloid-β peptide is able to coordinate copper ions [123], 
thus catalysing production of reactive oxygen species from molecular dioxygen [124]. Similar results 
were achieved with De Novo designed peptides. Korendovych and colleagues designed heptapeptides 
that self-assemble into fibres in presence of zinc ions [125]. The resulting scaffolds display esterase 
activity on p-nitrophenylacecate, zinc playing the role of metal cofactor in catalysis. Subsequently, 
Friedman et al. developed a library-based approach to screen for catalytic amyloids [126]. They 
demonstrated that at acidic pH, some of these short peptides do not require metal ions to perform 
catalysis. Some are even catalytically active in extreme conditions. These results led them to consider 
amyloids as a catalytic precursor of modern enzymes. 
Another approach consists in decorating fibres with catalytic species. Very recently, Bolisetty et 
al. proposed to use β-lactoglobulin membranes decorated with gold or palladium nanoparticles for 
continuous flow catalysis [127]. Nanoparticles are synthesized in presence of fibres and bind them by 
strong electrostatic interactions. When passing through the membrane, an aqueous solution of 4-
nitrophenol undergoes reduction into 4-aminophenol with total conversions. This system displays 
faster kinetics than free nanoparticles, showing the benefit of support immobilization.  
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III.  Molecular description of amyloid-β  peptides 
III.1.  Amyloid-β peptides 
III.1.a.  General features 
Alzheimer’s disease related amyloid-β peptide exist in two major forms in the brain, of 
respectively 40 (Aβ1-40) and 42 (Aβ1-42) amino acids. Their sequences differ one from another by the 
presence of two extra residues at the C-terminal end of Aβ1-42.Their molecular masses are of 4329.845 
g/mol (Aβ1-40) and 4514.082 g/mol (Aβ1-42). Their pI is estimated to be 5.59, and their total charge is 
of -3 at physiological pH.  
III.1.b.  Sequence 
When looking closely to their sequence, they are constituted of two distinct domains. In the N-
terminal part, residues 1 to 16 form a highly dynamic and poorly structured domain. It is mainly 
constituted of polar residues and is able to coordinate metal ions, such as Cu, Zn or Fe [123]. In the 
other hand, the C-terminal part of the peptide (residues 17 to the end) is mainly composed of 
hydrophobic residues. This domain is responsible for the hydrophobic interactions at the origin of the 
cross-β structure. More specifically, this domain is constituted of two β-strands, separated by a β-turn, 
which ensure the characteristic β-sheet conformation. The so-called central hydrophobic core, 
involving residues 17 to 21, is described as being an essential motif for aggregation (Figure 10).  
III.1.c. Solubility and storage 
Because of their high content in hydrophobic residues, amyloid-β peptides are poorly soluble in 
water, and have tendency to auto-assemble rapidly. Though, solubility is improved when solubilizing 
peptides at extreme pH (<2 or >11), maximizing the total charge. This also contributes to maintain 
peptides in a somewhat monomeric state, taking advantage of repulsive interactions. For this reason, 
stock solutions of peptides are often constituted at extreme pH, and pH is reset to physiological range 
right before experiments. 
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Figure 10: Numbered sequence of Aβ1-42 and the corresponding secondary structure.  Hydrophobic residues appear in 
bold. 
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III.1.d.  Spectrophotometry 
Aβ peptides contain a single tyrosine residue, which is used for their quantification by UV-Vis 
spectrophotometry. When pH is above pKa (>12), tyrosine is deprotonated and displays a 
characteristic absorption band at 293 nm, with a molar absorption coefficient of 2400 L.mol-1.cm-1. 
This band completely disappears for pH below pKa (<10), when tyrosine residue gets protonated. 
Measuring absorbance at high and low pH thus allows a precise quantification of tyrosine content of a 
sample, which is directly correlated to the amount of peptide [128].  
Because they contain no tryptophan residue, Aβ peptides have very low intrinsic fluorescence, 
attributed to the single tyrosine residue (λexc = 274 nm, λem = 303 nm, φ = 0.14 in water at 23 °C). 
III.1.e. Metal binding properties 
With its coordinating amino acids and its important flexibility, the N-terminal domain of Aβ 
peptides is able to coordinate metal ions. In particular, coordination of Fe(II), Zn(II), Cu(I) and Cu(II) 
with peptides was extensively studied, and coordination models were proposed [123,129,130].  
III.2. Amyloid-β fibres 
III.2.a.  Thioflavin-T: a reporter of amyloid-β aggregation 
Aβ aggregation is often studied using fluorescent reporters, for which at least one of the features 
is modified upon interaction with amyloid fibres. Among the existing reporters for aggregation 
(Congo Red, Nile Red, ANS, Bis-ANS…), the most widely used is Thioflavin-T (Th-T). Upon 
binding amyloid fibres, this benzothiazole derivative exhibits a red shift in excitation (λexc = 385 nm to 
λexc = 450 nm) and in emission (λexc = 445 nm to λexc = 482 nm). More importantly, its fluorescence 
intensity is exalted by several orders of magnitude upon interaction (Scheme 2.B). It is thus possible to 
follow Aβ aggregation by monitoring fluorescence at 482 nm with time, obtaining a typical sigmoidal 
curve [131] (see III.2.b).  
At the molecular scale, the recognition of amyloid fibres by Th-T is not fully understood. Yet, it 
is widely accepted that the exaltation of fluorescence upon binding is due to an immobilization of the 
rotatable bond of Th-T, which would stabilize the excited state responsible for fluorescence (Scheme 
2.A). Both experimental and computational studies also converge to say that Th-T intercalates in side 
chain channels of fibres, and is thus aligned to the fibre axis [132] (Scheme 2.C.). Although some 
sequence preferences were observed, no interaction between Th-T and specific amino acids have yet 
been reported.  
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Yet, several biases were reported on the use of Th-T in fibrillization assays. First, Th-T was 
shown to bind hydrophobic pockets of globular proteins, as exemplified by the crystal structure of Th-
T binding acetylcholinesterase (PDB 2J3Q). This lack of specificity represents an issue for studies in 
physiological medium. Moreover, Th-T fluorescence was shown to strongly depend on pH, ionic 
strength or presence of organic molecules/solvents, which prevent quantitative measurements 
[133,134]. Finally, a recent study demonstrated that Th-T promotes aggregation at high concentration 
by playing a role of template [135]. Despite that, Th-T remains the most convenient reporter for 
aggregation studies. 
III.2.b.  Aggregation process of amyloid-β fibres 
As stated before, Aβ aggregation can be monitored in vitro using Th-T as fluorescent probe. 
This aggregation assay displays a typical sigmoidal profile, which consists of three phases. First, a lag 
phase, resulting from monomers self-assembly into soluble oligomers. Follows a rapid growth phase, 
corresponding to the elongation of fibres, and finally a plateau, corresponding to a final stable fibrillar 
state. Several studies were conducted to investigate kinetics and thermodynamics of the aggregation 
process [136]. This profile is modified in the case of seeding, i.e. introduction of low amounts of pre-
aggregated forms at the beginning of aggregation. This results in a disappearance of the lag phase, 
aggregated forms playing the role of template and triggering aggregation (Scheme 3).  
A B 
C 
Scheme 2: Th-T binding to amyloid fibres. A. Structure of Th-T and schematic illustration of its rotative bond. B. UV-Vis 
and fluorescence spectra in presence and absence of Aβ fibres. C. Schematic illustration of Th-T binding site in side-chains 
channels on the surface of amyloid fibres. 
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Despite numerous studies aiming at elucidating Aβ aggregation mechanism, the precise nature 
of steps and intermediates remains unclear [136–138]. Among many other proposed mechanisms, 
Smith group suggested the existence of two distinct aggregation pathways for Aβ1-42 depending on 
initial monomer concentration [139]. At low concentration (< 20 μM), aggregation starts with a 
nucleation step, followed by an elongation of fibres by monomers addition (Scheme 4, Mechanism 1). 
This process is characterized by a high content of monomers and the absence of oligomers. NMR 
experiments showed that the shift from monomers to nucleated forms was reversible in the first hours 
of aggregation.  
At high monomer concentration (> 20-30 μM), the mechanism involves the formation of low 
molecular weight oligomers that stack together into higher molecular weight oligomers. This process 
is irreversible, and results in a rapid increase of fluorescence during the first hour of aggregation 
experiments. Follows a lag phase, corresponding to the lateral assembly of high molecular weight 
oligomers into protofibrils. This state displays a typical β-hairpin structure, with intramolecular H 
bonds. The formation of fibres is completed by a conformational change of protofibrils that shift from 
antiparallel β-hairpin to β-sheet conformation, stabilized by intermolecular H bonds between peptides 
(Scheme 4, Mechanism 2). This results in an important increase of Th-T fluorescence.  
These processes were shown to strongly depend on temperature: below 15°C, a high monomer 
content could be detected by NMR, whatever the initial Aβ1-42 concentration. At higher temperature, 
the monomer content depends on initial concentration.  
More generally, most studies agree that the aggregation process also strongly depends on other 
growth parameters, including agitation, pH or ionic strength. Many reports also indicate that Aβ1-42 is 
more aggregation-prone than Aβ1-40; an explanation may have been found by resolving fibre structures 
(see Section III.2.d.). 
Scheme 3: Typical aggregation curves with time in the presence and absence of seeding. 
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Depending on the aggregation process, the morphology of the fibres obtained is different. A 
study from Petkova et al. showed that the presence or not of agitation during aggregation has a strong 
influence on Aβ1-40 fibre morphology [140]. One could relate these effects to differences in 
stabilization of oligomeric species. Interestingly, the resulting fibres displayed differences in 
neurotoxicity in vitro. They also showed that morphologies were maintained upon seeding for several 
generations. This was used for preparation of highly structurally homogeneous samples for fibre 
structure elucidation (Section III.2.c). 
III.2.c. Fibre characterisation 
The formation of insoluble well-ordered protein aggregates is unusual in biology, and few 
characterization tools can be applied to them. Because of their one-dimensional structure, crystals of 
amyloid fibres cannot be isolated. Their insoluble nature also precludes the use of some conventional 
techniques such as circular dichroism or solution NMR. Microscopy techniques, such as AFM or 
TEM, enable the visualization of fibres, and can allow concluding on their morphological features 
when using high-resolution machines (Figure 11). The most suitable technique to obtain a structure of 
fibres at the atomic level is solid-state NMR, but it requires important amounts of highly 
homogeneous material and isotopic labelling. Indeed, differences in fibril growth conditions induce 
Scheme 4: Aggregation mechanisms for low and high peptide concentrations as described by Smith group. 
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important polymorphism, preventing structure resolution. Yet, model structures were proposed for 
Aβ1-40 and Aβ1-42 fibres. 
 
III.2.d.  Structures of amyloid-β peptides 
• Aβ1-40 
Different structures of Aβ1-40 are proposed in literature, all based on solid-state NMR studies. 
Figure 12 shows three models of Aβ1-40 fibres found on the Protein Data Base. Each of them shows 
fibres as the stacking of two or three protofilaments, the variations being attributable to differences in 
fibre growth conditions. Each structure displays a β-turn-β structural motif, in which the hydrophobic 
cluster is tightly packed, with side-chain contacts experimentally observed between Phe19 and Leu34, 
Val 36, Ile32. A salt bridge between Lys28 and Asp23 is also observed, stabilising the β-turn-β 
structure. Finally, a displacement along the fibre axis, called “staggering” is observed: one β-strand of 
a peptide “N” is facing the other β-strand of the peptide “N+1” [141–143].  
Figure 11: AFM (A) and TEM (B) images of Aβ  fibres. 
A B 
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•  Aβ1-42 
Two structures are proposed in literature for Aβ1-42 fibres, with respective PDB codes 2BEG 
[144] and 2MXU [145] (Figure 13). 2BEG was obtained in 2005 from quenched hydrogen/deuterium 
A B 
C 
Figure 12: Different model structures of Aβ1-40 fibres (PDB: (A) 2M4J, (B) 2LMP, (C) 2LMN). Red: non-polar residues, 
Green: polar residues, yellow: basic residues, blue: acidic residues. 
Figure 13: 2BEG (left) and 2MXU (right) model structures of Aβ1-42 fibre. Red: non-polar residues, green: polar residues, 
yellow: basic residues, blue: acidic residues, dotted line: salt bridge. 
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exchange NMR. It presents a U-shaped fibre in which contacts are formed between Phe19-Gly38 and 
Ala21-Val36. A salt bridge is formed between Asp23 and Lys28. Staggering is also observed, residues 
from peptide “N” facing residues of peptide “N+1”.  
The 2MXU structure was proposed in 2015 by solid-state NMR analyses [145]. It was obtained 
from highly structurally homogeneous samples, produced by multiple seeding cycles. This structure 
reveals a triple β-sheet motif, with three β-strands regions. The residues forming the “hydrophobic 
cluster” (Leu17-Ala21) are tightly packed with Ala30 and Ile32. In the other β-sheet, Ile32, Met35 and 
Val39 are in close contact. A salt bridge between Lys28 and Ala42 further stabilizes this structure. 
Aβ1-42 fibre is thus very rigid. Unlike Aβ1-40, no stacking between filaments or staggering has been 
observed. Distance between peptides is of 5 Å and diameter of fibril is of 4 nm. 
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IV.  Objectives of the study 
The aim of this thesis consisted in developing new hybrid catalysts made by interaction between 
catalytically active metal complexes and amyloid fibres. 
As stated before, amyloid fibres were successfully used as bionanomaterials for several 
applications (Section II.3). Their unique quaternary structure combined with their high stability and 
resistance to heat and organic solvents make them promising candidates for applications in catalysis. 
Because of their insoluble character, catalysts made of amyloid fibres would also be recyclable. 
Among amyloidogenic proteins, Aβ peptides are probably the most studied. Even though studying 
their aggregation remains complicated since very conditions-dependent, it is also well documented. 
Among the different existing approaches for artificial metalloenzyme elaboration, we chose to 
focus on the one relying on the non-covalent incorporation of coordination complexes into 
biomolecules (Section I.3). Firstly, because it encompasses the skills of the two research groups 
involved in this thesis, i.e. bioinorganic chemistry and protein engineering. Secondly, because amyloid 
fibres are known to interact with various types of molecules, providing a background for interaction 
studies. Finally, this approach enables the rapid screening of coordination complexes, to select the best 
hybrid candidate.  
Here, we propose an original use of amyloid fibres as a support for catalysis. 
This manuscript describes the elaboration of new hybrid catalysts by incorporating metal 
complexes into amyloid fibres made of Aβ peptides.  
• Chapter II describes the optimized expression of MAβ peptides in Escherichia coli, 
and their purification following a novel approach. Their aggregation properties were 
assessed, establishing recombinant MAβ peptides as suitable models for aggregation 
studies in vitro.  
• Chapter III describes the synthesis of a series of phenyl-terpyridine ligands and of the 
corresponding Cu(II), Fe(II) and Ru(II) complexes. The different compounds were 
characterized using various physicochemical techniques, and their catalytic activity on 
oxidation reactions was assessed.  
• Chapter IV describes the study of the interaction between metal complexes and Aβ 
fibres. Different techniques, such as fluorimetry, UV-Visible spectrophotometry, and 
NMR were used to assess the interaction. Interestingly, differences were observed 
depending on the nature of the complex.  
• Finally, preliminary catalytic assays were conducted on the hybrid scaffolds made of 
metal complexes inserted into Aβ fibres, as described in Chapter V. This constitutes a 
first proof of concept for hybrid catalyst elaboration based on amyloid fibres.  
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Chapter II. Recombinant production of Amyloid-β  
peptides 
This chapter is adapted from: Hoarau, M., Malbert, Y., Irague, R., Hureau, C., Faller, P., Gras, E., 
André, I., and Remaud-Siméon, M. (2016). A Robust and Efficient Production and Purification Procedure of 
Recombinant Alzheimers Disease Methionine-Modified Amyloid-β Peptides. PLOS ONE 11, e0161209. 
Original article appears in Annex III. 
Introduction 
Whereas Alzheimer’s Disease constitute a major health issue of the XXIst century, the causes 
and mechanisms of disease are still poorly understood. In particular, the implication of amyloid-β 
peptide, which aggregates to form insoluble plaques in the brain, is the focus of many investigations, 
both in vitro and in vivo [146,147].  
In this context, there is an increased need for reliable source of Amyloid-β peptides.  
This chapter describes a new production and purification protocol for Amyloid-β  1-40 and 
1-42 in Escherichia coli.  
In a first part, an overview of existing procedures for Amyloid-β production is given, 
including chemical and recombinant methods. 
In a second part, expression and purification of a His-tagged Amyloid-β 1-42 is proposed, 
taking advantage of affinity chromatography for purification. 
In a third part, an alternative strategy is proposed for Met-Amyloid-β production, taking 
advantage of inclusion body formation in bacteria.  
Finally, Met-Amyloid-β 1-40 and 1-42 were fully characterized using LC-MS, NMR, and 
Thioflavin-T aggregation assay. These results appear in the last part of this chapter. 
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I.  Production routes of Amyloid-β  peptides 
I.1.  Context: need for amyloid-β peptides 
Alzheimer’s disease constitutes a major health issue, and much research effort is currently being 
devoted to better understand the causes and mechanisms of the disease. In particular, understanding 
the behaviour of amyloid-β (Aβ) peptides is a key issue, their implication in the disease remaining 
unclear.  
For in vitro experimentation, disposing of reliable Aβ samples displaying reproducible 
behaviours is crucial. Indeed, aggregation was shown to be highly sensitive to many factors, such as 
temperature, concentration, agitation, but also storage or sample preparation [139,148]. But most 
importantly, both the presence of contaminants and the presence of pre-aggregated forms of the 
peptide were shown to strongly alter the course of aggregation, either inhibiting it or yielding no 
fibrillary material. In this regard, the easy access to pure and homogeneous Aβ samples is still 
challenging and essential for in vitro experimentation.  
I.2.  Different routes for amyloid-β peptides production 
I.2.a.  Solid phase peptide synthesis 
Most investigations on Aβ are usually performed with chemically synthesized peptides. Solid-
phase peptide synthesis consists of successive couplings of N-ter protected amino acids on a solid 
support. The desired peptide is obtained upon deprotection and cleavage. Although convenient and 
easily accessible, solid phase peptide synthesis can be complex in term of purification. Indeed, the 
presence of peptides with altered sequences caused by non-quantitative synthetic steps or of racemized 
peptides is observed, which can hardly be removed, even by up-to-date purification methods. Traces 
of salts or metal ions were also reported [149]. Finally, the presence of pre-formed aggregates due to 
storage conditions is frequent. All of this results in significant variations of aggregation properties 
from batch to batch. This has been recently exemplified in a study, which showed that the recombinant 
peptide is more aggregation-prone and more neurotoxic than its synthetic analogue, demonstrating a 
deleterious effect of synthetic procedures on peptide properties [150]. This has encouraged the 
exploration of various biological routes to access recombinant Aβ peptides and get rid of such issues.  
I.2.b.  Recombinant production 
Recombinant DNA expression, also referred as molecular cloning, is of huge importance in 
biochemistry and biotechnology. It consists in inserting a foreign DNA segment into a self-replicating 
DNA vector. When cloned in a suitable organism, the DNA fragment will replicate together with the 
vector. If the fragment is positioned downstream a promoter, this leads to the production of a 
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messenger RNA and the protein corresponding to its coding sequence [151].  
Recombinant peptide production can provide high yields of polypeptides with perfect sequence 
fidelity. It also enables the rapid generation of large mutant libraries by random mutagenesis. Finally, 
it represents a clean production process, all the materials used being issued from biological sources.  
Different recombinant production protocols are proposed in the literature for Aβ peptides. Some 
attempts were made in yeast [152] or by combining recombinant and synthetic procedures [153] but, 
to date, the most common expression system remains Escherichia coli. Most often, peptides are 
appended with a fusion protein that may enhance their solubility and facilitate their isolation and 
purification using affinity chromatography. However, such strategies raise several issues. First of all, 
despite the usually increased solubility of the fusion proteins, a non-negligible amount of the peptide 
frequently remains in the insoluble fraction, thus requiring an extra denaturation step for complete 
recovery [154,155]. Moreover, a cleavage site has to be intended, which position is critical. If not 
carefully chosen, cleavage will introduce amino-acids at the terminal end of the peptide, potentially 
modifying its aggregation and metal-binding properties [156,157]. The same drawback exists with 
smaller affinity tags [158,159]. This problem was solved with the use of proteolytic enzymes such as 
the Factor Xa or the enterokinase, whose cleavage sites was introduced in the construction to enable 
the formation of native Aβ [160,161]. Still, such methods are time-consuming and require many 
purification steps, including long affinity chromatography purification procedures that inevitably 
result in a loss of peptide. To overcome this drawback, it was proposed to express native Aβ in E. coli 
[162,163]. Notably, Aβ forms insoluble inclusion bodies (IBs) when expressed in E. coli in their 
native form. This was exploited by Walsh and co-workers to isolate pure recombinant MAβ1-40 and 
MAβ1-42 by anion-exchange purification [162] and by Cullin and co-workers, applying a dialysis-
based purification protocol [164]. 
I.2.c.  Our strategy 
In order to obtain clean Aβ peptide samples, we envisioned two parallel strategies for producing 
the recombinant peptides. In the one hand, we proposed to fuse the genes encoding the peptides with a 
gene coding for a cleavable 6xHis purification tag to promote the easy purification of the peptides 
(Scheme 5, construction 1). In the other hand, we also explored the recombinant production of the two 
Aβ peptides devoid of any tag in E. coli and investigate the development of a purification protocol 
taking advantage of inclusion body formation for purification (Scheme 5, constructions 2 and 3). 
These peptides will be referred as MAβ in the following, due to the presence of a codon start 
methionine on their N-ter end. Both strategies were conducted in parallel.  
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Construction 2: MAβ1-42 
 
MDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA 
Construction 1: His-tagged Aβ1-42 
 
MGSSHHHHHHSSGLVPRGSHMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA 
Construction 3: MAβ1-40 
 
MDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV 
Scheme 5: Targeted peptide sequences. Native Aβ sequence appears in black (Aβ1-42 in constructions 1 and 2, Aβ1-40 in 
construction 3). 6xHis tag appears in blue, thrombin recognition sequence appears in green, other amino acids appear in 
grey. T indicates thrombin cleavage site. 
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II.  His-tagged Aβ1-42 
II.1.  Vector construction 
Because we had no pre-existing plasmid containing sequence coding for Aβ peptides, a first 
plasmid, named pET28_His_Thromb_Ab42 was ordered (Scheme 6). It consists in a pET28a plasmid 
comprising a gene coding for His tag, thrombin cleavage site, and Aβ1-42 downstream a T7 promoter. 
It also possesses a kanamycin resistance gene. A second 6xHis tag is present, but will not be expressed 
in this construction. This plasmid was used as template for the formation of further constructions (see 
0.). 
II.2.  Expression and purification 
E. coli BL21 cells were transformed with pET28_His-Thromb_Ab42 and expression 
experiments were performed. Expression was induced for 4 h at 37 °C, and cells were harvested and 
lysed. Interestingly, the SDS-PAGE analyses showed that the overexpressed His-Thromb-Aβ1-42 
peptide was contained in the insoluble fraction. After the centrifugation of the cell lysate, the pellet 
was solubilized in 8 M urea, and applied on TALON resin. Elution with increasing concentrations of 
imidazole afforded peptides with acceptable purity (Figure 14). The nature of the peptide obtained was 
validated by anti-His Western-Blot analysis. A first attempt of thrombin cleavage was made, showing 
partial cleavage (Figure 15). 
Scheme 6: Representation of pET28_His_Thromb_Ab42 plasmid. 
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At this stage, we chose to stop efforts on this strategy to focus on the formation of native Aβ peptides. 
First of all, because we had no guarantee that once cleaved, the GSHMAβ1-42 peptide obtained would 
be able to aggregate into fibres, whereas MAβ1-42 aggregation was reported in literature. Secondly, the 
presence of the 6xHis tag implied at least one chromatographic purification step and preferably two 
steps to ensure a good level of purity. In addition, although a cleavage site had been introduced in our 
construct to remove the 6xHis tag, the cleaved peptide would contain 4 additional residues at its N 
terminal end, which could also affect aggregation. All of this prompted us to focus on MAβ 
production. 
 
  
  
1       2       3       4       5        6       7       8       9      10 
Figure 14: Purification of His-Thromb-Aβ1-42 peptide. Insoluble fraction from bacterial lysis was applied on TALON resin 
and incubated. Supernatant was discarded (lane 2) and resin was washed twice with lysis buffer (lanes 3 and 4). Peptide was 
then eluted using Imidazole 25, 50, 100, 200, 300 and 400 mM (lanes 5-9). Samples were compared with 10-250 kDa protein 
ladder (lanes 1 and 10). 
 1        2       3       4       5     
Figure 15: Preliminary result of Thrombin cleavage of His-Thromb-Aβ1-42. His-Thromb-Aβ1-42 (lane 2) was incubated for 
4h with thrombin at room temperature, leading to partial cleavage (lane 3). The resulting peptide presents a band similar to 
commercial Aβ1-42 (lane 4). Samples were compared with 10-250 kDa protein ladder (lanes 1 and 5). 
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III. MAβ1-42 and MAβ1-40  
A second strategy consisted in expressing amyloid peptides in absence of tags, the presence of a 
N-ter methionine due to the start codon being the only difference with Alzheimer’s disease related 
peptides. 
III.1.  Vector construction 
• pET28_MAb42 
The gene encoding MAβ1-42 was obtained by PCR from pET28_His_Thromb_Ab42, using 
primers with floating tails comprising the restriction sites NcoI and XhoI. The amplicon and the 
pET28 vector were digested with the same restriction enzymes. The two parts were ligated to yield the 
expected pET28_MAb42 (Scheme 7), which was transformed into competent E. coli cells. Sequencing 
of the insert confirmed the quality of the construction. 
 
• pET28_MAb40 
pET28_MAb40 was obtained from pET28_MAb42 using the same strategy. The sequence 
coding for MAβ1-40 was amplified by PCR. The forward primer used was complementary to 
pET28_MAb42, whereas the reverse primer possessed a floating tail with a BamHI restriction site. 
Both pET28_MAb42 and the insert were digested by NcoI and BamHI and ligated, to form 
pET28_MAb40, as shown in Scheme 8. 
Scheme 7: Representation of pET28_MAb42 plasmid. 
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These two plasmids were used to transform E. coli BL21(DE3) cells, and produce MAβ1-40 and 
MAβ1-42 peptides.  
III.2.  Expression of MAβ peptides 
III.2.a.  Formation of bacterial inclusion bodies 
MAβ peptide production analysis revealed that most of the peptides were recovered in the 
insoluble fraction after cell lysate, possibly corresponding to the formation of inclusion bodies (IB). 
Indeed, when insoluble proteins are overexpressed in E. coli, this may sometimes result in the 
formation of IB at the poles of the cell. First considered as amorphous aggregates, IB were found to 
display amyloid structural features [165]. In particular, they are positive to amyloid specific dyes. 
As such Thioflavin-S (Th-S), which is usually used for staining amyloid plaques, was recently 
shown to stain bacterial IBs of MAβ peptides, both in vivo and in vitro. This property was used to 
detect protein aggregation in bacteria [163], or to screen in vivo for aggregation inhibitors [166].  
In our case, microscopy of E. coli cells treated with Th-S confirmed the presence of inclusion 
bodies, located at the poles of cells (Figure 16). This property was used to assess the production of 
MAβ and optimise the expression conditions. 
 
Scheme 8: Representation of pET28_MAb40 plasmid. 
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III.2.b.  Optimisation of expression conditions 
To determine optimal conditions for peptide expression, we envisioned a procedure based on 
Th-S monitoring. Cells from different cultures were sampled, incubated with Th-S and their 
fluorescence spectra were recorded with a fluorimeter. This allowed us to study the effect of induction 
time, temperature, and inducer concentration on MAβ1-42 expression in E. coli. 
• Time of induction 
In order to use Th-S staining as a tool for the optimization of peptide expression, the correlation 
between IB content and the Th-S fluorescence level had to be established. To do so, cultures 
expressing MAβ1-42 were stopped at different induction times. The cells were sampled, incubated with 
Th-S, and their emission spectra were recorded. As shown in Figure 17.A, the fluorescence level 
increased during the first 4 hours of induction and then reached a plateau. The corresponding cultures 
were lysed and peptide was purified and analysed by SDS-PAGE. A good accordance was observed 
between the amount of purified peptide and the fluorescence level (Figure 17.B). Based on these 
results, a 4 h induction was considered as adequate and applied throughout the rest of the study. 
Figure 16: Visualisation of bacterial IB of MAβ1-42. A. E. coli cells expressing MAβ1-42 incubated in Th-S observed by 
fluorescence microscopy. B. Overlay of fluorescence and visible microscopy images. Experimental conditions: λexc = 340-
380 nm, dichroic = 400, λem = 425 nm, 63x magnification. 
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Figure 17: MAβ1-42 expression monitoring with time using Thioflavin-S. A. Variations of normalized fluorescence of Th-S-
treated E. coli cells expressing MAβ1-42 with induction time. B. SDS-PAGE of purified inclusion bodies from E. coli cultures 
expressing MAβ1-42; lane 1: 10-250 kDa protein ladder, lane 2 to 5: samples taken at 0, 2, 4, and 6 hours of growth, 
respectively. 
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• Inducer concentration 
Th-S monitoring was used to screen for the optimal concentration of IPTG inducer. No 
significant variations of IB production was observed with IPTG concentration comprised between 0.5 
and 1.5 mM (Figure 18). Contrariwise, increased levels of protein contaminants were observed when 
using 1 or 1.5 mM IPTG, which could be due to the overexpression of E. coli chaperones [167]. 
Induction at 0.5 mM IPTG was thus preferred for the rest of the study.  
• Temperature 
The optimal temperature of cell growth was investigated using the same strategy. E. coli cells 
expressing MAβ1-42 were grown at 23, 30 and 37 °C. As shown in Figure 19, the temperature allowing 
the formation of a maximal amount of IBs was 37 °C.  
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Figure 18: Th-S fluorescence of E.coli cells expressing MAβ1-42 induced with different IPTG concentrations. Cells were 
induced at 37°C for 4 h. 
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Figure 19: Th-S fluorescence of E. coli cells expressing MAβ1-42 at various temperatures. Cells were induced with 0.5 mM 
IPTG for 4 h. 
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III.3.  Purification of MAβ peptides  
III.3.a.  Inclusion body isolation 
As Aβ peptides were produced as IBs, the first step of the purification procedure consisted in 
isolating and purifying IBs. The main challenge of this approach was to succeed in removing proteins 
and nucleic acids that could be trapped in the IBs or stacked on their surface.  
First, the previously reported “soni-removal” method, which consists of multiple sonication and 
centrifugation cycles, was performed to roughly eliminate nucleic acids and proteins stacked at the IB 
surface [168]. At this stage, Th-S fluorescence visualization of isolated IBs confirmed that their 
average size remained unchanged, showing no deterioration due to sonication (Figure 20). 
 
III.3.b. Purification of monomeric MAβ peptides 
In a first trial to purify MAβ1-42, IBs were solubilized using 8 M urea and then passed through a 
DEAE Sepharose, following the described procedure. As seen in Figure 21, this protocol enables the 
removal of most protein contaminants. Unfortunately, it did not allow the elimination of a 13-kDa E. 
coli protein contaminant, regardless of IPTG concentration used for induction. This protein could not 
be eliminated by ultrafiltration, indicating that the urea treatment did not allow breaking the 
interaction probably existing between the 13-kDa protein and the peptide (Figure 21 lanes 4 and 5). 
Because the peptide and the protein are close in size, purification of the mixture seems complicated. 
We thus decided to turn to another denaturation method. 
  
Figure 20: Visualization of IB after bacterial lysis. A. MAβ1-42 IB incubated in Th-S observed by fluorescence microscopy. 
B. Corresponding visible microscopy image. Experimental conditions: λexc = 450-490 nm, dichroic = 500, λem = 500-550 
nm, 63x magnification. 
  

Recombinant production of Amyloid-β peptides 

 
54 
 
 
Aβ peptides have an isoelectric point of about 5-6, and are soluble at high pH. IBs were thus 
first incubated with 50 mM sodium hydroxide, to solubilize MAβ. Solution was then neutralized, 
leading to the precipitation of a large amount of proteins, while MAβ peptides remain in the 
supernatant (Figure 22.B, lanes S1 and P2). The high pH denaturation/neutralization cycle was applied 
twice to maximize MAβ recovery (Figure 22.B, lane S2). Further completion of contaminant 
elimination was carried out by ultrafiltration of the solubilized peptides followed by concentration, 
respectively on 30-kDa and 3-kDa molecular weight cut-off membranes. As shown on the 
electrophoresis gel (Figure 22.B, lane F), the ultrafiltration step allowed getting one single band 
around 5 kDa, the presence of any protein contaminant being excluded. The schematic representation 
of this protocol is shown in Figure 22.A.  
Contrariwise to urea denaturation, it seems that high pH treatment do break the interaction 
between peptide and contaminating protein, which is then easily removed by ultrafiltration. 
III.4. Monitoring of MAβ peptides purity 
At this step, one important issue was the monitoring of sample purity at the various stages of the 
purification procedure. The Bradford protein assay was eliminated because it does not give any 
information on sample purity and only allows the determination of a global protein content. 
Combination of UV-Vis spectrophotometry with gel electrophoresis was clearly preferred. Indeed, 
SDS-PAGE permits to visualize the presence of protein contaminants while UV-Vis analyses inform 
on the predominant presence of either nucleic acids (λ = 260 nm) or specific amino acids, namely 
tryptophan (λ = 280 nm), tyrosine/tyrosinate (λ = 274 nm/λ = 293 nm) and phenylalanine (λ = 257 
nm) [169]. Both methods were thus combined to assess the purity level of the peptide samples 
depending on the purification steps as shown in Figure 22.C. After denaturation (Figure 22.C, 
Figure 21: Purification protocol of MAβ1-42 IBs dissolved in 8M urea. Lane 1: 10-250 kDa protein marker, lane 2: IBs 
after urea denaturation, lane 3: after passing through DEAE resin, lane 4: after 30-kDa ultrafiltration, lane 5: after 3-kDa 
concentration. 
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spectrum D), a lot of species are present. The supernatant harvested after neutralization (Figure 22.C, 
spectrum S1+S2) still contain proteins but is already devoid of nucleic acids. After ultrafiltration, the 
sample was too diluted to give an informative UV spectrum (Figure 22.C, spectrum F). Finally, the 
concentration step yielded a pure sample showing a UV signature with the typical UV band at λ = 293 
nm corresponding to the tyrosinate form (Figure 22.C, spectrum C). This typical profile is conserved 
after size exclusion chromatography, which was performed to isolate only monomeric peptide before 
aggregation assays (Figure 22.C, spectrum SEC). Overall, these analyses confirmed the high level of 
purity of the peptide preparation. 
 
 
As the sample was devoid of any protein contaminants, the pH-dependent absorption of Tyr was 
used to estimate the peptide yield. Absorption spectra of the peptides were thus recorded at pH 12 
(showing the absorption band of tyrosinate at 293 nm) and at pH 2 (displaying no tyrosinate band). 
Subtracting spectra allowed the precise quantification of the tyrosine content of the sample, which 
Figure 22: Purification monitoring of MAβ . A. Simplified scheme of the purification procedure. Circled letters correspond 
to samples collected for either UV/Vis measurements or gel analysis. Supernatant S1 and S2, and pellet P1 and P2 
correspond to the supernatant and the precipitate obtained for the two cycles of denaturation/neutralisation. B. SDS-PAGE 
at different steps of purification, compared with 10-250 kDa protein marker (lane M). C. UV-Vis spectra at pH 12 after IBs 
denaturation (D), after denaturation/neutralisation cycles (S1+S2), after 30-kDa ultrafiltration (F), after concentration (C), 
and after size exclusion chromatography (SEC). 
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enabled the estimation of the peptide yield as being around 4 mg/L of culture, which is in the same 
range as those previously reported, comprised between 3 and 7 mg/L [154,155,160,170,171] (see 
Table 1).  
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IV.  Peptide characterization 
IV.1.  LC-MS analyses 
To characterize the peptides, LC-MS analyses were conducted right after the concentration step 
on both peptides. Because they are hydrophobic and aggregation-prone, chromatography of amyloid 
peptides is often complicated. Peptide samples were acidified and analysed on a C4 column. 
MAβ1-40 affords a clean chromatographic trace with a major peak at 10.8 min. The mass 
spectrum associated to this peak displays peaks corresponding to peptides protonated 3, 4 and 5 times 
(Figure 23.A and Figure 23.C). MAβ1-42 chromatogram is less resolved, with a shoulder arising in 
front of the main peak (Figure 23.B and Figure 23.D). The masses detected for both the shoulder and 
the peak are consistent with the calculated masses of MAβ1-42, indicating that oligomeric forms of 
MAβ1-42 could be present. This is consistent with the high propensity of Aβ1-42 to aggregate. 
 
 
Figure 23: LC-MS analysis of MAβ1-40 and Μβ1-42. A. LC trace of MAβ1-40 monitored by mass detection. B. LC trace of 
MAβ1-42 monitored by mass detection. C. MS of MAβ1-40 displaying [M+5H]5+, [M+4H]4+, and [M+3H]3+ peaks (expected 
values: 892.65, 1115.56, 1487.07). D. MS of MAβ1-42 displaying [M+5H]5+, [M+4H]4+, and [M+3H]3+ peaks (expected 
values: 929.47, 1162.17, 1548.44). 
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IV.2.  1H NMR analyses 
1H NMR spectra of both peptides were then recorded, and compared with commercially 
available synthetic Aβ1-40 (Figure 24). They display the typical signals usually observed for Aβ1-40 
peptide. In the aromatic region, signals corresponding to the Hδ and Hε of aromatic residues are well 
defined. As such, Phe 19 and 20 (ca. 7.2 ppm and ca. 7.3 ppm) and Tyr 10 (ca. 7.95 ppm and ca. 6.8 
ppm) can be distinguished. Slight shifts are observed for His 6, 13 and 14 (ca. 7.8 ppm and ca. 7.1 
ppm), which can be attributed to pH variations. The absence of signal ca. 7.5 ppm confirms the 
absence of Trp residue in the peptides. Expectedly, signals corresponding to Hα (4.5-3.8 ppm) and Hβ 
(3.2-2.6 ppm and 2.3-1.5 ppm) are more difficult to attribute in details. In the aliphatic region, signals 
corresponding to Lys 16 and 28 (1.4 ppm) and to Val and Leu (1.0-0.7 ppm) are observed. Finally, the 
signal at 3.9 ppm reveals the presence of a methionine residue for the recombinant peptides as 
expected.  
IV.3.  Thioflavin-T aggregation assay 
Because most in vitro studies on Aβ peptides consist in studying their aggregative properties in 
various conditions, it was essential to ensure that the auto-assembling properties of the peptides are 
conserved upon this purification process. Prior to this, it was important to remove traces of oligomeric 
species, to ensure a homogeneous aggregation process. The monomeric forms of the two peptides 
were thus isolated by SEC, and were then submitted to Th-T aggregation assay.  
In 26 h, both peptides afford a characteristic sigmoidal aggregation curve with aggregation half-
times around 15 h (Figure 25). The MAβ peptides obtained through our purification procedure thus 
conserved their auto-assembling properties. The same results were obtained with peptide batches from 
different cultures, showing the high robustness of the purification procedure in terms of 
reproducibility. This purification protocol could thus be applied for routine lab-scale MAβ production. 
Figure 24: 1H NMR of MAβ1-40 and MAβ1-42 compared with Aβ1-40. Samples of MAβ in water are diluted to 100 μM in 100 
mM phosphate buffer pH 7 in D2O. Synthetic Aβ1-40 is dissolved in NaOD and diluted to 100 μM in the same conditions. 
Signals at 4.75 ppm correspond to H2O, and signals at 3.25 ppm and 1.25 ppm correspond to traces of ethanol. 
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This also confirms that the presence of a N-ter Met residue does not affect the aggregation properties 
of MAβ peptides as previously reported [157]. Removing Met residue could be beneficial for specific 
studies such as metal coordination, but does not seem mandatory for classical aggregation assays.  
Long-term peptide storage was attempted by flash-freezing peptide samples in NaOH 15 mM, 
and storing it at -20°C. Peptide was then slowly defrozen at 4°C a few weeks later. However, this 
process completely inhibited peptide’s aggregation properties, and other strategies will be to envisage. 
 
  
Figure 25: Normalized aggregation curves of MAβ1-40 and MAβ1-42. Two different batches of MAβ1-40 (A and B) and MAβ1-
42 (C and D) (20 μM) aggregate in the presence of Th-T (10 μM) in phosphate buffer (50 mM, pH 7). Assay was run at 37°C 
with gentle shaking. Each experiment was run in triplicates. 
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Conclusion 
We proposed two strategies to produce Aβ peptides in E. coli. The first one consists in 
appending a cleavable 6xHis tag on the N-ter part of Aβ. This allows peptide purification on metal 
affinity resin, affording samples clean enough to be submitted to protease cleavage. The second 
strategy consists in expressing Aβ without any tag except the start codon associated Met. In that case, 
peptide is forming IBs, which are positive to Th-S fluorescent dye. This property was used to 
determine optimal conditions for IBs formation in E. coli. Following expression, IBs were isolated 
from bacterial lysate. At this stage, we chose to solubilize IBs using NaOH; upon neutralization, most 
of contaminant proteins precipitate, whereas MAβ remains in solution. This contrasts with usual urea 
denaturation, which does not allow to get rid of contaminants. Last purification steps consist in two 
successive ultrafiltrations, affording clean samples of peptides.  
Peptide characterization was achieved by LC-MS and 1H analyses, and Th-T aggregation assay 
was run with both peptides, confirming their good auto-assembling properties. 
Table 1 presents a comparison between our work and the previously reported procedures for Aβ 
production in E. coli. Many of them are using fusion proteins or tags, which implies long affinity 
chromatography procedures. Interestingly, these procedures do not necessarily allow complete 
purification, and further steps can be required. Finally, they often imply the presence of extra amino 
acids on the peptide upon cleavage. A strategy using MAβ was previously proposed, but here again 
the purification was completed using chromatography (Table 1, line 2). In contrast with all of this, our 
method is chromatography-free, purification being achieved by simple centrifugation and 
ultrafiltration steps. The whole production and purification process can thus be completed within two 
days. 
In terms of purity monitoring, we have proposed a combination of UV and gel electrophoresis, 
which had never been reported before. Yet, UV-Vis constitutes a convenient way to determine the 
presence of contaminating Trp-containing proteins (Aβ peptides being devoid of Trp). A final 
aggregation assay has also been conducted, appearing as crucial to ensure of the auto-assembling 
properties of the peptides obtained.  
Thanks to this method, we dispose of a rapid and convenient source of MAβ peptides. Further 
work would now consist in improving its properties to serve as support for coordination catalysts. As 
such, Th-S staining could be used to develop high-throughput screening for peptide mutants, seeking 
for sequence with increased aggregative properties. Interaction with metal complexes could also be 
improved with the help of directed evolution together with molecular modelling (see Chap. IV).  
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Table 1: Previously reported results for Aβ  recombinant production. 
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MG1655 pQE-80L  
15N isotope-
labelled Aβ1-
42  
IFABP IB + affinity 
2 x Ni-
NTA 
column + 
HPLC 
6 mg/L ✗ ✗ ✓ ✗ [160] 
BL21 
DE3 
PLysS 
Star 
PetSac  MAβ1-42 
MAβ1-42 
/ IB 
DEAE-
cellulose 
+ SEC  
n.d. ✗ ✓ ✓ ✓ [162] 
BL21 
(DE3) pSK+ XAβ1-42 GST affinity 
Ni-NTA + 
affinity 
column 
15 
mg/L ✗ ✗ ✗ ✗ [161] 
BL21 
star 
(DE3) 
pET14b Aβ1-40 / affinity  
2xNi-
NTA + 
HPLC 
n.d. ✗ ✗ ✓ ✓ [158] 
BL21-
Codon 
Plus 
(DE3) 
pGEX-
2T 
Aβ1-40 and 
GSIEGRAβ1-
42 
GST affinity 
affinity 
column + 
HPLC  
7 
mg/L  ✗ ✗ ✓ ✗ [170] 
MG1665 pQE-80L  
Aβ1-40 
Aβ1-42 
IFABP IB + affinity 
Ni-NTA 
column + 
SEC + 
HPLC  
3mg/L ✗ ✗ ✓ ✗ [155] 
BL21 
(DE3) 
pGEX-
4T-1  GSAβ1-42 GST affinity 
affinity 
resin + 
dessalting 
column + 
affinity 
column  
0.54 
mg/L ✗ ✗ ✗ ✗ [172] 
BL21 
DE3 
PLysS 
pCOLD-
TF XXXAβ1-42 Ubiquitin 
soluble 
fusion 
protein 
+ 
affinity 
Ni-NTA 
column  3mg/L ✗ ✗ ✗ ✗ [171] 
BL21 
(DE3) pET28a GGAβ1-42 Ubiquitin 
IB + 
affinity 
Ni-NTA 
column + 
affinity 
column + 
HPLC 
4 
mg/L ✗ ✓ ✗ ✗ [154] 
BL21 
star 
(DE3) 
pET15b GSHMAβ1-42 / affinity 
Ni-NTA 
column + 
HPLC  
n.d. ✗ ✗ ✗ ✓ [159] 
BL21 
(DE3) ? Aβ1-42 
Poly 
peptide 
IB + 
affinity 
Ni-NTA 
column + 
HPLC  
19 
mg/L ✗ ✗ ✓ ✓ [150] 
BL21 
(DE3) 
PLysS 
PetSac MAβ1-42 / IB 2xDialysis  n.d. ✗ ✓ ✗ ✓ [164] 
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Chapter III. Elaboration of coordination catalysts 
Introduction 
Towards the development of new hybrid bioinorganic catalysts, a key element is the elaboration 
of metal complexes displaying interaction with amyloid fibres.  
Inspired by existing amyloid probes, we chose to focus on flat aromatic ligands, expecting an 
interaction with β-sheet structures. In particular, poly pyridine ligands are of interest, as being widely 
used in coordination chemistry and catalysis. Several functionalizations were proposed, seeking to 
increase the non-covalent interactions between complexes and fibres and enabling coupling. 
 
This chapter describes the synthesis of a series of terpyridine ligands and of corresponding 
Cu(II), Fe(II) and Ru(II) complexes.  
In a first part, synthesis of five functionalized terpyridine ligands is described. The different 
synthetic routes available are introduced, including Kröhnke condensation, which was used in this 
project. 
In a second part, corresponding Cu(II), Fe(II) and Ru(II) complexes were synthesized, and 
fully characterized by different techniques, including X-rays crystallography, NMR, EPR, MS, UV-
Visible and fluorescence spectrophotometry, and cyclic voltammetry. 
Resulting metal complexes were subsequently tested for their interaction with amyloid fibres, 
and for their catalytic properties. 
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I.   Design of ligands 
I.1.  Requirements for hybrid catalysts elaboration 
In the context of this thesis, our aim was to develop coordination catalysts that would 
incorporate into fibres of amyloid-β peptides. Toward this goal, in addition to good coordination and 
catalytic properties, designed metal complexes had to display non-covalent interaction with fibres. 
These three parameters were thus considered for ligand elaboration. 
I.1.a. Interaction with fibres 
One of the searched property for our ligands was their ability to bind to amyloid fibres. In this 
view, we sought inspiration among the huge set of probes developed to visualize amyloid fibres [173]. 
These scaffolds go from very simple to more sophisticated structures. Some examples appear on 
Scheme 9, showing important structural diversity. 
Considering these structures, it is likely that the non-covalent interaction with fibres consist of 
π-stacking (due to the numerous aromatic cycles) and H-bonding (due to the presence of H-bonds 
accepting atoms). These two parameters will thus be considered for our structures. 
I.1.b.  Metal complex formation 
A second desired characteristic of our target was to be able to coordinate different metal ions. 
Indeed, one of the interests of the proposed hybrid systems is their versatility in terms of potential 
catalytic reactions. It would be of great interest to incorporate various metal ions within the same 
ligand, in order to extend the scope of reactivity of the system. 
N
S
N
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N
N
NH2
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O
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N
NH2
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O
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Congo Red
S HN
O OH
O
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N
SHO
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NC CN
DTM-2
O
N O
N
N
O
BF4-
AOI-987
I
N
m-I-stilbene
S S
CN
CN
HO
NIAD-4
Scheme 9: Variety of probes for amyloid-β  fibres. 
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It is well established that monomeric Aβ peptides display good affinity for biologically relevant 
metal ions [123,129,156]. As an example, apparent association constants of Aβ are ca. 106 M-1 for 
Zn(II), ca. 1010 M-1 for Cu(II) [137]. To ensure that there will be no competition between designed 
ligands and peptides to chelate metal ions, we sought for ligands with high metal affinity constants.  
I.1.c. Catalysis 
Several parameters are important to consider for a catalyst: 
• Stability 
A first important parameter is complex stability: the complex must be able to operate an 
important number of catalytic cycles without ligand decoordination or metal precipitation. Also, as the 
fibres are produced at μM scale, and could limit substrate accessibility, high turnover numbers (TON) 
are required to develop systems with measurable catalytic activity. 
• Catalytic cycle 
An important parameter for our scaffolds is that the interaction between fibres and complexes 
remains constant during the catalytic process. Though, during the catalytic cycle, metal ion is exposed 
to redox-cycle, and to substrate coordination/decoordination. It would thus be preferable to consider 
fibre-complex interaction would be promoted by ligands, whose geometry is unchanged along the 
catalytic cycle and remote of the metal centre.  
• Substrate accessibility 
When incorporating complexes into fibres, it is important to ensure that the catalytic site 
remains available to substrates. We thus chose hemilabile ligands, in order to allow substrate 
coordination. 
• Water compatibility 
In the context of development of green catalysts, we are interested in running catalytic reactions 
in aqueous environment. Metal complexes should thus be stable in presence of water. Because fibres 
constitute a hydrophobic environment, complexes and substrates should not necessarily be 
hydrosoluble. Yet, reaction intermediate should not be air or moisture sensitive.  
I.2.  Targeted structures 
Considering all these requirements, three types of ligands were selected: terpyridine, bipyridine, 
and its constrained analogue phenanthroline, and salophen (Scheme 10). All of them have been 
extensively described, for diverse applications including supramolecular chemistry [174], material 
sciences [175,176], sensor development [177,178], or catalysis [179–181]. Their strength resides in 
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their perfectly defined coordination geometry, and in their extended π-conjugation which confers 
unique electronic and photophysical properties [180,182,183]. 
Metal complexes of these ligands display very different geometries: M(tpy)2 is forming two 
perpendicular planes, whereas M(bpy)3 and M(phen)3 are rather spherical, and M(salophen) is planar. 
These differences might result in different interaction with amyloid fibres. 
Bipyridine, phenanthroline and salophen are commercially available, and were used to form the 
corresponding metal complexes. In addition to commercial terpyridine, we decided to design 
functionalized terpyridines to increase the available aromatic region and enable the study of the effect 
of functional groups variations on fibre-complex interaction to be studied.  
I.3.  State of art on terpyridine ligands 
I.3.a.  Advantages of terpyridine 
Based on these requirements, we considered the synthesis of terpyridine ligands. Firstly, to take 
advantage of their relatively straigthforward synthesis and functionalization (see I.3.b). They can also 
form complexes with several metal ions, including Fe, Ru, Os, Cu, Mn, Co, Ni [184,185] with binding 
constant above 108 M-1 in ACN [186] and are very stable, as examplified by the reported dissociation 
rate of 10-7 s-1 for Fe(tpy)2 in water [187]. For these reasons, they have been reported for numerous 
catalytic applications [188,180,189]. Different examples of artificial metalloenzymes using terpyridine 
metal complexes have even been reported in literature [51,60,190] (see Chapter I).  
I.3.b. Synthetic routes for terpyridine 
• Kröhnke condensation 
Kröhnke synthesis of terpyridine occurs between α-pyridinium methyl ketone and pyridinyl 
prop-2-enone in the presence of ammonium acetate [191]. The reaction starts with an enolization, 
followed by a Michael addition. Addition of ammonium acetate on the ketone followed by cyclisation 
affords the terpyridine. Scheme 12 depicts the reaction mechanism as proposed in literature [192]. 
This reaction presents a good atom economy, the only by-products of this reaction being pyridine and 
acetic acid. The resulting terpyridine can be substituted on the lateral pyridine and in para position of 
the central one [193,194].  
N
N N N
N
N
N
N N
OH HO
Terpyridine Bipyridine Phenanthroline Salophen
Scheme 10: Ligands selected for this study. 
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A reaction based on a similar mechanism consists in starting with 2,6-diacetylpyridine. Upon 
reaction with I2 and pyridine, a bis(pyridinium) iodide is formed, which undergoes condensation with 
α,β-unsaturated aldehyde (Scheme 11). This yields terpyridine substitutable in positions 4,4’’ and 
5,5’’ [195].  
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Scheme 11: Proposed mechanism for terpyridine synthesis starting from 2,6-diacetylpyridine. B stands for base, which can 
be either ammonia or acetate. 
Scheme 12: Reaction mechanism of Kröhnke terpyridine synthesis. Reaction occurs in methanol in presence of NH4OAc in 
excess, heating to reflux for 6h. Py stands for pyridine. 
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• Condensation of 1,5-diketones 
A different strategy consists in the condensation of 1,5-diketones with ammonium acetate, 
cyclizing the central pyridine ring. The resulting terpyridine can be substituted in 4’ position (Scheme 
13) [196]. 
• α-oxoketene dithioacetal method  
An alternative procedure relies on the condensation of 2-acetylpyridine enolate with α-
oxoketene dithioacetal in presence of ammonium acetate (Scheme 14). Further reaction on the 
thiomethyl group enables the functionalization in position 4’. Terpyridines can also be substituted in 
an asymmetric manner, by starting with the suitably substituted enolate [197].  
The mechanism of this reaction involves a Michael addition, followed by the release of a 
thiomethyl group. Nucleophilic attack by ammonia followed by cyclization afford the 4’ thiomethyl 
terpyridine (Scheme 14). Thiomethyl group can subsequently react to give a variety of derivatives. 
• Jameson method 
A very similar strategy consists in starting with (dimethylamino)enone instead of dithioacetal. 
Here again, ammonium acetate plays both the role of base and nucleophile. The mechanism involved 
is also similar, the most significant difference being the difference between the leaving groups 
(Scheme 15). 
Scheme 13: Terpyridine synthesis by 1,5-diketone condensation. 
N
R
N
O O N
N N
R
NH4OAc
Scheme 14: Terpyridine synthesis by α-oxoketene dithioacetal method. R, R’ = H, alkyl, vinyl. 
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Scheme 15: Jameson method for terpyridine synthesis. 
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• Cross-coupling strategies 
A more modern strategy consists in performing cross-coupling reactions to obtain symmetric 
terpyridines. As such, Stille coupling was often used, either using dihalogenated central pyridine with 
tin-substituted lateral pyridine [198], or in the other way round [199] (Scheme 16.1). Suzuki-Miyaura 
cross-coupling was also proposed, here again the halogen atom and the borate group can be held by 
one partner or the other [193] (Scheme 16.2).  
Cross-couplings present the advantage of being very specific while allowing various 
substitutions of the two partners. However, terpyridines being very chelating ligands, formation of 
metal complexes is difficult to avoid, and purification can become tricky.  
Cross-couplings are catalysed by Pd(0), which is often formed in situ from Pd(II) precursor. A 
first step consists in the oxidative addition of the aryl halide on Pd(0), forming a Pd(II) adduct. 
Transmetallation with an organometallic compound provides the bi-aryl adduct, that is released 
through a reductive elimination step, while Pd(0) is regenerated (Scheme 17).  
[Pd(II)]
[Pd(0)]
[Ar-Pd(II)-X]
[Ar-Pd(II)-Ar']
Ar-X
Ar'-MYn
X-MYn
Ar-Ar'
Oxidative 
addition
Reductive
elimination
Transmetallation
Scheme 17: Schematic catalytic cycle of cross-coupling reactions. Ar stands for Aryl, X is a halogen, M is a metal, and Y is 
a ligand. 
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Scheme 16: Synthetic routes for terpyridines by cross-coupling strategy. 1: Stille coupling. 2: Suzuki-Miyaura coupling. 
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I.3.c. Targeted structures 
In the frame of this project, we chose to functionalize terpyridine with a phenyl ring in position 
4’, further increasing the aromatic surface available for interaction (Scheme 18). The phenyl ring was 
functionalized in position 10 with different groups. First of all, this enables a preliminary screen for 
interacting moieties. This also allows the conjugation of various functional groups, such as 
interacalating moieties or probes. A covalent grafting to peptides could also be envisaged in future 
studies.  
Our synthetic efforts thus focused on developing a series of p-functionalized 4-phenyl-
2,2’ :6’,2’’-terpyridine ligands (Scheme 18).   
I.4.  Results 
I.4.a. Experimental procedure 
A one-pot procedure for the Kröhnke condensation was performed between an aldehyde bearing 
the desired substituent with two molecules of acetylpyridine in presence of potassium hydroxide in a 
mixture of ethanol and ammonia [194]. The solution was refluxed overnight, leading to a white 
precipitate, which was collected by filtration. When observed, residual impurities were removed by 
simple recrystallization in ethanol. 
Interestingly, the substituent seems to have an effect on the reaction yield. As such, nitrophenyl 
and phenol did not lead to the desired product, whereas other aryl groups did react, according to our 
expectations. 
 
Scheme 18: Targeted ligands with corresponding numbering scheme. 
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In the case of nitrophenyl, this was solved by synthesizing separately the enone and the 
pyridinium salt [200]. The condensation was then achieved in pyridine in presence of ammonium 
acetate, heating overnight to reflux (Scheme 20). 
 
 
 
 
 
 
 
 
p-nitrophenyl terpyridine can then be reduced to form p-aminophenyl terpyridine. A first 
possibility is the reduction of the nitro group with hydrazine in the presence of Pd/C. The desired 
amino ligand is obtained upon 3 h reflux in ethanol [198] (Scheme 21.A). 
Another approach is a reduction by tin chloride under acidic conditions (Scheme 21.B). Both 
strategies are similar, affording p-aminophenyl terpyridine in good yields within a few hours, and in 
both cases, metal salts are removed by filtration on Celite. 
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Scheme 20: Stepwise synthesis of p-nitrophenyl terpyridine. 
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Scheme 19: Direct synthesis of p-substituted phenyl terpyridine derivatives. 
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Finally, 4’-furyl terpyridine can be oxidized by potassium permanganate under basic conditions, 
forming 4’-carboxylic acid terpyridine (Scheme 22) [201]. Here again, the product is recovered by 
simple filtration. 
 
I.4.b. Products obtained 
 A series of six terpyridine ligands was obtained from this strategy (Scheme 23). All these 
compounds were fully characterized by NMR, IR, and MS, to ensure of their nature and purity (see 
Experimental procedures). The different functional groups could induce variable interaction with 
fibres. In particular, L2 and L6 have pKa around 4, and will be under carboxylate form at physiological 
pH. L1 might form H-bonds with peptides, whereas L3 could interact via polar interaction. Different 
binding behaviour can thus be expected from these ligands. 
Scheme 21: Two possible synthetic routes for p-aminophenyl terpyridine. 
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Scheme 22: Synthesis of 4’-carboxylic acid terpyridine. 
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I.4.c.  1H NMR preliminary assessment of electronic properties 
A first determination of the electronic effect of the different substituents was achieved by 
comparing the chemical shifts of terpyridine protons. Variability in chemical shifts would attest of an 
important inductive or mesomeric effect.  
To determine the extent of the electronic effect of the functional group three sets of protons 
were chosen: H9,9’, which are the closest from the substituting group, H3’,5’, to see the effect on the 
central pyridine, and H6,6’’ which are directly linked to the coordinating N. The chemical shifts 
appear in Figure 26.A. It appears that the influence of the functional group is limited to the phenyl 
ring. Indeed, protons 9,9’ display important variations, but chemical shifts of protons 3’,5’ and 6,6’’ 
remain unchanged. Expectedly, the variations of chemical shift can be directly correlated to the 
electro-withdrawing character of the substituents (Figure 26.C). As such, among the ligands holding a 
phenyl group, nitro group induces the most important deshielding, followed by the carboxylate and the 
bromide. 
 
Scheme 23: Summary of available terpyridine ligands. 
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Figure 26: Variations of 1H NMR chemical shifts of phenyl-substituted terpyridines. A: Chemical shifts obtained for the 
ligands. All spectra were recorded in DMSO-d6, except those noted * which were recorded in CDCl3. B: Numbering scheme 
for phenyl-substituted terpyridine. C: Classification of ligands as a function of the deshielding due to their functional groups. 
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R
Ligand H3'+5' H9+9' H6+6’’ 
L1 8.62 8.5 8.75 
L2 8.74 8.04 8.78 
L3* 8.76 8.37 8.74 
L4 8.71 / 8.78 
L5 8.71 8.50 8.73 
L6 8.79 / 8.72 
tpy* 8.62 / 8.71 
Average 8.71 ± 0.08 8.35 ± 0.31 8.74 ± 0.03 
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II.  Synthesis of metal complexes 
II.1.  Copper (II) complexes 
II.1.a.  Synthesis 
The synthesis of CuL2 complexes is straightforward, consisting in a reaction between Cu(II) 
nitrate and two equivalents of terpyridine. Dropwise addition of a Cu(II) solution to a ligand solution 
causes an immediate change in colour. The metal complex is then isolated by precipitation, thanks to 
an ion exchange between nitrate and hexafluorophosphate (Scheme 24). 
Cu(bpy)3 and Cu(salophen) were synthesized following the same protocol with 47% and 88% 
yields, respectively. Cu(salophen) being neutral, the anion exchange step was not required to induce 
complex precipitation.  
II.1.b. X-ray structures 
• Cu(L1)2(PF6)2 
Crystals were obtained for Cu(L1)2(PF6)2 by slow diffusion of diethyl ether in ACN. The 
structure shows the two terpyridine in nearly perpendicular planes centred on the Cu(II) (angle N1-Cu-
N4 ca. 91.6 degrees). Cu-N distances are shorter for central pyridines (ca 1.97 Å) than for the lateral 
ones (2.17 Å). The phenyl rings show a torsion angle with central pyridine rings, respectively of 17.98 
and 35.77 degrees. 
Scheme 24: Synthesis of CuL2(PF6)2 complexes. 
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• Cu(salophen) 
Crystals of Cu(salophen) were obtained by slow evaporation of ACN. The X-ray structure 
shows a primitive motif constituted of two parallel complexes. Complex is almost planar (angles O1-
Cu-N2 and O2-Cu-N1 ca. 176 degrees), with Cu(II) in a square planar geometry (angles N1-Cu-O1 
and N2-Cu-O2 ca. 94.4 degrees). 
Figure 27: Crystal structure obtained for Cu(L1)2(PF6)2. 
Figure 28: Crystal structure obtained for Cu(salophen). 
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II.1.c. EPR  
Cu(L1)2 was submitted to X-band Electronic Paramagnetic Resonance (EPR) measurements. As 
reported for many hexacoordinate Cu(II) complexes, Cu(L1)2 displays a Jahn-Teller distortion [202]. 
In Cu(L1)2, this results in an axial elongation of the complex in solution. Unexpectedly, EPR spectrum 
of this complex is made of two components, whose contributions are shown to vary with temperature 
(Figure 29.A) [203]. Component a, predominant at low temperature, displays a signature consistent 
with an elongated D4h symmetry, whereas component b, observed at higher temperature, seems to 
display a rhombic symmetry. Considering this, we have hypothesized an equilibrium between two 
distinct Jahn-Teller axially-elongated forms of the complex, as depicted on Figure 29.B.  Parameters 
were calculated for component a as g// = 2.24 and A// = 164 e-4 cm-1. 
II.1.d. UV-Visible  
UV-Vis spectra were recorded for the different complexes in ACN, showing different 
signatures: Cu(L1)2 and Cu(salophen) display intense bands in the visible region, whereas Cu(L2)2 and 
Cu(bpy)3 absorb farther in the UV region. 
Table 2: Absorption wavelengths and corresponding molar extinction coefficients of Cu(II) complexes in ACN.*: spectra 
recorded in H2O. 
Complex λmax (nm) ε(L/mol/cm) 
Cu(bpy)3 299 48,260 
Figure 29: Jahn-Teller dynamic effect observed for Cu(L1)2 complex. A: X-band EPR spectra (v ca. 9.5 MHz) obtained for 
Cu(L1)2 in ACN at variable temperatures. B: Proposed equilibrium in Cu(L1)2. Atoms in red are close to Cu(II), atoms in blue 
are more distant.  
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Cu(L1)2 397 8,454 
Cu(L2)2* 334 11,200 
Cu(salophen) 420 14,340 
 
UV-Vis was also used to determine pH stability of terpyridine complexes. Acidification of a 
Cu(L1)2 solution leads to a decrease of its UV band, presumably corresponding to a protonation of the 
amine group on terpyridines. This is consistent with the reported pKa of aniline ca. 4.6 [204]. Even at 
pH 2.2, the signature remains different from free ligand in acidic conditions, attesting that the complex 
is not degraded (Figure 30).  
From these data, it is thus possible to work with Cu(II) bis terpyridine complexes in acidic 
conditions, which would be of interest for catalytic experiments.   
II.1.e. Electrochemical characterization 
To get a preliminary idea on the redox behaviour of our complexes, cyclic voltammetry 
measurements were run on Cu(L1)2. In reduction, a quasi-reversible wave at -0.052 V vs. NHE is 
observed (ΔEp = 89 mV), corresponding to the reduction of Cu(II) into Cu(I) (Figure 31, red curve). 
When scanning at much lower potential, irreversible peaks are observed, corresponding to the 
reduction of ligand aromatic rings. An intense peak is also observed on the reverse scan, 
corresponding to the deposition of Cu(0) onto the surface of the electrode (Figure 31, blue curve). In 
oxidation, an irreversible wave is observed, possibly corresponding to the oxidation of the amine 
groups (Figure 31, green curve).  
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Figure 30: Decomposition of Cu(L1)2 in acidic conditions. Red: free L1 at pH ca. 2, blue: Cu(L1)2.Conditions: [Cu(L1)2] =  
50 μM in H2O + 10% ACN. 
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This study confirms that Cu(L1)2 is able to switch from Cu(II) to Cu(I) without important 
reorganisation of the coordination sphere. 
II.1.f.  Study of solution equilibriums 
Working with [Cu(L1)2]2+ complex, it seemed important to investigate the possible 
coordination/decoordination equilibriums in solution.  
We started this study by completing a UV-Vis titration: Starting from a 50 μM solution of L1 in 
ACN, increasing amounts of CuSO4 were added. This results in the apparition of a band at 397 nm, 
which increases in a linear manner until 1 eq Cu(II) (Figure 32). Changes are also observed in the 250-
350 nm region, with an isobestic point ca. 350 nm.  
Figure 31: Cyclic voltamogrammes obtained for Cu(L1)2 . Conditions: [Cu(L1)2] = 1 mM, [TBAPF6] = 0.1 mM in ACN, 
scan rate = 0.1 V/s, argon atmosphere. WE: glassy C, CE: Pt, RE: SCE. 
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Figure 32: UV-Vis study of Cu(L1)2 formation in solution. A: UV-Vis spectra obtained upon addition of CuNO3 in a 50 μM 
solution of L1 in ACN. B: Titration curve monitored at 397 nm. 
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This titration does not allow to distinguish [Cu(L1)2]2+ and [Cu(L1)]2+ from their UV-Vis 
signatures: a single MLCT band at 397 nm is observed for all Cu(II) equivalents. One hypothesis 
would be that CuL2 is formed at substoichiometric ratios, that is then converted into CuL when above 
0.5 eq Cu(II). In this case, CuL2 and CuL would have similar molar absorption coefficients, 
considering the titration curve obtained. Another possibility would be that only CuL is formed in 
solution, if the addition of a second ligand on Cu(II) is not favourable. 
To address this question, similar investigations were conducted in parallel by CV and solution 
EPR. To a 1 mM solution of L1 in ACN were added increasing amounts of CuNO3. For each point, 
cyclic voltamogram was recorded (Figure 33.A), and solution was immediately sampled and shock-
frozen to be submitted to EPR measurement (Figure 33.B). 
In sub-stoichiometric amounts of Cu(II) (red curves), a single specie is observed, which displays 
a splitting of signals due to a dynamic Jahn-Teller effect (see II.1.e). This specie is likely to be 
[Cu(L1)]2+.  
For 0.8 eq of Cu(II) (blue curves), CV shows a peak ca. 0.15 V vs. NHE, and the previously 
observed reversible wave ca. -0.2 V vs. NHE. However, EPR spectrum attests of the presence of a 
single specie, different from [Cu(L1)]2+, likely [Cu(L1)]2+. We propose that this specie is irreversibly 
reduced at the electrode into [Cu(L1)]+. But since coordination with a planar tridentate ligand is not 
favourable for Cu(I), we hypothesize that [Cu(L1)]+ releases its ligand in solution. This ligand 
immediately coordinates to [Cu(L1)]2+, forming [Cu(L1)2]2+. This last specie is then reduced, as 
A B 
Figure 33: Formation of CuL complexes in solution. A. Cyclic voltamogrammes of L1 upon addition of various equivalents 
of Cu(NO3)2 in ACN. Conditions: [L1] = 1 mM, [TBAPF6] = 0.1 mM, scan rate = 0.1 V/s, argon atmosphere. WE: glassy C, 
CE: Pt, RE: SCE. B. Species observed and corresponding reduction potentials.  
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attested by the reversible wave.  According to this, [Cu(L1)2]2+ would not be present in solution, but 
would be formed in situ following [Cu(L1)]2+ reduction. 
Similar behaviour is observed at 1.1 eq of Cu(II) (green curves), with an extra reversible wave 
attributed to free Cu(II) ca. 0.8 V vs. NHE. 
Finally, addition of chloride ions in solution results in a shift of the different waves at lower 
potential (black curves). 
This parallel EPR/CV study confirms the successive formation of [Cu(L1)2]2+ and [Cu(L1)]2+ in 
solution in the case of the titration of a ligand solution with Cu(II). Both species seem stable enough to 
be observed in solution, and a precise control of stoichiometry should enable to control the nature of 
species in solution. Importantly, when comparing these results with the ones obtained with solid 
[Cu(L1)2](PF6)2 dissolved in ACN (see II.1.e), it appears that the only specie detected from the powder 
is [Cu(L1)2]2+. No partial decoordination is observed for this compound in ACN solution. 
II.2. Iron (II) complexes 
II.2.a.  Synthesis 
The synthesis of iron complexes is straightforward, consisting in a reaction between Fe(III) 
nitrate and the suitable stoichiometry of ligands. Ethanol plays a dual role, serving both as solvent and 
as reducing agent for Fe(III) [174]. The resulting complexes are formed within 1 h, and are soluble in 
ethanol. Upon anion exchange between NO3- and PF6-, the formation of a purple precipitate in ethanol 
is observed, while traces of ligands and salts remain in solution. Resulting Fe(II) complexes are 
soluble in ACN at the mM range.  
Scheme 25: Synthesis of FeL2(PF6)2 complexes. 
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II.2.b.  X-ray structures 
Slow diffusion of diethyl ether into an ACN solution of Fe(L1)2(PF6)2 yielded crystals suitable 
for X-ray diffraction. The resulting structure is close to the one obtained for Cu(L1)2(PF6)2, the two 
terpyridine ligands being in perpendicular planes (angle N1-Fe-N5 of 75.91 degrees). Here again, 
distances between Fe(II) and central pyridine is shorter than for lateral pyridines (1.89 vs. 1.98 Å). 
Phenyl rings also display a small rotation from the central pyridine (dihedral angles of 16.53 and 37.67 
degrees, respectively).  
II.2.c. NMR 
Fe(II) terpyridine complexes being diamagnetic (configuration 4s0 3d6 low-spin), 1H NMR 
spectra of the complexes were recorded. Figure 35 shows the 1H NMR spectra of L1 and Fe(L1)2. It 
Figure 35: Modifications of 1H NMR upon complexation of Fe(II) by L1. Green: L1, Red: Fe(L1)2. Spectra were 
recorded on 300 MHz NMR in DMSO-d6. 
 
 
  
  
Figure 34: Crystal structure obtained for Fe(L1)2(PF6)2. 
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appears that Fe(II) complexation results in a global deshielding of the NMR signals of terpyridine 
protons. The only exception are protons 6+6’’ (noted ) and protons 5+5’’ (noted ) which undergo a 
shielding. This effect is likely due to the fact that these protons are situated in the anisotropy cone of 
the central pyridine of the facing ligand. 
II.2.d. UV-Visible 
UV-Vis spectra of Fe(II) bis-terpyridine complexes display several ligand-centred π→π* and 
n→π* transitions in the UV region, as well as a metal-to-ligand charge-transfer (MLCT) ca. 550-580 
nm [205]. The corresponding bpy and phen complexes display MLCT bands at slightly higher energy 
(ca 510 nm) and ligand-centered transitions much more intense than for Fe(tpy)2 complexes (Figure 
36, red).  
Table 3 shows absorption wavelengths and molar extinction coefficients of the different Fe(II) 
complexes synthesized. These complexes were tested in fluorescence, but did not display any emissive 
properties.  
Table 3: MLCT absorption wavelength and corresponding molar coefficient extinction of Fe(II) complexes in ACN. 
Complex λmax (nm) ε  (L/mol/cm) 
Fe(bpy)3 520 9,400 
Fe(phen)3 509 9,820 
Fe(tpy)2 551 7,620 
Fe(L1)2 576 32,700 
0
1
2
3
4
5
6
240 320 400 480 560 640
Fe(bpy)3
Fe(L1)2
A
bs
or
ba
nc
e
Wavelength (nm)
Figure 36: UV-Visible spectra of Fe(bpy)3 (red) and Fe(L1)2 (blue). 
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Fe(L2)2 568 24,400 
Fe(L3)2 574 34,700 
Fe(L4)2 576 32,000 
Fe(L5)2 567 21,830 
 
II.3. Ruthenium (II) complexes 
Ru(II) polypyridine complexes are reported in literature for their unique chemical, 
photophysical and electrochemical properties. In chemistry, their applications go from dye-sensitized 
solar cells [180], electron transfer [206] to catalysis [207]. Their biological applications cover 
anticancer therapy, DNA binding or imaging [208]. Interesting examples show the use of Ru 
complexes to monitor AD-related aggregation of tau protein [209] and to recognize insulin fibrils 
[210]. We thus got interested in Ru(II) polypyridine complexes, both for their use as probes to 
investigate their intercalation in amyloid fibres, and for their potential catalytic applications. 
II.3.a.  Synthesis 
As for Fe(II), Ru(II) complexes were synthesized starting from Ru(III), reduction being 
promoted by EtOH. Upon 1 h reflux, the desired [RuL2]Cl2 complex is formed. For purification 
purpose, chloride ions are exchanged with hexafluorophosphate ions, leading to the precipitation of a 
purple solid corresponding to the complex.  
 
Scheme 26: Synthesis of RuL2(PF6)2 complexes. 
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II.3.b.  NMR characterization 
Similarly to Fe(II), Ru(II) complexation leads to a global deshielding of terpyridine protons, the 
only exceptions being protons 5,5’’ (noted ) and 6,6’’ (noted ) due to their presence in the 
anisotropy cone of the facing ligand (Figure 37). This effect is a bit lower than observed for Fe(II) 
complex.  
II.3.c.  UV-Visible signatures 
UV spectrum of Ru(II) polypyridine complexes displays to different types of transitions. In the 
UV region, different bands correspond to spin-allowed ligand-centred π→π* and n→π* transitions. In 
the visible region, a characteristic 1MLCT band is observed, conferring to complexes an intense 
orange-red colour [180].  
Absorption bands of phenyl-terpyridine complexes are slightly red-shifted compared to 
complexes of commercial ligands, certainly due to the presence of an extra aromatic ring. Ligand-
centered bands are also much more intense (Figure 38).  
Figure 38: UV-Visible spectra of Ru(bpy)3 (red) and Ru(L1)2 (blue). 
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Figure 37: Modifications of 1H NMR upon complexation of Ru(II) by L1. Spectra were recorded on 300 MHz NMR in 
DMSO-d6. 
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All absorption wavelengths and corresponding molar extinction coefficients were recorded and 
appear in Table 4.  
Table 4: MLCT absorption wavelength and corresponding molar coefficient extinction of Ru(II) complexes in ACN. 
Complex λmax (nm) ε  (L/mol/cm) 
Ru(bpy)3 451 15,575 
Ru(phen)3 444 15,280 
Ru(tpy)2 474 14,980 
Ru(L1)2 502 24,100 
Ru(L2)2 492 24,700 
Ru(L3)2 494 25,100 
 
II.3.d.  Fluorescence properties 
Ru(II) polypyridine complexes possess an emissive 3MLCT state, which conveys them emissive 
properties at room temperature (Scheme 27). Their emission wavelength are ca. 600 nm in ACN 
[211]. 
Ru(bpy)3 is often used as a reference for quantum yield measurements, with a reported value of 
1.8% in aerated ACN [212], and a corresponding fluorescence lifetimes ca. 800 ns. Contrariwise, 
Ru(tpy)2 was found to display much lower fluorescence (Φ = 0.07%), together with a lower 
fluorescence lifetime (0.2 ns) [213]. This difference comes from the stabilisation of the 3MC state in 
Ru(tpy)2, which promotes a deactivation process (Scheme 27). Quantum yields of other Ru(II) 
complexes were determined using Ru(bpy)3 as reference, fluorescence wavelengths and quantum 
yields appear in Table 5.  
Scheme 27: Electronic diagram of Ru(bpy)3. MLCT = metal-to-ligand charge transfer excited state, MC = metal centre 
excited state, ISC = intersystem crossing. 
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Table 5: Excitation and emission wavelengths and quantum yields of Ru(II) complexes in ACN. Values in brackets are 
those reported in literature. 
Complex λ exc (nm) λ em (nm) Φ  (%) 
Ru(bpy)3 450 620 (1.8) 
Ru(phen)3 450 596 1.33 
Ru(tpy)2 475 550 0.053 (0.07) 
Ru(L1)2 490 570 0.0174 
Ru(L2)2 490 570 0.0169 
Ru(L3)2 490 570 0.0130 
 
Expectedly, Ru(phen)3 displays similar characteristics as Ru(bpy)3. Unfortunately, RuL2 
complexes are 100 times less fluorescent than Ru(bpy)3, and their Stokes shift is also shorter. 
Compared with Ru(tpy)2, it is likely that the presence of the phenyl ring linked with a rotatable bond 
partially quenches the fluorescence of the complex. Yet, the fluorescence can be observed for 
concentrations until 1 μM, which makes possible their use as fluorescent probes. 
II.3.e.  Electrochemical characterization 
Electrochemical behaviour of Ru(II) complexes was assessed by cyclic voltammetry. To this 
aim, complexes were dissolved to 1 mM in ACN using 0.1 mM tetrabutylammonium 
hexafluorophosphate as support electrolyte. Figure 39 shows the cyclic voltamogrammes obtained for 
Fe(L1)2. A single oxidation wave is observed ca. 1.27 V vs. NHE, actually corresponding to two 
distinct processes: (a) the reversible oxidation of Ru2+ into Ru3+ and (b) the irreversible oxidation of 
the amine of L1, as observed for the corresponding Cu(L1)2 complexes (Figure 31). In reduction, 
Figure 39: Cyclic voltamogrammes of Ru(L1)2 in ACN. Conditions: [Ru(L1)2] = 1 mM, [TBAPF6] = 0.1 mM, scan rate = 
0.1 V/s, argon atmosphere. WE: glassy C, CE: Pt, RE: Ag/Ag+.  
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several quasi-irreversible waves and irreversible peaks are observed, corresponding to the reduction of 
the pyridyl and phenyl rings, consistently with literature [206].  
Similar studies were conducted with other Ru(II) complexes, showing reversible Ru2+/Ru3+ 
waves for all the complexes. Apparent redox potentials appear in Table 6, showing almost identical 
values for all the complexes. From these data, similar properties in terms of redox cycling can be 
expected for the different complexes, with no effect of the substituting group.  
Table 6: Apparent redox potentials for Ru(II)/Ru(III) in various complexes. 
Complex Ε1/2app (V vs. NHE) 
Ru(tpy)2 1.26 
Ru(L1)2 1.27 
Ru(L2)2 1.25 
Ru(L3)2 1.28 
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Conclusion 
In addition to commercially available bpy, tpy and salophen, we synthesized a series of six 4’-
substituted terpyridines, using the Kröhnke method. The compounds are obtained in satisfying yields, 
and purified by simple filtration.  
1H NMR revealed that the nature of the substituent has no effect on the electronic properties of 
the terpyridine, the only affected protons being those of the phenyl ring. Their coordination properties 
should thus be similar. 
A total of 18 metal complexes were synthesized, including four Cu(II) complexes, eight Fe(II) 
complexes, and six Ru(II) complexes.  
A few crystal structures were obtained, confirming that terpyridine complexes are constituted of 
two perpendicular planes, whereas salophen remains planar. 1H NMR showed consistent results, 
protons 5,5’’ and 6,6’’ being shielded due to the anisotropy cone of the other terpyridine. 
The spectrophotometric characteristics of the different complexes were assessed, showing 
various properties. In particular, RuL2 complexes revealed lower fluorescence properties than 
Fe(tpy)2, possibly due to rotation of the phenyl ring. Yet, this could be sufficient to test them as probes 
for amyloid-β aggregation (see Chapter IV.I.1.c).  
Finally, cyclic voltammetry confirmed that Cu(II) and Ru(II) complexes were able to cycle to 
Cu(I) and Ru(III) in a reversible way, making possible their use in catalysis.   
Given all of this, the next step was to study the interaction of the different metal complexes and 
amyloid-β fibres. 
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Chapter IV.  Study of metal complexes - amyloid fibres 
interaction 
Introduction 
Biologists dispose of a wide set of techniques to study protein-ligand interactions. In solid state, 
X-ray crystallography is widely used to resolve the three-dimensional structure of protein-ligand 
complexes and identify molecular determinants involved in molecular recognition. In solution, 
calorimetric techniques, such as Isothermal Titration Calorimetry, and hydrodynamic techniques, such 
as Dynamic Light Scattering, are powerful tools to obtain thermodynamic constants of the protein-
ligand interaction. Spectrophotometric techniques, such as Infrared or Circular Dichroism also 
represent convenient techniques for this type of investigations.  
Unfortunately, all these techniques require either soluble or crystalline proteins, which is not the 
case of amyloid fibres. They are also too large to be studied by solution NMR. To highlight the 
interaction between Aβ fibres and metal complexes, we propose to run indirect measurements looking 
for variations of metal complex or fibre properties upon interaction. 
This chapter describes our investigations on complexes-fibre interaction. Because the 
development of recombinant peptide was still in progress at this time, these studies were 
conducted using commercial synthetic Aβ1-40 peptide. 
The first part describes experimental assessment of fibre-complex interaction. Firstly, 
qualitative results are obtained from spectrophotometric studies on metal complex in presence of 
fibres. More quantitative results are then obtained from indirect UV-Vis titration.  
To investigate metal complexes binding site(s), studies were conducted on several truncated Aβ 
peptides, using solution NMR and UV-Vis titration. The nature of the interaction motif was also 
considered, using fragment molecules. 
In a second part, docking studies were conducted on fibres models using selected complex 
candidates, seeking for insights on the nature of fibre-complex interaction. 
All of this allowed finding complexes candidates that display good affinity for amyloid fibres, 
and gave clues on interaction determinants.  
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I.   Interaction studies  
I.1. Validation of metal complex-fibres interaction 
Because we had no preliminary report on the binding of polypyridine metal complexes to 
amyloid fibres, a first step thus consisted in investigating the possible binding of the whole series of 
metal complexes synthesized (see Chapter III.II). To avoid interference with fibre formation, we chose 
to put aside Cu(II) complexes and to focus on Fe(II) and Ru(II) complexes (Scheme 28).  
I.1.a. Effect of metal complexes on aggregation kinetics 
A first study to evaluate the interaction between Aβ1-40 fibres and metal complexes consisted in 
looking for a variation of Aβ1-40 aggregation kinetics. In the case of Th-T, which is used to monitor 
fibre formation (Chapter I.III.2.a), it was shown that its presence during the aggregation process was 
actually promoting aggregation, Th-T playing the role of template and pre-organizing peptides for a 
faster self-assembly [135]. To be able to detect aggregation, the presence of Th-T is mandatory. We 
thus proposed to run aggregation experiments in the presence of both Th-T and metal complexes. A 
significant modification of aggregation kinetics would be a first evidence of interaction between metal 
complexes and fibres. 
Figure 40 shows the Th-T monitored aggregation curves obtained for Aβ1-40 alone and in the 
presence of Fe(L1)2 or Fe(bpy)3. Because stock solutions of complexes are in acetonitrile, a 
corresponding control with identical amount of acetonitrile was performed.  
Scheme 28: Metal complexes used in this study. 
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It appears that the presence of Ru(bpy)3 weakly affects aggregation kinetics, its aggregation 
half-times (t1/2) being close to the peptide alone (ca. 22 h and ca. 29 h, respectively). Contrariwise, 
Ru(L1)2 and Ru(L3)2 drastically alters aggregation course, with a half-time around 4 h. Ru(L2)2 has an 
intermediate effect. Fluorescence intensity of the plateau (I) is also drastically modified. Because this 
effect does not correlate with variations in t1/2, we attribute this to an inner-filter effect of complexes 
that would absorb part of the light emitted by Th-T [133,214]. Differences between complexes would 
thus be due to their intrinsic spectrophotometric properties. 
This aggregation experiment was reproduced with different available metal complexes. The 
variations in t1/2 and I are shown in Table 7. 
Table 7: Variation of the t1/2 of Aβ1-40 aggregation in presence of various coordination complexes. Complexes displaying 
important effect are highlighted in bold. 
Compound Δt1/2 (%) ΔI (%) 
Ru(bpy)3 24 95.2 
Ru(phen)3 34 95.5 
Ru(tpy)2 25 95.6 
Ru(L1)2 85 96.5 
Ru(L2)2 56 78.4 
Figure 40: Effect of metal complexes on Aβ1-40 aggregation kinetics. Aggregation assay was performed with Aβ1-40 alone 
or in the presence of Ru complexes. Insert shows a zoom on Ru(L1)2 aggregation curve.  Conditions: [Aβ1-40] = 50 μM, [Th-
T] = 10 μM, [PB] = 50 mM, [complex] = 50 μM, pH = 7, ACN 5%.  
0
500
1000
1500
2000
2500
3000
0 10 20 30 40 50 60 70
Fl
uo
re
sc
en
ce
 in
te
ns
ity
 (A
.U
.)
Time (h)
Aβ40
Aβ40 + Ru(L3)
2
Aβ40 + Ru(bpy)
3
Aβ40 + Ru(L2)
2
Aβ40 + Ru(L1)
2
20
40
60
80
100
0 5 10 15 20 25 30
  

Study of metal complexes - amyloid fibres interaction 

 
94 
 
Ru(L3)2 78 42.5 
Fe(bpy)3 0 5 
Fe(L1)2 83 95.5 
Fe(L2)2 19 38.9 
Fe(L3)2 77 49 
Fe(L4)2 77 89 
Fe(L5)2 83 92 
 
It appears that only complexes of phenyl-terpyridine affect aggregation kinetics. Interestingly, 
Ru(L1)2 has similar effect as Fe(L1)2, as well as Ru(L3)2 has similar effect as Fe(L3)2. L4 and L5 
complexes also seem to promote interaction, whereas the effect of L2 complexes is less defined. The 
lack of correlation is confirmed between Δt1/2 and ΔI, confirming the hypothesis of inner-filter effect. 
This study attests of an effect of some metal complexes on Aβ1-40 aggregation, but is not 
sufficient to confirm an interaction. More quantitative experiments were thus designed to validate the 
incorporation of metal complexes into fibres.  
I.1.b.  Indirect quantification of bound species 
 Because it was not possible to directly quantify the amount of compound inserted into fibres, 
we proposed an indirect method based on spectrophotometric titration. At the end of the aggregation 
process, wells are sampled and centrifuged to separate fibres from soluble species. Complex 
concentration is then assessed by UV-Vis titration of the soluble fraction. Comparison with negative 
controls in absence of fibres allows the evaluation of the amount of metal complexes inserted into 
fibres. A schematic representation of this protocol is given in Scheme 29.  
Scheme 29: Experimental protocol for quantification of inserted complex. 
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Several biases can arise from such an experiment. (a) First, a precipitation of complexes could 
be observed when diluted into buffered solution, or while incubating. To take this into account, 
negative controls were prepared in the exact same conditions. (b) Non-specific coprecipitation of 
complexes together with fibres could also be observed. To evaluate this, we have proposed to wash 
fibres with ACN, to remove unbound complexes. However, only traces of complexes were recovered, 
showing the limited extent of coprecipitation. (c) Competition between ligands and peptide to chelate 
metal ions could be envisaged. But we have shown that the UV-Vis signature of complexes was 
unchanged in presence of monomeric Aβ peptide. (d) Finally, it was mandatory to confirm the 
presence of fibres (oppositely to amorphous aggregates). To do so, Th-T control wells were 
systematically added, and samples were periodically submitted to atomic force microscopy. 
Considering all of this, we approximate in the following that the amount of complex disappearing 
from solution was equal to the amount of complex inserted into the fibres, although keeping in mind 
these potential biases.  
Figure 41 shows fibre samples before and after centrifugation. A first visual estimation allows 
to conclude that L1 metal complexes (tubes 2 and 6) and L3 metal complexes (tubes 4 and 8) seem to 
insert into fibres, affording a colourful pellet upon centrifugation. L2 complexes seem to have 
moderate incorporation (tubes 3 and 7), while none is observed for Ru(bpy)3 (tube 5). This correlates 
with the previously reported variations in aggregation kinetics of Aβ1-40 (Figure 40). Corresponding 
controls in absence of fibres show no metal complex precipitation.  
The resulting supernatants were submitted to UV-Visible titration to quantify the amount of 
complexes in the soluble fraction. To take into account the possible precipitation of complexes in 
these buffered conditions, corresponding controls containing no Aβ were considered.  
The amount of metal complexes inserted into fibres was deduced by difference between the 
initial amounts of metal complex minus the amount left in the supernatant. The results appear in Table 
8, confirming the visual evidence: complexes of L1 and L3 get incorporated much better than others. 
Figure 41: Tubes containing fibres mixtures before and after centrifugation. 
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Table 8: Amount of metal complexes inserted into Aβ1-40 fibres during aggregation process. 
Complex % Inserted complex 
Ru(bpy)3 1 
Ru(phen)3 2 
Ru(tpy)2 3 
Ru(L1)2 55 
Ru(L2)2 0 
Ru(L3)2 100 
Fe(bpy)3 10 
Fe(L1)2 81 
Fe(L2)2 0 
Fe(L3)2 99 
Fe(L4)2 67 
Fe(L5)2 93 
 
It seems that Fe(L3)2, Ru(L3)2 and Fe(L5)2 can incorporate one complex for one peptide. This 
ratio is slightly lower for Fe(L1)2, Ru(L1)2 and Fe(L4)2.  
I.1.c.  Spectrophotometric evidences of interaction 
For small molecules, moving from solution to fibres constitutes a drastic change, comparable to 
a shift from aqueous to hydrophobic environment [215]. The solvation of the molecule is thus affected 
by this variation. Binding to fibres also decreases intramolecular rotations in the molecule, which 
results in modifications of fluorescence properties [216]. This affects the spectrophotometric 
properties of molecules, and thus constitutes a tool for investigating interaction.  
(a) Effect of interaction on UV-Vis spectra 
For a ligand, interaction with amyloid fibres is similar to a shift from an aqueous environment 
to a hydrophobic environment. This difference in solvation results in variations of their UV-Vis 
spectra. This is the case for Th-T, whose λmax goes from 410 nm to 420 nm upon interaction with Aβ 
(Figure 42, red curves) [217].  
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In the same way, Ru(L1)2 displays a red shift upon incorporation into fibres, but of lower 
amplitude (λmax = 495 nm to λmax = 500 nm), as shown on Figure 42.  
 
(b) Effect of interaction on fluorescence spectra 
In the case of Th-T, interaction with fibres induces a shift in emission wavelength together with 
an increase in quantum yield. These effects are attributed to an immobilization of Th-T in fibres: the 
benzylamine ring and the benzothiazole ring are prevented from rotation, which results in the 
stabilization of Th-T fluorescence excited state, resulting in an enhanced fluorescence [132]. 
Investigations were conducted on fluorescent Ru(L1)2 complex, trying to see if similar effects can be 
observed.  
Figure 43 displays emission spectra obtained for Ru(L1)2 alone (red) and in presence of Aβ1-40 
fibres (green). Corresponding control containing only Aβ1-40 fibres appears in blue.  
It appears that fluorescence of Ru(L1)2 at 660 nm is enhanced by approximately 50% in the 
presence of fibres. A slight shift of λem may be noted, but spectra resolution does not allow a precise 
determination.  
The effect of interaction on Ru(L1)2 is considerably less important than for Th-T. Indeed, 
fluorescence comes from a MLCT state of Ru(tpy)2 (see Chapter III.II.3.d), whose coordination is 
rather rigid. Although the immobilization of the p-amino phenyl ring could contribute to the observed 
fluorescence enhancement, its effect should be of limited extent.  
Figure 42: UV-Vis monitoring of absorption shift of metal complexes upon insertion in fibres. Spectra were recorded for 
fibres containing only Th-T (red line) or in presence of 0.5 eq (green line). Corresponding negative controls without peptide 
appear in dashed lines. Conditions: [Aβ1-40] = 50 μM, [Th-T] = 10 μM, [PB] = 50 mM, [complex] = 50 μM, pH = 7, 
aggregation for 4 days at 37°C.  
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Yet, the enhanced fluorescence of Ru(L1)2 in the presence of fibres constitutes a proof of 
interaction. However, it does not give information on the strength of this interaction or on the nature of 
the binding site. NMR experiments were thus envisaged to answer these questions. 
I.1.d. NMR experiments 
Solution NMR being limited to proteins below 35 kDa, it cannot be applied to amyloid fibres 
[218]. In order to highlight its interaction with metal complexes, NMR experiments were run on 
monomeric Aβ1-40. The existence of an interaction with monomeric peptide does not imply a similar 
interaction with fibres because peptide configuration in monomeric and fibrillary states are very 
different [139]. Yet, it gives preliminary information on the propensity of metal complexes to interact 
with peptides. 
(a) 1H NMR 
1H NMR spectra of Aβ1-40 were recorded in the presence or absence of metal complexes, total 
amount of ACN being identical (Figure 44). In the aromatic region of the spectra, a broadening of the 
signals is observed, attesting of an interaction. Tyr (6.6 ppm) and His (7.0 and 7.6 ppm) signals 
become particularly large. In the aliphatic region, Ala signal (1.25 ppm) is also broadened. However, 
no splitting of peaks is observed, in line with a weak interaction. Expectedly, aromatic amino acids 
seem to be the most involved in the interaction. 
Figure 43: Enhanced fluorescence of Ru(L1)2 inserted in fibres. Emission spectra were recorded at the end of aggregation 
for Aβ1-40 50 μM (blue line), Ru(L1)2 50 μM (red line) and for a mixture of both (green line). Conditions: [Aβ1-40] = 
[complex] = 50 μM, [PB] = 50 mM, pH = 7, aggregation for 4 days at 37°C, λexc = 490 nm. 
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(b)  DOSY NMR 
A typical experiment allowing highlighting the interaction between a protein and its ligand 
consists in measuring their diffusion coefficients. Upon interaction with the protein, the ligand loses 
mobility, and its diffusion coefficient decreases. To a certain extent, it is possible to extract a global 
binding constant of the system. In order to study diffusion coefficients, a DOSY NMR experiment was 
set up [219].  
Figure 45: DOSY NMR spectrum evidencing Aβ1-28 - Fe(L1)2 interaction. Blue line: diffusion of Fe(L1)2, green line: 
diffusion of Aβ1-28. Conditions: [Aβ1-28] = 200 μM, [PB] = 50 mM, [Fe(L1)2] = 200 μM, pH = 7. Spectrum recorded on 500 
MHz NMR. 
Figure 44: Effect of metal complexes on Aβ1-40 1H NMR spectrum. (a) Aβ1-40 alone, (b) Aβ1-40 with Fe(L1)2, (c) Aβ1-40 with 
Fe(L3)2. Experimental conditions: [Aβ1-40] = 200 μM, [PB] = 50 mM, [complex] = 200 μM, pH = 7, total ACN-d3 content 
of 10% in each tube. Spectra recorded on 500 MHz NMR.
(a) 
 
(b) 
 
(c) 
His His Tyr Ala 
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Because this experiment requires long accumulation times (especially at low peptide 
concentration), it was not possible to proceed with Aβ1-40, which aggregates too fast. We thus studied 
the variation of Fe(L1)2 diffusion coefficient in the presence of monomeric Aβ1-28. To do so, DOSY 
NMR spectra of Fe(L1)2, Aβ1-28, and of a mixture of both were recorded (Figure 45).  
In the horizontal dimension appears the 1H NMR signal of the mixture, and in the vertical 
dimension the diffusion coefficients of the different species. Two sets of spots are present, 
corresponding to Fe(L1)2 (blue line) and to the peptide (green line). Precise diffusion coefficients were 
extracted from spectra and presented in Table 9. 
Table 9: Diffusion coefficients obtained by DOSY NMR. 
Compound Diffusion coefficient (m2.s-1) 
Aβ1-28 0.76 e-10 
Fe(L1)2 3.10 e-10 
Aβ1-28+ Fe(L1)2 1.78 e-10        0.76 e-10 
 
As expected, the diffusion coefficient of Fe(L1)2 is modified in presence of peptide, going from 
3.1e-10 to 1.78e-10 m2.s-1. Yet, the diffusion coefficient of Fe(L1)2 upon interaction remains different 
from the peptide’s. This result is in line with a weak interaction between Fe(L1)2 and Aβ1-28, with an 
estimated Kd of 10-4 M. The equations used for Kd determination appear in Annex I. 
Unfortunately, this experiment could not be reproduced with Fe(L3)2 due to solubility issues. 
I.1.e.  Conclusion: Interacting species 
These studies highlight that four species seem to interact with Aβ1-40 fibres: Fe(L1)2, Fe(L3)2, 
Ru(L1)2 and Ru(L3)2. All of them were shown to accelerate aggregation kinetics, possibly pre-
organizing peptides and facilitating their auto-assembly, and all were shown to efficiently incorporate 
into Aβ1-40 fibres. L3 complexes seem to incorporate in stoichiometric ratios compared to the peptide, 
which could denote the existence of several binding sites according to the side-chain channel model. 
L1 complexes incorporate in lower ratios, which could be attributed to different binding sites or 
affinities. Solution NMR demonstrates a weak interaction between the monomeric form of peptide and 
Fe(L1)2, but do not allow to conclude on interacting residues. Further studies were thus conducted to 
better understand interaction sites in fibres. 
  
  

Study of metal complexes - amyloid fibres interaction 

 
101 
 
I.2.  Investigation of metal complex binding sites 
I.2.a.  Investigation of Thioflavin-T binding site 
Gaining insights on ligand binding sites in Aβ fibres is very difficult, and limited information is 
available on the amino acids involved in interactions with ligands. In the case of Th-T, experimental 
and computational studies have suggested that binding site(s) are located in side-chains channels, Th-
T being parallel to the fibre axis (Chapter I.III.2.a), but no interaction with specific amino acids was 
reported [132].   
A first investigation consisted in titrating unbound Th-T at the end of the aggregation process. 
As described before for metal complex quantification (Scheme 29), wells containing fibres were 
sampled and centrifuged, and supernatants were analysed by HPLC. Amount of unbound Th-T 
allowed determining the amount of Th-T inserted in fibres. 
Table 10: Amount of Th-T inserted into Aβ1-40 fibres during aggregation process in presence of various metal complexes. 
Conditions: [Aβ1-40] = 50 μM, [Th-T] = 10 μM, [PB] = 50 mM, [complex] = 50 μM, pH = 7, ACN 5%. 
Complex % Inserted Th-T 
Ru(bpy)3 50 
Ru(L1)2 38 
Ru(L2)2 43 
Ru(L3)2 66 
Fe(bpy)3 36 
Fe(L1)2 31 
Fe(L2)2 39 
Fe(L3)2 45 
Ø 43 
 
Table 10 shows results obtained for Th-T quantification, showing limited variations. It seems 
that none of the complexes prevent Th-T from inserting into fibres.   
To confirm this first result, a competition assay was set up between interacting complexes and 
Th-T. To address this objective, aggregation assays were run in presence of increasing amounts of 
metal complexes. At the end of aggregation, samples were centrifuged and soluble fractions were 
analysed by HPLC to evaluate the amount of unbound Th-T. Results are reported on Figure 46. 
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It appears from these data that both metal complexes display low affinity for Th-T binding site. 
Indeed, 75 μM of metal complex are needed to displace 1 μM of Th-T. In other words, in the case of 
Ru(L3)2, which fully incorporate in fibres at 50 μM, this means that among the 50 μM of complex 
inserted, only ca. 0.25 μM take the place of Th-T (Figure 46, black arrow). This amount can be 
considered as negligible, leading to the conclusion that Th-T and metal complexes bind Aβ1-40 fibres in 
different sites.  
I.2.b.  Incorporation in fibres made of truncated peptides  
Another experiment enabling to gain further insights into metal complex binding sites consists 
in studying their incorporation into fibres made of truncated Aβ peptides [220]. We focused on Aβ11-28 
peptide, which comprises the hydrophobic core of Aβ [221], and Aβ1-28 which holds Aβ N-ter end 
[222] (Scheme 30). By comparison with results obtained with Aβ1-40, some information could be 
retrieved on the residues involved in the interaction. For example, if metal complexes display affinity 
for the N-ter end of peptides, there should be no incorporation in Aβ11-28, etc. Aggregation assays were 
thus run with Aβ1-28 and Aβ11-28, in the presence of stoichiometric amounts of metal complexes. 
Figure 46: Th-T displacement by metal complexes. Unbound Th-T was quantified in the end of Aβ1-40 aggregation in the 
presence of Ru(L1)2 (blue) or Ru(L3)2 (green) in variable concentrations. Conditions: [Aβ1-40] = 50 μM, [Th-T] = 10 μM, 
[PB] = 50 mM, [complex] = variable, pH = 7.  
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Scheme 30: Amino acid sequences of Aβ11-28, Aβ1-28, and Aβ1-40. 
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Because they are less aggregation-prone compared with Aβ1-40, aggregation parameters are 
slightly different for Aβ11-28 and Aβ1-28. Firstly, to work in comparable time frame, their aggregation 
has to be triggered by addition of 0.5 eq Zn(II) [223]. In the case of Aβ1-28 concentration is also 
increased to 100 μM, to promote auto-assembling. Metal complex and Zn(II) concentrations were thus 
increased accordingly. Finally, their aggregation is monitored at 25°C. Aggregation curves obtained 
appear in Figure 47. 
As for Aβ1-40, a decrease of fluorescence intensity is observed in presence of metal complexes, 
particularly noted for L1 complexes. A variation in t1/2 cannot be distinguished for Aβ11-28 due to a very 
fast aggregation process. Despite differences in curve profiles, it seems that no variations in t1/2 can be 
observed for Aβ1-28. Unbound complexes were quantified at the end of aggregation following the 
previously described procedure (Scheme 29). Table 11 gathers the results obtained. 
Table 11: Amount of metal complexes inserted into Aβ11-28, Aβ1-28, Aβ1-40 fibres during aggregation process. 
Complex Aβ1-40 Aβ1-28 Aβ11-28 
Ru(L1)2 55% 0% 0% 
Ru(L3)2 100% 4% 0% 
Fe(L1)2 81% 0% 0% 
Fe(L3)2 99% 17% 40% 
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Figure 47: Aggregation curves obtained for Aβ11-28 and Aβ1-28 in presence of various metal complexes. A: Curves obtained 
for Aβ11-28. Conditions: [Aβ11-28] = [complex] = 50 μM, [Th-T] = 10 μM, [ZnSO4] = 25 μM, [PB] = 50 mM, pH = 7, 25°C. 
B: Curves obtained for Aβ1-28. Conditions: [Aβ1-28] = [complex] = 100 μM, [Th-T] = 10 μM, [ZnSO4] = 25 μM, [PB] = 50 
mM, pH = 7, 25°C. 
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These results indicate that metal complexes incorporation is very specific to Aβ1-40 fibres, and 
does not occur with Aβ1-28 or Aβ11-28. An explanation could be the affinity of metal complexes for 
specific residues situated between Gly29 and Val40. However, a difference in the peptide 
conformation in fibres cannot be excluded [142]. As such, some amino acid side chains may be 
oriented outwards of the fibre in the case of Aβ1-40, and inwards in truncated peptide fibres, which 
would explain the absence of interaction in the latter case.  
To investigate this last hypothesis, an NMR study was carried out with the monomeric truncated 
peptides. 
I.2.c.  NMR evidence of binding sites 
To compare the binding abilities of the different peptides, we propose to examine 1H NMR 
spectra of peptides in the presence of ligands. The shift, enlargement, or splitting of certain peaks 
provide information on the amino acids interacting with the complexes.  
Figure 48 shows aromatic region of 1H NMR spectra of Aβ11-28, Aβ1-28 and Aβ1-40 in the 
presence of Fe(L1)2 and Fe(L3)2. As region 29-40 does not contain any aromatic residues, we focused 
on aliphatic region of spectra. Although slight differences exist between spectra, no significant 
variation can be observed in presence of metal complexes, either in the aliphatic or in the aromatic 
region. It seems that 1H NMR of monomeric peptide does not constitute an appropriate model for 
metal complex-fibres interaction. At this stage, an interaction with residues 29-40 thus cannot be 
confirmed or excluded.  
I.2.d.  Conclusion: Metal complex binding site 
Even though these experiments do not allow concluding on the nature of binding site(s), they 
provide different pieces of information. First of all, we learnt that metal complexes bind very weakly 
to Th-T binding site in Aβ1-40. Other binding sites might exist for metal complexes.  
Metal complexes do not get incorporated within fibres made of truncated peptides. The 
difference of incorporation could be due either to a specific interaction with residues from segment 29-
40, or to a difference in fibre structures. Unfortunately, 1H NMR on monomeric peptide did not allow 
concluding on this point. ssNMR would constitute an appropriate alternative to investigate residues 
involved in interaction. 
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Aβ1-40 
Aβ11-28 + Fe(L1)2 
Aβ11-28  
Aβ11-28 + Fe(L3)2 
Aβ1-28 + Fe(L1)2 
Aβ1-28  
Aβ1-28 + Fe(L3)2 
Figure 48: 1H NMR spectra of Aβ1-40, Aβ1-28 and Aβ11-28 in the presence of metal complexes. Experimental conditions: 
For Aβ1-40: [Aβ] = [complex] = 200 μM, [PB] = 50 mM, pH = 7, total ACN content of 10%. Spectra recorded on 500 MHz 
NMR. For Aβ11-28 and Aβ1-28: [Aβ] = [complex] = 500 μM, [PB] = 50 mM, pH = 7, total ACN content of 10%. Spectra 
recorded on 400 MHz NMR. 
Aβ1-40 + Fe(L1)2 
Aβ1-40 + Fe(L3)2 
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I.3.  Investigation of recognition patterns 
Among the metal complexes tested, the best interaction with fibres seems to be achieved by L1 
and L3 complexes. To better understand what the recognition motif in these structures is, we compared 
the interaction of different fragment molecules with Aβ1-40 fibres.  
I.3.a. Incorporation of fragment molecules 
(a) Case of L1 complexes 
Table 12 displays the results obtained for incorporation of fragment molecules of L1 in Aβ1-40 
fibres. 
Table 12: Insertion of fragment molecules from L1 complexes in Aβ1-40 fibres during aggregation process. Conditions: 
[Aβ1-40] = 50 μM, [Th-T] = 10 μM, [PB] = 50 mM, [compound] = 50 μM, pH = 7, ACN 5%.  
Compound Structure % Inserted 
Fe(L1)2 
 
81 
Ru(L1)2 
 
55 
Ru(tpy)2 
 
3 
L1 
 
42 
Aniline  8 
 
Several observations arise from these results. Firstly, the presence of p-amino phenyl on the 
terpyridine appears crucial for the interaction. Though, the result obtained with aniline shows that this 
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motif is not sufficient to promote interaction. A hypothesis would be that the presence of three 
aromatic rings is required to promote interaction. 
Secondly, the interaction of fibres with L1 metal complexes is similar to that with free L1. 
Because the ligands are in perpendicular planes, it is unlikely that they have additive contributions to 
the interaction. From this, one can conclude that interaction is predominantly promoted by ligand. 
Finally, the shift from Fe(II) to Ru(II) seems to slightly decrease the interaction. These 
complexes being isostructural, there is no structural reason for this difference. 
(b) Case of L3 complexes 
Similar experiments were run for L3 complexes, the results appear in Table 13. 
Table 13: Insertion of fragment molecules from L3 complexes in Aβ1-40 fibres during aggregation process. Conditions: 
[Aβ1-40] = 50 μM, [Th-T] = 10 μM, [PB] = 50 mM, [compound] = 50 μM, pH = 7, ACN 5%. 
Compound Structure % Inserted 
Fe(L3)2 
 
99 
Ru(L3)2 
 
100 
Ru(tpy)2 
 
3 
L3 
 
N/D 
 
Here again, quantification of incorporated compounds seems to strongly rely on the presence of 
the p-nitro phenyl group on the pyridine, evidenced by the drop between Ru(L3)2 (100% inserted) and 
Ru(tpy)2 (3% inserted). Contrariwise to L1 complexes, the switch from Fe(L3)2 to Ru(L3)2 does not 
affect the incorporation. Control experiment with L3 could not be achieved due to solubility issue. 
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I.3.b. STD NMR experiment 
 Another NMR experiment available to investigate peptide-complex interaction is Saturation 
Transfer Difference (STD). This technique relies on the fact that when a protein is irradiated to 
saturation, this saturation is transferred to its ligand by spin diffusion. In the case of weak-binding 
ligands (Kd from 10-8 to 10-3 M), the signal of bound ligands should then decrease. The STD spectrum 
is obtained by subtracting this saturation spectrum to a standard one (i.e. without protein saturation). 
The signals appearing on the STD spectrum correspond to hydrogen atoms of the molecule interacting 
with the protein [224]. Figure 49 displays spectra obtained for STD experiment with monomeric Aβ1-
40 in the presence of Fe(L1)2. Three signals appear on the difference spectrum (middle) corresponding 
to Fe(L1)2. These peaks do not appear on control spectrum (bottom). This attests of a weak interaction 
between the complex and the peptide. Despite a low resolution, it seems that the signal of protons 3’ 
and 5’ (ca. 9 ppm) and of protons 5, 5”, 6 and 6” (ca. 7.3 ppm) are the more intense, and would thus 
be the more involved in interaction. Figure 49.B shows the numbering scheme of L1, protons involved 
in interaction appearing in red. On this scheme, all the protons were represented on one ligand for 
simplification, but they could also be distributed on both ligands. However, because ligands are in 
perpendicular planes, it is unlikely that the same protons of both ligands interact in the same way with 
the fibre. 
 
Figure 49: STD NMR experiment. A: Top: 1H NMR of Aβ1-40 with Fe(L1)2. Middle: STD difference spectrum.* indicates 
appearing signals. Bottom: control without Aβ1-40. B: Numbering scheme of Fe(L1)2, atoms in red are those displaying 
signals on STD spectrum. Conditions: [Aβ1-40] = 50 μM, [PB] = 50 mM, [Fe(L1)2] = 1 mM, pH = 7. Spectra recorded on 
500 MHz NMR. 
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I.3.c.  Conclusion: Recognition pattern 
Athought it is difficult to define a precise recognition pattern in our complexes, several points 
can be underlined. Firstly, the presence of a phenyl ring on the terpyridine ligand holding a p-amino or 
p-nitro group is mandatory to get interaction. However, phenyl amine alone is not sufficient to 
promote interaction. The presence of metal ion slightly modifies the interaction, indicating that 
interaction properties are mainly held by ligands. In complexes, the two p-amino phenyl terpyridine 
ligands are in perpendicular planes, centred on the metal ion (Scheme 31.A). It is thus unlikely that 
both side pyridines of a ligand could interact with fibres at the same time. All of this led us to consider 
the minimal recognition motif as constituted by a lateral pyridine, the central pyridine, and the phenyl 
ring, as appears in red on Scheme 31.B. 
From this, we imagined a binding model for Fe(L1)2 that encompasses the different interactions 
observed experimentally, i.e. with the amino group, the phenyl ring, and a side pyridine (Scheme 
31.C). This model is very preliminar, considering fibres as linear channels.  
When comparing structures, a similarity is observed between Th-T and L1 and L3, all of them 
being composed of a phenyl substituted by a nitrogen group (either nitro or amino) and by an aromatic 
heterocycle in para position (either pyridine or benzothiazole) (Scheme 31.D). This motif is found in 
various amyloid probes [173]. Both Th-T and metal complexes are also positively charged, the charge 
being higher (+II) but farther from the phenyl ring in the case of metal complexes.This motif could 
serve as a starting point for elaboration of probes for Aβ fibres (see Chap 5). 
A 
B 
Scheme 31: Interaction pattern of metal complexes. A: Fe(L1)2 crystal structure, atoms proved to be involved in interaction 
appear in red; B: Interaction pattern on Fe(L1)2. C: Proposed model for fibre binding. Grey rectangle represents amyloid 
fibre. D: structure similarities between Th-T, L3 and L1. 
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The only method that would enable concluding unambiguously on the location of metal 
complex binding sites on Aβ1-40 fibres would be ssNMR. Unfortunately, we did not dispose of 
sufficient amounts of materials to run such experiment. To better understand this system, we 
performed computational studies, seeking to identify molecular determinants involved in interactions. 
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II. Modelling hybrid systems 
II.1.  General considerations 
Computational approaches enable to overcome the lack of experimental data and provide 
insightful structural information. Among these techniques, molecular docking constitutes a convenient 
way to predict the possible binding sites of a ligand in a protein. It can also provide some indication 
regarding their binding affinity. However, the lack of crystallographic structure of amyloid fibres is a 
real issue. Because they are hierarchically assembled in one dimension, no crystal formation can be 
envisaged. To overcome this limitation, several studies proposed 3D structural models for Aβ1-40 and 
Aβ1-42 based on NMR experiments. These structures are of lower resolution compared with 
crystallographic structures, and are generally composed of 10 models, all satisfying experimental data. 
Using the 10 models, docking experiments were first carried out using Th-T as ligand. Docking 
results, in terms of binding site location and binding energies were then used as reference for 
comparison with docking of complexes. Molecular docking experiments were run with metal 
complexes, seeking possible interaction sites. Because we had no presupposition on the location of 
binding site(s), the whole fibre was considered. The fibre being constituted of repeating units, we 
chose to consider amino acid side-chain channels as single binding sites. Docking protocol is 
described in Annex I. 
II.2. Amyloid-β 1-40 
II.2.a. Available structures 
Among the available structures of Aβ1-40 fibres in the Protein Data Bank (PDB), we chose to 
focus on the solid state NMR-structure of PDB code 2LMN [141], which was previously used for 
docking experiments [225,226]. Fibre is composed of two filaments, made of six peptides each. 
Structure 2LMN is constituted of 10 models, each fitting with experimental data.  
Figure 50.A shows the model 1 of structure 2LMN. It is composed of two filaments, each of 
them having a β-turn shape. Hydrophobic residues (red) are mainly pointing inwards β-turns, whereas 
polar (green), acidic (blue) and basic (yellow) residues are pointing outwards. The two filaments are 
stacked by their most hydrophobic face (i.e. residues 31-37). Amino acids involved in β-turn 
stabilization are Phe19, Ile32 and Leu34, whereas residues Gly33 and Met35 promote inter-filament 
interaction.  
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When comparing all 10 models of 2LMN structure, it appears that both filaments contain some 
rigid regions, whereas other regions are more flexible (conformationally variable). Figure 50.B shows 
a superposition of models 1, 5 and 10 for the first peptides of each filament. It reveals that residues 17-
22 and 31-36 (blue) are well superposed, indicating no conformational variability. Contrariwise, 
conformation of residues 9-16, 23-30 and 37-38 appears to vary significantly upon the model (red). 
This enables to distinguish two types of regions, either rigid or flexible.  
 
 
II.2.b. Docking: Th-T 
The first step of our docking study consisted in testing the different models of 2LMN to choose 
one that would be representative for further studies. To do so, we chose Th-T as a model ligand, as its 
interaction with fibres is experimentally validated (see Chapter I.III.2.a). The results obtained are 
summarized in Table 14. Three main sites are highlighted: in the channel delimited by Ala21 and Ile32 
(site A), at the interface between filaments between Ile31 and Val39/40 (site B), and in the β-turn 
between Val36 and Gln15 (site C). The corresponding sites are highlighted in Figure 51. 
 
 
 
 
 
Figure 50: Solid-state NMR structure of Aβ1-40 fibres (PDB code: 2LMN). A:  2LMN model 1. Red: non-polar residues, 
green: polar residues, yellow: basic residues, blue: acidic residues. Side-chains of peptides 2-6 and 8-12 are omitted for 
clarity. B: Superposition of models 1, 5 and 10 of the first peptides each filament.  Regions in blue are rather rigid, 
whereas regions in red are more flexible. 
A B 
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Table 14: Percentages of docking solutions and corresponding energies obtained for the docking of Th-T on the different 
models of 2LMN. Results in bold highlight the main binding site.  
Model 
Site A Site B Site C 
Percentage 
of solutions 
(%) 
Lowest 
binding 
energy 
(kcal/mol) 
Percentage 
of solutions 
(%) 
Lowest 
binding 
energy 
(kcal/mol) 
Percentage 
of solutions 
(%) 
Lowest 
binding 
energy 
(kcal/mol) 
1 28 -8.31 64 -7.17 7 -6.43 
2 42 -7.62 9 -6.42 9 -6.35 
3 20 -7.31 71 -7.30 3 -6.62 
4 19 -8.18 33 -7.32 46 -6.87 
5 14 -7.91 50 -7.68 22 -7.80 
6 53 -8.61 3 -6.99 38 -7.72 
7 42 -7.56 20 -7.47 21 -7.18 
8 46 -8.39 0 / 52 -7.17 
9 32 -8.36 0 / 64 -9.60 
10 3 -7.23 42 -6.80 32 -6.83 
 
The existence of three different binding sites for Th-T has been reported in literature, without 
evidence on the involved residues [227]. When comparing the three sites, it appears that the 
percentage of solutions for each site varies significantly from a model to another, and it seems that 
solutions are distributed along the three sites, with distinct populations. The important dynamic 
character of binding sites can explain this important variability. Indeed, the three sites reported are 
located at the interface between the “flexible regions” and the “rigid regions” previously described. 
The important mobility of the backbone in flexible regions can prevent Th-T insertion in some 
models, and promote binding into others. In all cases, Th-T is positioned into grooves parallel to the 
fibre axis, as reported in literature [132,228,229].  
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To be able to compare complexes and Th-T binding sites, we chose to work with a model in 
which the three binding sites for Th-T are accessible. For further studies with metal complexes, model 
7 was thus chosen as an average model of 2LMN. 
II.2.c.  Docking: Fe(L1)2 and Fe(L3)2  
Docking experiments were run for Fe(L1)2 and Fe(L3)2 into 2LMN model 7. A vast majority of 
solutions (100% for Fe(L1)2, 87% for Fe(L3)2) positioned metal complexes at the end of the fibre 
(Figure 52). The corresponding binding energies are very favourable (-9.6 kcal/mol). This experiment 
thus confirms that unlike Th-T, metal complexes cannot intercalate in grooves of β-turns, or at the 
interface of filaments. Of note, no binding site on the external faces of fibre was observed. This could 
be due to the fact that the 2LMN structure is only constituted of six peptides, which is not enough to 
model the fibre amino-acid side-chain channels. 
Figure 51: Representation of 3 distinct representative docking modes of Th-T in 2LMN model 1. A: Top view, B: side 
view, C: molecular surface representation. Th-T binds either in site A (red), site B (green) or site C (yellow). Corresponding 
symmetric binding sites are omitted for clarity. 
A 
B 
C 
A B 
C 
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II.3.  Amyloid-β 1-42 
II.3.a. Available structures  
Only two structures of Aβ1-42 fibres can be found in the Protein Data Bank, referred as 2MXU 
[145] and 2BEG [144]. 2MXU was preferred for our study, as it is more recent and better resolved, 
since benefitting from better technical advances than for 2BEG. It also consists of more peptide 
repeating units than 2BEG, which fits better the side chain channel model. Of note, the recent 2MXU 
structure has never been used for docking experiments in the literature. The docking of Th-T was 
performed to validate the use of 2MXU as fibre model. 
Solid-state NMR structure 2MXU is composed of 12 assembled peptides forming two 
successive β-turns. As for Aβ1-40 model, non-polar amino acids are mostly pointing inwards β-turns, 
whereas polar, acidic and basic ones are mostly pointing outwards (Figure 53.A). A saline bridge 
between Lys28 and the C-term carboxylate further stabilizes the system. 2MXU is composed of 10 
models, each of them satisfying NMR constraints. Figure 53.B shows the superposition of models 1, 5 
and 10 of the first peptide chain. It appears that the conformation of the peptide remains quite similar 
among the 10 models, the only conformational differences were observed in regions being between 
Leu34 and Val36 and between Lys16 and Glu11 (residues in red). Overall, amino acid side-chains 
adopt similar orientations (residues in blue).   
 
B A 
Figure 52: Representations of docking modes for Fe(L1)2 (blue) and Fe(L3)2 (pink) into 2LMN model 7. A: molecular 
surface representation, B: side view. 
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II.3.b.  Docking: Thioflavin-T 
Th-T was docked using the 10 models of 2MXU and considering the whole fibre as protein 
receptor. The results obtained are clear-cut, showing selectivity of Th-T for the channel formed by 
Ile32 and Leu34 (Table 15). Only two models (models 2 and 4) differ led to different results, what can 
be explained by important conformational changes: In model 2, the Ile32-Leu34 channel does not 
exist, Leu34 pointing inward the β-turn. In model 4, a large cavity is present between Ile31 and Val39, 
which hosts Th-T. All other models are in agreement to placeTh-T along the channel Ile32-Leu34. 
 This result validates the use of 2MXU for docking studies: A major solution is found for 8 
models over 10, which is consistent with previously reported side-chain channels binding model of 
Th-T. Because all the models (except 2 and 4) afford similar binding sites of similar binding energies, 
we selected model 1 as an average model for the following studies of complex docking (Figure 54). 
 
 
 
 
 
 
Figure 53: 2MXU model structures for Aβ1-42 fibres. A:  2MXU model 1. Red: non-polar residues, green: polar residues, 
yellow: basic residues, blue: acidic residues. Side-chains of peptides 2-10 are omitted for clarity. B: Superposition of models 
1, 5 and 10 of the first peptide.  Regions in blue are rather static, whereas regions in red are more dynamic.  
A B 
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Table 15: Main docking mode observed for Th-T in the 10 different models of 2MXU and corresponding binding energies 
corresponding to channel Ile32-Leu34.  
Model 
Ile32-Leu34 
Percentage of solutions 
(%) 
Lowest binding energy (kcal/mol) 
1 86 -7.57 
2 37 -5.56 
3 88 -6.80 
4 15 -8.27 
5 95 -6.29 
6 75 -7.04 
7 69 -7.04 
8 79 -7.15 
9 73 -7.60 
10 99 -8.21 
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II.3.c.  Docking: Fe(L1)2 
Similar docking experiment was run with Fe(L1)2. Contrarily to Th-T, three different binding 
sites come apart: between Glu22 and Asp23 (site A), between Asp23 and Gly25 (site B), and between 
Ile32 and Leu34 (site C). Distribution of docking solutions among the three sites (A, B, and C) and 
associated lowest binding energies calculated at each site appear in Table 16, and corresponding 
representations are shown in Figure 55. 
Table 16: Main docking sites identified by docking of Fe(L1)2 in 2MXU model 1.  
 Site A 
(Glu22-Asp23) 
Site B 
(Asp23-Gly25) 
Site C 
(Ile32-Leu34) 
Docking 
solutions 
(%) 
53 25 18 
Lowest 
binding 
energy 
(kcal/mol) 
-6.47 -6.50 -7.05 
Figure 54: Representative docking modes of Th-T in 2MXU model 1. A: Top view, B: Side view, C: molecular surface 
representation. Three representative docking poses of Th-T in the Ile32-Leu34 channel are depicted in yellow, pink, green, 
respectively. 
A B 
C 
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Figure 55: Representative docking poses obtained for Fe(L1)2 in 2MXU model 1.  
Site A 
  

Study of metal complexes - amyloid fibres interaction 

 
120 
 
Site A proposes a binding of Fe(L1)2 along the channel between Glu22 and Asp23. This site is 
stabilized by two hydrogen bonds between an amino group of Fe(L1)2 and the two carboxylate group 
side-chains of Glu22 and Asp23. The interaction involves the two terpyridine ligands of the metal 
complex, one interacting by the amino phenyl moiety, and the other one interacting by a lateral 
pyridine.  
Site B is close to site A, Fe(L1)2 being positioned along the channel between Asp23 and Gly24. 
Here again, the two terpyridine ligands on Fe(L1)2 are involved in interaction, but only one hydrogen 
bonding interaction stabilizes the system. The binding energy is also comparable to result A. These 
two sites are located in regions where the conformation is maintained, and involve residues keeping 
similar orientation in the different models. 
Contrariwise, site C constitutes an “energetically favoured” binding site, but not frequently 
observed. Unlike other results, complex is not distributed along the channel, but localized at the 
entrance of the fibre, and no polar contacts are evidenced between Fe(L1)2 and fibre. More 
importantly, some residues involved in interaction undergo significant conformational variability 
(region 11-16), and the interaction might be weakened if considering fibre dynamics. 
This first docking experiment provides information on Fe(L1)2 binding: (a) Firstly, it validates 
that Fe(L1)2 can bind in side-chain channels of the fibre. (b) It also confirms the experimental evidence 
that the binding of Fe(L1)2 at Th-T site is not favourable. The main binding site for Fe(L1)2 is on one 
side or the other of Asp23, with similar predicted binding energy of -6.50 kcal/mol. From this, Fe(L1)2 
seems to be a slightly weaker ligand than Th-T. (c) According to calculations, interaction between 
fibres and metal complexes is promoted by the amino phenyl moiety and one lateral pyridine. This is 
in good accordance with experimental observations. 
II.3.d. Docking: Fe(L3)2   
Similarly to Fe(L1)2, docking studies were conducted with Fe(L3)2 using 2MXU model 1 as 
receptor. Two main binding sites were observed, whose percentage of solutions and energies appear in 
Table 17. 
Table 17: Main binding sites identified by docking of Fe(L3)2 in 2MXU model 1.  
 Site A 
(Ile32-Leu34) 
Site B 
(Glu11-His13) 
Docking 
solutions (%) 
69 13 
Lowest 
binding energy 
(kcal/mol) 
-8.08 -6.39 
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The main docking pose places Fe(L3)2 at the entrance of the first β-turn (Figure 56 site A).  
Metal complex is positioned slantwise, interacting with both sides of the β-turn motif. On one side, 
Fe(L3)2 is positioned in the channel Ile32-Leu34 (Th-T binding site). On the other side, stacking with 
His14 and H-bonding with NH2 from Glu11 are observed. The predicted binding energy for this 
position is slightly better than for Th-T. However, it is to remind that His14 and Glu11 are highly 
flexible among the different models (see II.3.a). Furthermore, the N-ter amine on Glu11 does not exist 
on WT-Aβ1-42. The interaction of Fe(L3)2 in this site is thus likely to be decreased if considering full-
length Aβ1-42. Molecular Dynamic simulations could be considered to validate this first result. 
The other docking mode positions Fe(L3)2 in the channel between Glu11 and His13 (Figure 56 
site B). The interaction being promoted by a single ligand, and no polar contact was found between the 
complex and the fibre. Expectedly, the calculated energy is thus weaker than for the main site A. Here 
Figure 56: Representative docking poses of Fe(L3)2 in 2MXU model 1. A: Fe(L3)2 binding in site A, interacting with Ile32, 
Leu34, His14 and Glu11. B: Fe(L3)2 binding in site B, interacting with Glu11 and His13. 
Site A 
Site B 
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again, the important dynamic character of the residues involved in the interaction has to be considered, 
and Molecular Dynamic simulations could be beneficial to further investigate this interaction. 
From these results, it seems that Fe(L3)2 is able to bind Aβ1-42 fibres, mainly interacting with 
residues of flexible character. Calculated binding energies are in the same range as for Th-T, but could 
potentially improve when considering the dynamic character of the fibre. 
II.4.  Conclusion: docking studies 
• Th-T 
These docking studies provide insightful information on Th-T binding with fibres. First of all, it 
confirms the experimental evidence that Th-T binds in side chain channels, its axis being parallel to 
the fibre axis in both fibre models. In the case of Aβ1-40, molecular docking suggests that Th-T 
intercalates inside the β-turn motif, and between filaments, whereas with Aβ1-42, the β-turn is too 
packed, and Th-T intercalates in a channel at the entrance of the main β-turn. In both models, Th-T 
binds at the interface between rigid and flexible regions, with estimated binding energies nearly 
similar. 
• Fe(L1)2 
Docking with Aβ1-40 model only yielded binding sites at fibre extremities, probably due to too 
few repetition units in the fibre model. From study with Aβ1-42 fibre model, Fe(L1)2 appears to be able 
to bind fibres in side-chain channels. The interaction is promoted by both ligands, and stabilized by H-
bond interactions between the amino group on terpyridine and carboxylate side chains of amino acids. 
The calculated binding energy is slightly higher than for Th-T. This binding mode is fully compatible 
with experimental observations, interaction being promoted by amino-phenyl group and lateral 
pyridinyl rings of terpyridine (see Chapter IV.I.3.). 
According to this study, Fe(L1)2 should also be able to bind at Th-T binding site with low 
binding energy. However, because amino acid residues involved in this interaction have important 
flexibility, this might be unfavoured when considering fibre dynamics. Here again, this is consistent 
with the experimental evidence of low affinity of metal complexes for Th-T binding sites (see Chapter 
IV.I.2.a). 
• Fe(L3)2 
Fe(L3)2 appears less prone to bind in side-chain channels, probably because of the lack of 
stabilizing H-bonds. Yet, a solution positioning Fe(L3)2 in the channel between Glu11 and His13 is 
obtained, with a moderate energy. But the main docking solution remains Th-T binding site, in which 
the binding is of low energy. Here again, both results involve amino acids with high dynamic 
character, interactions thus have to be confirmed by molecular dynamic simulations.  
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Docking studies thus enabled a first confirmation that metal complexes could bind fibres at 
binding sites different from Th-T. Interaction involves the phenyl ring and a pyridine ring, either from 
a single ligand or from both. Calculated binding energies are in the same range as Th-T. However, 
molecular dynamic simulations would be mandatory to explore in details inter-molecular interactions. 
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Conclusion 
This study showed that some of the synthesized metal complexes were able to interact with Aβ1-
40 fibres. Interestingly, their interaction is modulated by the substituting group on the phenyl 
terpyridine ligands: amine, nitro, and bromo groups seem to promote interaction, whereas carboxylate 
seems to prevent it. M(tpy)2 complexes display no incorporation within fibres, confirming the 
importance of the extended aromaticity. Contrariwise, the nature of the metal ion has no effect on 
interaction, which is of interest for future catalytic applications. Upon interaction, Ru complexes 
display a shift in absorbance together with an increase of fluorescence, which is in accordance with a 
shift from aqueous to hydrophobic environment. These complexes could thus constitute new probes 
for Aβ aggregation. 
Investigations on the precise localization of complexes within fibres remain tough, due to the 
insoluble nature of fibres and to their polymorphism. Yet, a first result shows a specificity of 
interacting metal complexes for Aβ1-40 fibres compared with shorter amyloid peptides. This suggests 
that our complexes might recognize specific binding site(s) on Aβ1-40, and not only the general side-
chain channel motif. 
To further investigate this question, docking studies were performed with Fe(L1)2 and Fe(L3)2 
on ssNMR models of Aβ1-40 and Aβ1-42 fibres. Results tend to show that metal complexes cannot 
intercalate into Th-T binding site, confirming experimental data. They also demonstrate the possible 
binding of metal complexes along the side-chain channels of fibres. To support these results, an 
experimental study with various mutants of Aβ1-40 would be of interest, seeking for residues that 
influence interaction.  
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Chapter V. Towards hybrid bioinorganic catalysts 
Introduction 
The objective of this thesis is the development of new hybrid catalysts made by incorporation of 
coordination complexes into amyloid fibres. In a first step, a library of complexes was synthesized and 
evaluated for their interaction with fibres (Scheme 32, arrow 1). The next step to progress towards our 
goal is to test metal complexes for their catalytic activity regarding benchmark reactions (Scheme 32, 
arrow 2). Once the reaction conditions optimized, the catalytic activity when incorporated into fibres 
must be demonstrated to make the proof of concept on the potential of the hybrid catalysts. 
Observations coming from interaction and catalytic studies provide clues for hybrid catalyst 
improvement, including modifications on the metal complex and on the peptide.  
This chapter describes preliminary results for our systems, and proposes evolution outlooks. 
The first part describes the optimization of styrene epoxidation as catalytic benchmark reaction 
using our Fe(II) bis terpyridine complexes.  
In a second part, preliminary results obtained in catalysis with our hybrid catalyst candidates 
are presented.  
Lastly, different optimisation routes are proposed, considering requirements for both catalysis 
and fibre-complex interaction. This would constitute a first optimisation cycle for our hybrid catalysts 
(Scheme 32, arrow 3). 
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Scheme 32: Representation of the different steps for hybrid catalyst elaboration and optimisation. 
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I.   Iron terpyridine complexes as catalysts 
I.1.  State of art on iron terpyridine complexes in catalysis 
Organic chemistry abounds with examples of Fe complexes used in catalysis. Reactions include 
substitutions, additions, eliminations, cycloadditions, metathesis, reductions and oxidations [230].  
Among those, only a few reactions are described using Fe(tpy)2-type complexes. In 2006, Beller 
and colleagues showed that acetophenone undergoes hydrogenation in the presence of iron salt 
together with tpy and phosphine ligands with perfect selectivity for the alcohol. This reaction occurs in 
refluxing iPrOH in the presence of base [189]. Subsequently, they showed that this system could also 
catalyze formic acid dehydrogenation in DMF with good TON [231]. But in these two examples, 
complexes are formed in situ, and without control experiments it is hard to conclude on the nature of 
the active catalytic species.  
Yeung et al. also showed that Fe(tpy)Cl2 catalyzed styrene cyclopropanation in the presence of 
ethyldiazoacetate in hot dichloromethane, with ee’s reaching 83% [232]. In 2012, Nakazawa’s group 
proposed to use Fe(tpy)X2 complexes to catalyze alkene hydrosilylation. Reaction with 1-octene 
shows a TON of 1533 at 100°C for 24 h [233]. All these examples, although interesting, require mono 
terpyridine complexes, and work in harsh conditions i.e. in organic solvents at high temperature. 
Alternatively, alkene epoxidation was shown to operate with bis terpyridine Fe complexes in 
biologically-compatible conditions. Che’s group developed 4,4’,4’’-substituted terpyridine Fe(II) 
complexes which catalyze epoxidation of alkenes using Oxone as oxidant (Scheme 33) [234]. The 
reaction operates in 5 mL of a ACN/water 2:1 mixture in the presence of 4 eq of ammonium 
bicarbonate, 1.3 eq Oxone and 5 mol% catalyst at room temperature, and is completed in 2 h. 
Conversion is obtained by GC analysis of the crude product or by 1H NMR, after an extraction in 
diethyl ether. The control with Fe(tpy)2 shows a decrease of conversion to 30%, whereas with FeSO4 
no conversion is observed. Reaction was tested on a series of 17 substrates, including electron-rich and 
electron-deficient aryl alkenes, steroids and allylic alkenes, showing conversions between 56% and 
100%. Corresponding yields go from 42% to 96%, based on conversion. Although it is specified that 
Scheme 33: Epoxidation reaction described by Che's group. 
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no diol formation is observed, there is no information on the nature of by-products observed. A 
subsequent study showed that this reactivity is conserved using oligopyridine Fe(II) complexes [235].  
Because it was conducted under suitable conditions for our future hybrid catalysts, this reaction 
was chosen as a catalytic benchmark reaction to test on our FeL2 complexes. The conditions proposed 
by Che’s group were used as starting point, and the different parameters were optimized for our Fe(II) 
complexes.  
I.2.  Results 
As a starting point, we chose to keep the same conditions as those reported by Che’s group. We 
worked with styrene, to which we add 1.3 eq of Oxone, 4 eq of ammonium bicarbonate and 5 mol% 
Fe(L1)2 in 5 mL of a mixture ACN/H2O 3:2. After 2 h shaking at RT, reaction medium was sampled 
and analysed by GC. 
Preliminary results show 97% conversion after 2 h. Unexpectedly, a total of five products is 
detected: epoxide and diol, but also benzaldehyde, phenyl acetaldehyde, and 2-hydroxy 1-phenyl 
ethanone (Scheme 34).   
Considering this result, we decided to study the effect of the different parameters of the 
reaction, trying to find conditions for which a single product would be obtained, if possible displaying 
an asymmetric carbon atom. To this aim, several points seemed of importance: 
• The catalytic charge required: diminution of catalyst loading could be a way to limit 
substrate over-oxidation. Moreover, considering that amyloid fibres are available at 
Scheme 34: Different products observed by GC for styrene epoxidation reaction.  
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μM scale, running reactions with low catalyst loadings would be of interest for hybrid 
catalysts. 
• The role of ammonium bicarbonate: investigating the amount needed could allow 
concluding on its role in the reaction. In particular, its role of pH modulator should be 
considered.  
• Screening of oxidants: studying various oxidative agents would allow finding the 
most suitable one for our specific reaction. 
• Screening of reaction conditions: several reaction conditions, such as temperature or 
addition order could have an impact on product selectivity. 
Those different points were investigated, looking for optimal reaction conditions. To this goal, 
we decided to scale down our experiments to 1 mL, enabling to run reaction in micro centrifuge tubes. 
Concentration of substrate was also lowered to 4 mM, which is in better accordance with the 
availability of our hybrid system (ca 50 μM metal complex). Reactions were run in a Thermomixer 
and samples were analysed by GC using toluene as internal standard (see Annex I).  
I.2.a.  Effect of ammonium bicarbonate 
A first investigation consisted in determining the ideal amount of ammonium bicarbonate to 
perform epoxidation reaction. Reaction was run at 60°C for 4 h, in different tubes containing various 
amounts of ammonium bicarbonate. Results obtained show that it should be used in 1eq vs. styrene, 
any higher amount being detrimental for conversion rates (Table 18). Interestingly, this corresponds to 
substoichiometric amount vs. Oxone. This salt would thus play a role of additive in the reaction. 
Table 18: Effect of ammonium bicarbonate on conversion. Conditions: styrene (4 μmol), Fe(L1)2 (0.04 μmol), oxone (20 
μmol) in 1 mL ACN/H2O 3:2, 60°C, 4h. 
NH4HCO3 eq Conversion (%) Major product 
1 100 Benzaldehyde 
2 94 Benzaldehyde 
4 78 Benzaldehyde 
25 33 Traces 
 
To assess this first observation, we tried to replace ammonium bicarbonate by phosphate buffer 
pH 7 at 100 mM, trying to see if the reaction was promoted by pH stabilization. It resulted in a drop of 
conversion below 10%, confirming that the promoting effect of NH4HCO3 was not due to a 
stabilization of pH. 
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I.2.b.  Effect of oxidant 
• Amount of Oxone 
In a first experiment, we assessed the amount of oxidant needed to complete the reaction. 
Reaction was run at 60°C for 4 h, using different amounts of Oxone freshly solubilized in water. 
Results show that 5 eq Oxone are required to achieve full conversion, yielding benzaldehyde. If using 
higher amounts, styrene is oxidized into 2-hydroxy 1-phenyl ethanone (Table 19). A discoloration of 
the solution is also observed, probably corresponding to the decomposition of metal complexes. 
Table 19: Effect of Oxone amount on conversion rates. Conditions: styrene (4 μmol), Fe(L1)2 (0.04 μmol), ammonium 
bicarbonate (8 μmol) in 1 mL ACN/H2O 3:2, 60°C, 4h. 
Oxone eq. Conversion (%) Major product 
1.25 2.8 Traces 
2.5 45.4 Benzaldehyde 
5 100 Benzaldehyde 
10 100 2-hydroxy 1-phenyl ethanone 
15 100 2-hydroxy 1-phenyl ethanone 
 
• Comparison with other oxidants 
Other oxidants, namely hydrogen peroxide and tert-butyl hydroperoxide were tested in the same 
conditions. Temperature was lowered to 25°C to avoid oxidant decomposition. Unfortunately, none of  
Table 20: Effect of the oxidant on conversion rates. Conditions: styrene (4 μmol), Fe(L1)2 (0.04 μmol), ammonium 
bicarbonate (8 μmol), oxidant (20 μmol) in 1 mL ACN/H2O 3:2, 25°C, 4h. 
Oxidant Additive Conversion (%) Major product 
Oxone NH4HCO3 100 Benzaldehyde 
H2O2 / 0 / 
H2O2 NH4HCO3 2.6 Traces 
H2O2 AcOH 26 Traces 
tBuOOH / 0 / 
tBuOOH NH4HCO3 0 / 
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them afforded satisfying conversions (Table 20). The use of Oxone in presence of ammonium 
bicarbonate thus seems to be the best combination to oxidize styrene. 
I.2.c.  Effect of catalyst 
• Catalyst loading 
Several loadings of catalyst were also tested, our aim being to lower the catalytic charge as 
much as possible in our hybrid systems. Results show that catalytic charge could be lowered to 0.5 
mol% without altering conversion (Table 21). 
Table 21: Effect of catalytic charge on conversion. Conditions: styrene (4 μmol), Fe(L1)2 (variable), Oxone (20 μmol), 
ammonium bicarbonate (8 μmol) in 1 mL ACN/H2O 3:2, 60°C, 4h. 
Catalytic charge Conversion (%) Major product 
0.5 mol% 100 Benzaldehyde 
1 mol% 100 Benzaldehyde 
3 mol% 100 Benzaldehyde 
 
• Screen for catalysts 
Our different metal complexes were tested for their catalytic activity on styrene epoxidation. 
Reaction was run at 37°C overnight using identical amounts of various metal complexes. Luckily, 
results showed that the interacting Fe(L1)2 and Fe(L3)2 are the most efficient, converting all styrene  
Table 22: Screen of metal complexes. Conditions: styrene (4 μmol), catalyst (0.04 μmol), oxone (40 μmol), ammonium 
bicarbonate (8 μmol) in 1 mL ACN/H2O 3:2, 37°C, overnight. 
Compound Conversion (%) Major product 
Fe(L1)2 100 2-hydroxy 1-phenyl ethanone 
Fe(L2)2 72.8 Benzaldehyde 
Fe(L3)2 100 2-hydroxy 1-phenyl ethanone 
Fe(bpy)3 36.4 Benzaldehyde 
Fe(salophen) 9.9 Benzaldehyde 
Ru(L1)2 51.3 Benzaldehyde 
Ru(bpy)3 18.3 Benzaldehyde 
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into 2-hydroxy 1-phenyl ethanone. The non-interacting L2, bpy and salophen complexes are poorly 
efficient, and oxidize styrene into benzaldehyde only with moderate conversions (Table 22). 
I.2.d.  Effect of reaction conditions 
• Temperature 
Even though amyloid fibres have high heat resistance, moderate reaction temperature would be 
more suitable to ensure stability of our hybrid catalysts. Temperatures of 4, 25 and 60°C were tested 
on 4 h reactions, showing a moderate improvement of conversion rates.  
Table 23: Effect of temperature on conversion rates. Conditions: styrene (4 μmol), Fe(L1)2 (0.04 μmol), Oxone (20 μmol), 
ammonium bicarbonate (8 μmol) in 1 mL ACN/H2O 3:2, 4h. 
Temperature Conversion (%) Major product 
4°C 80.5 Benzaldehyde 
25°C 94 Benzaldehyde 
60°C 100 Benzaldehyde 
 
• Addition order 
Through our experiments, we noticed that the order of addition had an effect on the reaction. In 
particular, addition of oxidant before substrate leads to a rapid discoloration of the reaction mixture, 
and corresponds to a drop of conversion. This effect is less noted when Oxone is added as a powder 
than when it is freshly solubilized in water. In any case, the major product formed is benzaldehyde 
(Table 24). We thus chose to systematically add Oxone solution last, to avoid catalyst deterioration. 
Table 24: Effect of addition order on conversion rates. Conditions: styrene (4 μmol), Fe(L1)2 (0.04 μmol), oxone (20 μmol), 
ammonium bicarbonate (8 μmol) in 1 mL ACN/H2O 3:2, 60°C, 4h. 
Addition order Conversion (%) Major product 
Solvent>NH4HCO3>cat>Oxone (solution)>styrene 38.6 Benzaldehyde 
Solvent>NH4HCO3>cat>Oxone (solid)>styrene 73.6 Benzaldehyde 
Solvent>NH4HCO3>cat>styrene>Oxone (solution) 100 Benzaldehyde 
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I.2.e.  Reaction kinetics 
A kinetic experiment was conducted, running reaction in parallel vials. The resulting curve 
shows a rapid increase of conversion during the first hour, followed by a slower increase. Final 
conversions are reached within 6-8 h (Figure 57). Replicates show identical results. 
 
I.3.  Conclusion: catalytic activity of FeL2 complexes 
This study enabled to determine the optimal conditions for styrene oxidation used our bis 
phenyl-substituted terpyridine Fe(II) complexes. Indeed, using 0.5 mol% catalyst, 1 eq of ammonium 
bicarbonate and 5 eq oxone provide 100 % conversion. However, in these conditions, benzaldehyde 
remains the major product. Increasing oxidant allows forming 2-hydroxy 1-phenyl ethanone as major 
product, but also leads to a discoloration of the solution, probably due to a degradation of the metal 
complex. Attempts with other oxidants have proven less successful, and variations of temperature 
showed limited effects. 
Bis phenyl-substituted terpyridine Fe(II) complexes (that were proven to interact with fibres, see 
0) are more active than their bpy and salophen analogues (that display no interaction). Ru(II) 
analogues also display promising properties. A preliminary catalytic experiment was thus conducted 
using Fe(L1)2 incorporated into fibres. 
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Figure 57: Kinetic curve of styrene conversion with time. Conditions: styrene (4 μmol), Fe(L1)2 (0.04 μmol), oxone (20 
μmol), ammonium bicarbonate (8 μmol) in 1 mL ACN/H2O 3:2, 25°C. Each point is the average of triplicates, corresponding 
to separate vials. 
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II.  Preliminary results: catalysis supported on fibres 
After 3 days of Aβ1-40 aggregation in the presence of metal complexes, fibres are harvested by 
centrifugation, and supernatant is titrated to determine the amount of inserted complex. Pellet of fibres 
is then redispersed in catalytic medium and used for oxidation reaction. 
In normal conditions, Aβ1-40 aggregation is monitored by Th-T. A control experiment was thus 
mandatory to assess the effect of the presence of Th-T on catalysis. For comparison, a control without 
fibres was also added.  
Table 25: Results obtained for styrene epoxidation with Fe(L1)2 inserted in Aβ  fibres. Conditions: styrene (4 μmol), 
catalyst (0,04 μmol), ammonium bicarbonate (10 μmol), Oxone (variable), 25°C, 4h. 
Catalyst Oxone eq Conversion (%) Major product 
Fe(L1)2 4 93 Benzaldehyde 
Fe(L1)2 8 100 Benzaldehyde 
Fibres + Fe(L1)2 4 15 Traces 
Fibres + Fe(L1)2 8 51 Benzaldehyde 
Fibres + Fe(L1)2 + ThT 4 0 / 
Fibres + Fe(L1)2 + ThT 8 63 Benzaldehyde 
 
Results show a drop of conversion for catalysts inserted in fibres. This effect could be due to a 
difference in substrate accessibility to the active site. Yet, when using 8 eq of Oxone, satisfying 
conversions can be obtained. From this, it seems that Th-T does not disturb catalysis, which will be 
convenient for aggregation monitoring. In any case, benzaldehyde is formed as major product. A little 
difference is observed: in absence of fibres, traces of phenylacetaldehyde, epoxide and 2-hydroxy 1-
phenyl ethanone are observed, whereas in presence of fibres only benzaldehyde is detected. This could 
be explained either by an incorporation of these side-products in fibres, or by a better selectivity of the 
hybrid system. To answer this question, a careful washing of fibres with an appropriate solvent could 
be envisaged. 
This first result validates the concept of hybrid catalysts made of metal complexes inserted in 
amyloid fibres. Catalytic activity of coordination complexes is maintained through fibre intercalation, 
even though a small drop of conversion is observed. Investigations on the different parameters of this 
reaction would be required to optimize reaction conditions. In a next step, this system could be 
improved in many different ways, as presented in the next section.  
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III.  Outlooks: how to improve our hybrid systems 
III.1.  Improving catalytic efficiency 
III.1.a. Screening of metal ions 
The interaction between fibres and metal complexes being mostly promoted by ligands, it 
enables to screen different metal ions. In addition to the Cu(II), Fe(II) and Ru(II), one could imagine 
the use of Mn(II), Ni(II), Pt(II) or Pd(II) for their catalytic properties. 
 In a preliminary study, [Mn(L1)(OAc)2] and [Mn(salophen)Cl] were synthesized according to 
previously described procedures [60,82]. Both complexes were tested on thioanisole sulfoxidation 
reaction, in conditions reported by Pordea et al. [82] (Scheme 35).  
Results obtained appear in Table 26, showing that good conversion rates can be obtained with 
salophen complex. However, according to GC, both sulfoxide and sulfone are formed in these 
conditions. Increasing catalyst loading allows formation of sulfone as major product. Further 
investigations on reaction time and temperature might help to isolate sulfoxide. MnL1 complex 
displays poor conversion rates, that might be improved by using the corresponding Mn(III) complex. 
Table 26: Results obtained for thioanisole sulfoxidation. Conditions: Thioanisole (5 mmol), catalyst (variable), H2O2 
(variable), 20°C, overnight. 
Catalyst Catalyst loading (%) H2O2 eq Conversion (%) GC ratio sulfoxide:sulfone 
Mn(salophen)Cl 1 2 64 1:1 
Mn(salophen)Cl 1 10 95 1:1 
Mn(salophen)Cl 2 1 70 1:2 
Mn(L1)(OAc)2 2 1 11 1:1 
Scheme 35: Conditions for thioanisole sulfoxidation reported by Pordea et al. 
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Mn(salophen)Cl 2 2 85 1:2 
Mn(salophen)Cl 2 10 95 1:1 
Mn(salophen)Cl 4 2 91 1:9 
Mn(salophen)Cl 4 10 96 1:2 
Mn(salophen)Cl 2 0 0 / 
 
Unfortunately, interaction studies showed a poor incorporation of salophen complexes into 
fibres. But modifications on the salophen scaffold could help to improve its affinity for fibres (see 
III.1.c). 
III.1.b.  Seeking for other reactivities 
Despite epoxidation, other reactions were attempted with our metal complexes: aziridination, 
which was reported by Che to work under similar conditions as epoxidation [234], and 
cyclopropanation, which normally works in DCM with Cu(I) catalysts [236]. Conditions were slightly 
modified, as appearing in Scheme 36.  
Aziridination was tested using Fe(L1)2 and Fe(salophen), in air or under argon, showing 
maximum conversion of 15% by GC analysis. Traces of products were detected, but could not be 
analysed. The only variation from the article is the nature of the terpyridine ligands of the catalyst. As 
for epoxidation, it seems that this has a huge impact on catalytic activity (see Chapter I.I. ).  
Cyclopropanation was attempted with Cu(L1)2, CuL1Cl2, Cu(bpy)3 and Fe(L1)2. Here again, 
conversion rates did not exceeded 10% by GC analysis. Such disappointing result can be explained by 
the use of Cu(II) instead of Cu(I), and by a difference in solvents. 
Scheme 36: Other catalytic reactions tested with Fe and Cu complexes. 
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Other reactions using Fe(tpy)X2 complexes could also be attempted in future studies, but they 
are unlikely to be transposed to Fe(tpy)2 complexes. To achieve good catalytic efficiency, it might be 
more efficient to operate modifications on ligands and complexes. 
III.1.c. Ligand evolution 
Going back to existing epoxidation catalysts, we notice that a huge majority display a vacant 
coordination site, which enables oxidant coordination to form an iron high-valent reactive specie. This 
was reported with enzymes (Scheme 37.A and 3.B) as well as with metal complexes [11] (Scheme 
37.C). 
 
With their chloro-substituted bis terpyridine Fe(II) complexes, Che and coll. showed that this 
rule could suffer exceptions. Yet, this requirement should be taken into account when developing a 
second generation of ligands, while keeping in mind requirements for supramolecular interaction.  
Interesting examples would include the formation of heteroleptic [Fe(L)(bpy)]2+ complexes, that 
would combine an interacting ligand (i.e. L1, L3 or L5) and would leave vacant a position on Fe. Their 
synthesis might be a little tricky compared to homoleptic complexes, possibly requiring isolation of 
the mono-ligand intermediate.  
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Scheme 37: Efficient iron-based catalysts. A: Catalytic cycle of Cytochromes P450. Electrons come from NAD(P)H and 
transit through the electron transport system. Red: Peroxide shunt. B: Catalytic cycle of Rieske-type dioxygenases. The 
electron source is a Fe2S2 complex proximal to the active site. Red: Peroxide shunt.C. Ligands reported for hydrocarbons 
Fe(II)-catalysed epoxidation with H2O2. Reprinted from [11]. 
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To go further into coordination sphere optimization, one could also imagine working with 
quaterpyridine scaffold substituted with the suitable phenyl moiety (Scheme 38, ligand 1). Ligands of 
this type were synthesized starting from bipyridine, the corresponding Ru(II) complexes displaying 
unique spectrophotometric properties [237]. In our case, Fe complex would combine the pyridinyl-
pyridinyl-phenyl motif that seems required for interaction, together with the 4N coordination sphere 
important for catalysis. Replacing two pyridyl rings by phenol could also be of interest, considering 
the high efficiency of salen-type ligands in oxidation catalysis (Scheme 38, ligand 2).  
Another strategy could consist in starting from dipyridophenazine (dppz, Scheme 38), which 
was described as an efficient intercalating moiety. Substitution with pyridyl or phenol rings could 
provide dppz a 4N or 2N2O coordination sphere suitable for catalysis (Scheme 38, ligands 3 and 4). 
Synthesis of ligand 3 has been described by Thummel et al. in three steps starting from dichloro 
phenanthroline [238]. Pyridinyl rings being coupled using Stille strategy, similar reaction could be 
envisaged using phenol rings.  
Scheme 38: Proposition for a second generation of ligands. 
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This series could constitute a second generation of ligands that would encompass interaction 
and catalysis requirements. To further improve the hybrid system, modifications can also be operated 
on Aβ peptide. 
III.1.d.  Modifications of peptide 
Different strategies can be applied to improve the peptide scaffold. 
• Directed mutagenesis on Aβ: helped by experimental data together with calculations, 
it could be envisaged to operate some specific mutations on Aβ sequence to improve 
fibre-complex interaction. However, at this point, this option is limited by the lack of 
experimental data. Further experimentation with probe-modified terpyridine ligands 
might help to gain insights into residues implicated in interaction (see Chapter V.III.2). 
• Random mutagenesis on Aβ: Considering the lack of experimental data, an alternative 
option could be to operate random mutagenesis on Aβ peptide. MAβ expression in E. 
coli being well managed, it would be possible to obtain mutant libraries. However, it 
would be mandatory to develop a straightforward screening assay to determine the 
potential of each mutant directly in bacteria. Screening for aggregation-prone mutants is 
already possible, using Th-S to stain inclusion bodies. One could imagine using a 
biocompatible Ru complex to screen for amyloid-complex interaction. 
• Moving to amyloid proteins: Now that the interaction of our bis terpyridine complexes 
was assessed with Aβ, it could be interesting to see if it can be transposed to amyloid 
proteins. As an example, albumin proteins produce fibres in large amounts when heated 
and are easy to handle [239]. Their use could enable to run catalysis at synthetically 
relevant scale.  
• Moving to shorter amyloid peptides: Finally, an opposite approach would consist in 
developing a library of amyloid-forming short peptides issued from solid-phase peptide 
synthesis. Such approach has been described in literature with seven residues peptides, 
enabling the rapid screening of catalytic efficiency [240]. 
III.2.  Other possible strategies 
Although not considered here, the grafting of an intercalating moiety onto the ligand could also 
constitute a convenient way to promote interaction. However, the chiral effect of amyloid fibre might 
be decreased, as described before for DNA based catalysts (see Chapter I.I.3.b). 
In the same way, this project focused on non-covalent interaction between metal complexes and 
fibres; though, the covalent grafting of the complex also remains relevant. It could be achieved by 
bioconjugation using Lys or Cys residues, or by incorporation of non-natural amino acids. In that case, 
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ligands could be reduced to the minimum, since having no impact on interaction, and the distance 
between catalyst and fibre would remain short. But that would require huge efforts of synthesis. 
An alternative approach developed in our group consists in functionalizing terpyridine with 
diazirine moiety. Upon irradiation of ligand inserted into fibres, a carbene is formed, which reacts with 
neighbouring residues to form a covalent bond. Hence, the ligand is immobilized at its most favoured 
position [241]. 
All these approaches remain of interest, and should be kept in mind for further studies. 
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Conclusion 
Our Fe(II) complexes were tested on styrene epoxidation reaction, which has been reported to 
work with Fe(tpy)2-type complexes. Our complexes display high conversion rates; unfortunately, they 
do not form the expected epoxide, but benzaldehyde, which prevent the possible observation of chiral 
induction from the catalytic scaffold. 
Yet, a preliminary catalytic assay using Fe(L1)2 inserted into Aβ1-40 fibres was attempted, 
showing that the presence of fibres does not preclude the catalytic reaction, even though a little loss of 
conversion is noticed. This first result constitutes a proof of concept for hybrid catalyst elaboration 
from amyloid fibres. A screening of various substrates could be of interest, to conclude on the effect of 
the peptide environment on the substrate.  
To improve this primary scaffold, we propose to operate chemogenetic optimisation, i.e. 
combining variations on the peptide and on the metal complex to reach an optimal system. In this 
view, developing a second generation of ligands is envisaged, which would encompass the 
requirements noted for both interaction and catalysis. Namely, interesting ligands would be constituted 
of four coordinating nitrogen atoms, while keeping the pyridyl-pyridyl-phenyl moiety that appeared 
crucial for interaction. Intercalating dppz scaffold could also be interesting.  
Operating modifications on peptide is also to envisage. Considering the lack of structural 
information, random mutagenesis appears more appropriate. Future work would include the 
development of a new in vivo screening method for complex-fibre interaction. 
 
  

General conclusion 

 
141 
 
General conclusion 
Along this thesis, we have focused on the elaboration of hybrid bioinorganic catalysts, prepared 
by incorporation of coordination complexes in amyloid fibres. Three main points were to be 
considered: the production of peptide, the synthesis of metal complexes, and the study of their 
interaction, the ultimate goal being to study the catalytic activity of the final scaffold. 
To this aim, amyloid-β recombinant production was attempted in Escherichia coli. First 
considered as more convenient, production of His-tagged Amyloid-β was abandoned in favour of 
untagged Met-Amyloid-β. Indeed, this peptide is produced as inclusion bodies in bacteria, which can 
be easily isolated from bacterial residues. Based on a previously published procedure, we have 
developed a new purification procedure for Met-Amyloid-β peptides, consisting in basic solubilisation 
followed by two ultrafiltration steps. This chromatography-free protocol afford pure peptide samples 
in good yields and with intact aggregative properties. This protocol constitutes a convenient procedure 
for routine Aβ sample production, and makes possible peptide variations by mutagenesis.  
The next important point was to develop a series of metal complexes candidates that might 
display good interaction with amyloid fibres. Based on observation of known amyloid-β intercalating 
agents, we chose to focus on phenyl-functionalized terpyridine ligands. A series of five ligands was 
developed, each of them holding different functional groups, expected to modulate interaction with 
fibres. Corresponding Cu(II), Fe(II), and Ru(II) complexes were prepared and fully characterized. 
Fe(II) complexes caught our attention for its potential catalytic activity, whereas Ru(II) complexes had 
interesting luminescent properties. 
These two series of complexes were thus tested for their interaction with amyloid fibres. Among 
the series, L1, L3 and L5 complexes showed high incorporation into Aβ1-40 fibres. This comes together 
with an acceleration of Aβ1-40 aggregation kinetics. Investigations on metal complex recognition 
pattern demonstrated that the pyridine-pyridine-phenyl was responsible for interaction, regardless the 
coordinated metal ion. Finally, experiments were conducted to binding site(s) of metal complexes in 
fibres. Results attest that metal complexes and Th-T have different binding sites. Unfortunately, no 
precise localization was obtained, although a clear difference of incorporation was observed with short 
peptides Aβ11-28 and Aβ1-28.  
To get further insights on this last point, docking studies were conducted on ssNMR structures 
of Aβ1-40 and Aβ1-42 fibres. Results confirm that Th-T and metal complexes cannot bind in the same 
sites, due to geometric constraints. Docking of Fe(L1)2 into Aβ1-42 model provides a first proof of 
concept for metal complexes binding in side-chain channels on the surface of fibres. This result is in 
accordance with the key role played by phenyl ring and lateral pyridine in interaction.  
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To conclude this study, a last step was to assess catalytic activity of coordination complexes 
when incorporated into fibres. To this aim, styrene epoxidation reaction was selected as benchmark 
reaction. Surprisingly, catalysis with our Fe(II) complexes afforded benzaldehyde as major product. 
Preliminary experiments in presence of fibres allowed us to validate that this catalytic activity of metal 
complexes is preserved upon insertion.  
This result validates the proof of concept for bioinorganic hybrid catalysts based on amyloid 
fibres. Even though these systems already present advantages, such as their easy production and their 
biocompatibility, they will have to be improved to compete with existing catalysts. In this view, a 
chemogenetic optimization procedure could be applied, combining peptide mutagenesis and metal 
complex evolution to reach an optimised system. 
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Experimental procedures for Chapter II 
General remarks 
All experiments were run at room temperature unless otherwise noted. All experiments were run 
using fresh ultrapure water (Synergy). All chemicals and solvents were purchased from Sigma-Aldrich 
and used without further purification. pET28a plasmid was purchased from Novagen. NcoI, XhoI and 
BamHI restriction enzymes Antarctic phosphatase and T4 DNA Ligase were purchased from New 
England Biolabs and used with the provided buffer according to supplier’s recommendations. 
pET28a_His_Thromb_Ab42 plasmid was synthesized by Genecust. E. coli TOP10 cells and E. coli 
BL21 (DE3) cells were obtained from Invitrogen. QIAprep spin MiniPrep kit was purchased from 
Qiagen. Sequence analyses of the constructions were performed by GATC Biotech. 
Vectors construction and cloning procedure  
The commercial pET28a plasmid was digested by NcoI and XhoI restriction enzymes, 
dephosphorylated using Antarctic phosphatase, and gel purified on an agarose 0.8% Tris acetate 
EDTA (TAE) gel. The pET28a_His-Thromb-Ab1-42 plasmid was used as template for PCR 
amplification of the Aβ1-42 coding sequence using pR_pET28_Ab42: 
AGCGGTGGCAGCAGCCAACTCAGCT and pF_pET28_Ab42: 
GACCTACCCATGGACGCTGAATTTCGCCACGACTCCGGCTAT as primers. The PCR product 
was digested by NcoI and XhoI, gel purified on an agarose 1.2% TAE gel and ligated in the 
NcoI/XhoI digested pET28a yielding the desired pET28a_MAb42 plasmid. The construction was used 
to transform chimiocompetent E.coli TOP10 cells that were grown on solid Luria-Bertani (LB) 
medium (10 g/L tryptone, 10 g/L NaCl, 5 g/L yeast extract) containing 50 mg/L kanamycin (1X). One 
colony was used to inoculate 5 mL LB kanamycin 1X at 37 °C. Cells were grown overnight, harvested 
before plasmid extraction using a MiniPrep kit. 
The pET28a_MAb40 was obtained from pET28a_MAb42 using a similar procedure except that 
the sequence coding for Aβ1-40 was PCR-amplified with pR_pet28_Ab40: 
AATGGATCCTAATTAAACAACGCCGCCAACCATCAGACCGATG and pF_pet28_Ab40: 
AATTGTGAGCGGATAACAATTCCCCTCTAG as primers. The PCR-product was digested using 
NcoI and BamHI, and ligated into NcoI/BamHI digested and dephosphorylated pET28_MAb42. 
Expression of His-Thromb-Aβ1-42, MAβ1-40 and MAβ1-42  
Chemically competent E. coli BL21 (DE3) cells transformed with corresponding plasmids were 
used for peptide production. One single colony was used to inoculate 10 mL LB kanamycin 1X 
medium. The cells were grown for 16 h. 100 mL of LB medium containing kanamycin 1X were 
inoculated to an OD600 of 0.05 with an overnight pre-culture performed from one single clone in 10 
mL LB-Kana medium. Cells were grown at 37 °C under agitation to an OD600 of 0.8. Expression was 
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induced with 0.5 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) during for 4 additional hours of 
culture at 37 °C.  
His-Thromb-Aβ1-42 purification 
Cells are harvested by centrifugation (8,000 g, 10 min) and re-suspended to an OD600 of 80 in 
lysis buffer (50 mM Tris-HCl, 100 mM NaCl, pH 8) containing 1% Tergitol-type NP40 detergent. 
Cells were then lysed by 30 s sonication on ice and the lysate was centrifuged (12,000 g, 10 min). 
Pellet was resuspended in 8 M urea under slow agitation until the solution turns clear. Solution is then 
applied on TALON resin in batch mode equilibrated with lysis buffer and incubated 30 min at RT. 
Supernatent is discarded, and resin is washed twice with lysis buffer. Peptide is finally eluted with 
imidazole solutions of increasing concentration (25, 50, 100, 200, 300, 400 mM, respectively). 
Samples were analysed by SDS-PAGE.  
MAβ1-40 and MAβ1-42 inclusion bodies isolation 
Cells were harvested by centrifugation (8,000 g, 10 min, 4°C) and re-suspended to an OD600 of 
80 in lysis buffer (50 mM Tris-HCl, 100 mM NaCl, pH 8) containing 1% Tergitol-type NP40 
detergent. Cells were then lysed by 30 s sonication on ice and the lysate was centrifuged (12,000 g, 10 
min, 10°C). From then, pellets of IBs can be stored at -20°C at least for a few days. The insoluble 
fraction was re-suspended in 1 mL lysis buffer, containing phenylmethanesulfonyl fluoride (15 mM) 
and lysozyme (300 μg/mL), and incubated for 1 h at room temperature. IBs were harvested by 
centrifugation (12,000 g, 10 min, 10°C), washed with Triton X100 0.5% and twice with phosphate 
saline buffer (PBS) 1X pH 8. IBs were finally resuspended in PBS buffer and submitted to 10 cycles 
of 10 s sonication followed by centrifugation to remove nucleic acid contaminants that could be 
stacked on their surface, according to a previously reported procedure. Samples can then be combined. 
MAβ  peptides purification 
IBs were denatured by 2 h incubation in 500 μL of NaOH 50 mM under smooth shaking at 
room temperature. Solution must be almost perfectly translucent and pale yellow. The resulting 
mixture was centrifuged (12,000 g, 5 min, 10°C), and the supernatant neutralized to pH 7 by addition 
of 500 mM HCl. The formation of a white precipitate was observed. The mixture was centrifuged 
once again, and the supernatant was collected. To optimize recovery, this denaturation/neutralisation 
cycle was applied twice. Supernatants were mixed and passed through a 30-kDa Amicon-Ultra 
centrifugal device, to remove high molecular weight contaminant proteins, and then concentrated on a 
3-kDa Amicon-Ultra centrifugal device. Final volume should be below 500 μL to enable SEC 
purification (see below). 
For short-term storage purpose (not more than a few hours/days), it is possible to add NaOH to 
final concentration 50 mM. This can be done either before 30-kDa filtration (if filtrations are extended 
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to a long period of time), or after concentration (operating a “buffer exchange” on the 3-kDa 
membrane). Samples can then be stored at 4°C. NaOH addition is mandatory for SEC purification in 
our elution conditions (see below). No solution has been found yet for long-term storage 
(weeks/months). 
SDS-PAGE analysis 
15 μL protein samples were mixed with 5 μL Laemli Sample buffer (Bio-Rad) containing 10% 
β-mercaptoethanol, and denatured at 95 °C for 10 min. Samples were then loaded on a Mini-protean 
TGX Stain-Free Any Kd Precast Gel (Bio-Rad) and electrophoresis was run for 30 min at 150 V in 
Tris/Glycine/SDS buffer (Bio-Rad). Gel was then stained using PageBlue Protein Staining solution 
(Bio-Rad). 
Thioflavin-S staining 
Samples of Aβ peptide producing cells or purified IBs are centrifuged (12,000 g, 10 min) and 
resuspended in 200 μL Thioflavin-S 125 μM in PBS 1X pH 8. After 15 min incubation, cells or IBs 
were harvested by centrifugation, washed with 200 μL PBS, and re-suspended in PBS, and submitted 
to fluorescence experiments. 
Fluorescence microscopy 
50 μL samples of Th-S stained cells or IBs were dispensed on a microscope glass slide and 
imaged using a Leica microscope with a 63x lens with a DAPI filter (λexc = 340-380 nm, dichroic = 
400, λem = 425 nm).  
Fluorescence spectrophotometry 
1 mL samples of Th-S stained cells or IBs were placed in a quartz cuvette and their emission 
spectra were recorded using a Jasco fluorimeter (λexc = 375 nm). Right after each measurement, OD600 
was measured, to normalize the signal. 
1H NMR 
Pure samples of peptides in water were diluted to 100 μM in phosphate buffer 50 mM pH 7 in 
D2O. 1H NMR spectra were recorded on a 500 MHz NMR (Bruker) at 25 °C using solvent as 
reference. As a control, synthetic Aβ1-40 was dissolved in NaOD and diluted to 100 μM in the same 
conditions. 
LC-MS 
Peptide samples were analysed by LC-MS on an Agilent 1200 HPLC fitted with a Macherey 
Nagel Nucleodur 300-5 C4 ec 250 mm x 2 mm 5 μm at 30 °C coupled with a Thermo Fisher Scientific 
LCQ Fleet mass spectrometer fitted with an H-ESI II Probe. 
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Samples were eluted at 0.33 mL/min using a gradient of acetonitrile going from 5% to 90% in 
aqueous formic acid 0.1% in 12 min. Multiply-charged peptides were detected by mass spectrometry 
(ESI +). 
Thioflavin-T aggregation assay 
To ensure of the homogeneity of the starting sample, monomeric peptides were isolated by 
steric exclusion chromatography (SEC). An Aktä Purifier system equipped with a Superdex 75 10/300 
column was equilibrated with 2 column volumes of 15 mM NaOH. Peptide samples in NaOH 50 mM 
(volume below 500 μL) were then eluted at RT using NaOH 15 mM at 1 mL/min, with UV monitoring 
at 220 and 293 nm. Monomeric MAβ peptides display retention times around 9 min. Fractions 
containing peptides were collected, centrifuged, and their concentration was assessed by UV-Vis at pH 
12 (λ = 293 nm, ε = 2400 L.mol-1.cm-1).  
In a 384-wells microplate (Greiner) were added phosphate buffer (50 mM), thioflavin-T (10 
μM) and freshly SEC-purified peptide (20 μM or 50 μM). Fluorescence intensity was recorded every 
5 min for a total duration of 4 days using a ClarioStar plate reader (BMG Labtech) set at 37 °C. 
Fluorescence parameters were set as follows: λexc = 440 nm, λem = 490 nm, gain = 650, shaking at 200 
rpm for 12 s before each measurement. Aggregation curves were fitted using KaleidaGraph software.  
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Experimental procedures for Chapter III 
 
Synthesis of 4-(p-nitrophenyl)- 2,6- (2’,2’’-pyridyl)pyridine (L3) 
(E)-3-(4”-nitrophenyl)-1-(pyridine-2’-yl)prop-2-enone (0.4 g, 1.57 mmol) and 9-(2-
pyridinylcarbonyl)pyridinium iodide (0.51 g, 1.57 mmol) are dissolved in methanol (20 mL) and the 
mixture is heated to reflux for 6 h, leading to a thick grey precipitate. The mixture is allowed to cool at 
room temperature, then in ice. The precipitate is filtered, washed with cold methanol, and dried with 
diethyl ether, affording the desired compound as a light grey solid (0.37 g, 68%). 
Synthesis of 4-p-carboxyphenyl—2,6 (2’,2’’-pyridyl)pyridine (L2) 
Terephtaldehydic acid (2.46 g, 16.4 mmol) and KOH (5.52 g, 98.4 mmol) are dispersed in 50 
mL of ethanol. 4-acetyl pyridine (3.67 mL, 32.8 mmol) is added, followed by 60 mL of NH4OH, 
leading to a clear yellow solution. The mixture is heated at 75°C and stirred overnight. The mixture is 
cooled to RT, and resulting white solid is filtered off, rinsed with ethanol, diethyl ether, and dried 
under vacuum. Recrystallization in ethanol affords the desired product as a white solid (1.82 g, 30%). 
Synthesis of 4-furyl-2,6 (2’,2’’-pyridyl)pyridine (L4) 
Furaldehyde (1.66 mL, 20 mmol), 2-acetyl pyridine (4.48 mL, 40 mmol) and KOH (3.08 g, 55 
mmol) are dissolved together in ethanol (100 mL). Ammoniac is added (60 mL) and the mixture is 
heated at 60 °C for 24 h, forming a precipitate. The solution is cooled at RT and part of the solvent is 
evaporated. The solid is filtered off, washed with ethanol and dried under vacuum to afford the desired 
compound (3 g, 51 %). 
Synthesis of 4-p-bromophenyl-2,6 (2’,2’’-pyridyl)pyridine (L5) 
4-bromobenzaldehyde (1.65 g, 9 mmol), 2-acetyl pyridine (2 mL, 18 mmol) and KOH (2.76 g, 
50 mmol) are dissolved together in ethanol (50 mL). Aqueous ammoniac (25 %) is added (30 mL) and 
the mixture is heated at 60 °C for 24 h, forming a white precipitate. The solution is cooled at RT and 
part of the solvent is evaporated. The solid is filtered off, washed with methanol and dried under 
vacuum to afford the desired compound (2.38 g, 70 %). 
Synthesis of 4-p-aminophenyl-2,6- (2’,2’’-pyridyl)pyridine (L1) 
Synthesis 1: L3 (0.43 g, 1.21 mmol) and Pd/C 10% (0.06 g, cat.) are dissolved in ethanol (15 
mL) and heated to reflux for 45 min. Hydrazine (1.47 mL, 47.3 mmol) is then added dropwise, and the 
resulting solution is refluxed for 3 additional hours. The resulting mixture is cooled at room 
temperature, filtered over Celite and washed with DCM (75 mL). The supernatant is washed with 
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NaHCO3 sat. (100 mL), brine (100 mL), dried over Na2SO4, filtered and dried under reduced pressure, 
leading to the desired ligand as a bright yellow powder (0.2g, 52%). 
Synthesis 2: L3 (2 g, 5.63 mmol) and tin (II) chloride (4.28 g, 22.5 mmol) are dissolved in HCl 
37% and the mixture is heated at 70°C for 5 h. The resulting mixture is then cooled to RT, and 40 mL 
of 20% NaOH are added. The mixture is stirred for 30 min. pH is then set to 10 by addition of 
concentrated NaOH, which afford a brown precipitate. After 15 min stirring, the solid is filtrated, 
washed with ether, and dried under vacuum. The solid is then dispersed in acetonitrile and heated to 
reflux. The resulting mixture is filtrated hot over Celite, and evaporated, affording a yellow solid (0.7 
g, 30%). 
General procedure: CuL2 complexes synthesis 
Copper (II) nitrate (36.4 mg, 0.154 mmol) and L (100 mg, 0.3 mmol) are dissolved separately in 
methanol and warmed at 50°C. The copper solution is then added drop wise to the ligand solution, 
resulting in an instantaneous change of colour. The solution is cooled to RT, and a concentrated NaPF6 
solution is added drop wise, forming a precipitate. The solid is then filtered, washed with methanol, 
and dried in vacuo (87-98% average yield). 
General procedure: FeL2 complexes synthesis 
Iron (III) nitrate (60 mg) and L (100 mg, 2 eq) are dissolved separately in ethanol and refluxed. 
The iron solution is then added dropwise to the ligand solution, resulting in an instantaneous change of 
colour, from light yellow to dark purple. The solution is refluxed for 1 h, and cooled to RT. A 
concentrated NaPF6 solution is added drop wise, forming a light purple precipitate. The solid is 
collected by centrifugation, washed with ethanol, and dried in vacuo. Desired complexes are afforded 
as purple solids (56-72% average yield). 
General procedure: RuL2 complexes synthesis 
Ruthenium (III) chloride (80 mg) and L (2 eq) are dissolved separately in methanol and 
refluxed. The ruthenium solution is then added dropwise to the ligand solution, resulting in an 
instantaneous change of colour, from light yellow to dark brown. A spatula of sodium ascorbate is 
added and the solution is refluxed for 1 h. The mixture is cooled to RT, then on ice. Subsequently the 
solution is filtered, and the volume of supernatant is reduced under low pressure. A concentrated 
NaPF6 solution is added drop wise, forming a light red precipitate. The solid is collected by 
centrifugation, washed with methanol, and dried in vacuo. Desired complexes are afforded as red 
solids (42-61% yield). 
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Nuclear Magnetic Resonance (NMR) 
Dried samples were dissolved in 500 μL of deuterated solvent and placed in a 5 mm borosilicate 
NMR tube. 1H and 13C NMR spectra were recorded either on a 300 MHz or a 400 MHz NMR (Bruker) 
at 298 K using solvent as reference. Spectra were processed using MestReNova software. 
Electron Paramagnetic Resonance (EPR) 
Metal complex was dissolved to 1 mM in ACN containing 0.1 mM tetrabutylammonium 
hexafluoro phosphate and 10% glycerol. Samples were placed in a 2 mm quartz EPR tubes and frozen 
in liquid nitrogen. Band X EPR spectra (9,5 GHz) were recorded on a Elexsys E500 machine 
(Brucker). Spectra were processed using Kaleidagraph software. 
Following formula were applied to calculate EPR parameters: 
     with ν in GHz and B in mT. 
           
Cyclic voltammetry (CV) 
Cyclic voltammetry experiments were run with a three electrodes system in a 2 mL cylindrical 
cell at room temperature. The working electrode is in glassy carbon, and was polished using a 
colloidal silica suspension between each measurement. The counter electrode is a platinum wire. In the 
case of Cu complexes, reference electrode was SCE, isolated from the cell by a salt bridge ended with 
a frit. In the case of Ru complexes, reference electrode was Ag/Ag+ in 0.01 M AgNO3 in ACN, 
directly connected to the system. Dissolved dioxygen was removed by sparging Ar before each 
measurement.  
Complex samples were dissolved in ACN containing 0.1 M tetrabutylammonium tetrafluoro 
borate, and cyclic voltamogrammes were recorded at 0.1 V/s scan rate, with ohmic resistance was set 
to 300 Ω. Data were collected, and all potentials were converted into V vs. NHE, using the following 
relations:  
     
    
 
UV-Visible measurements 
UV-Vis spectra were recorded on a Spectro Star Nano spectrophotometer (BMG Labtech) in a 
100 μL 1 cm pathlength quartz cuvette at room temperature. 
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Fluoresence measurements 
Fluoresence spectra were recorded on a Optima ClarioStar plate reader (BMG Labtech) in a 
384-well plate (Greiner) at 25°C. 
Quantum Yield determination 
In a 384-well plate (Greiner) were prepared six solutions of 0, 1, 2, 3, 4, and 5 mM of 
compound in ACN. Similar solutions were prepared with Ru(bpy)3 which are used as reference. 
UV-Vis and emission of solutions at suitable wavelength were recorded on a Optima ClarioStar 
plate reader (BMG Labtech) at 25°C. Quantum yields were calculated for each solution using the 
following formula: 
        
 
 

 
with Φ: fluorescence quantum yield, F: fluorescence intensity at λem, A: absorbance at λmax, n: 
refractive index of the medium. 
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Experimental procedures from Chapter IV 
Aβ1-40 aggregation assay 
To ensure of the homogeneity of the starting sample, commercial synthetic Aβ1-40 (Genecust) is 
purified by steric exclusion chromatography. Lyophilized Aβ1-40 is gently dissolved in 50 mM NaOH 
to a concentration of 10 mg/mL. The solution is then injected on a Aktä system equipped with a 
Superdex 75 10/300 column previously equilibrated with 2 column volumes of 15 mM NaOH. Peptide 
sample is eluted using NaOH 15 mM at 1 mL/min, with UV monitoring at 220 and 293 nm. 
Monomeric Aβ1-40 displays retention times around 10 min. Fractions containing peptides are collected, 
centrifuged, and their concentration was assessed by UV-Vis at pH 12 (λ = 293 nm, ε = 2400 L.mol-
1.cm-1).  
In a 384-wells microplate (Greiner) were added water, phosphate buffer pH 7 (50 mM), 
thioflavin-T (10 μM), metal complex (50 μM) and freshly purified Aβ1-40 (50 μM). Final ACN content 
is of 5%. Fluorescence intensity was recorded every 5 min for a total duration of 4 days using a 
ClarioStar plate reader (BMG Labtech) set at 37 °C. Fluorescence parameters were set as follows: λexc 
= 440 nm, λem = 490 nm, gain = 650, 200 rpm shaking for 12 s before each measurement. t1/2 values 
were obtained by sigmoidal curve fitting using Kaleidagraph software. 
Aβ11-28 aggregation assay 
Because it is less aggregation prone than Aβ1-40, Aβ11-28 was used without further purification. 
Lyophilized synthetic Aβ11-28 was dissolved in 50 mM NaOH at 10 mg/mL. In a 384-wells microplate 
(Greiner) were added water, phosphate buffer pH 7 (50 mM), thioflavin-T (10 μM), metal complex 
(50 μM), ZnSO4 (25 μM) and Aβ11-28 (50 μM). Final ACN content was of 5%. Fluorescence intensity 
was recorded every 5 min for a total duration of 40 h using a ClarioStar plate reader (BMG Labtech) 
set at 25 °C. Fluorescence parameters were set as follows: λexc = 440 nm, λem = 490 nm, gain = 2000, 
200 rpm shaking for 12 s before each measurement. Aggregation curves were fitted using 
KaleidaGraph software. 
Aβ1-28 aggregation assay 
Lyophilized synthetic Aβ1-28 was dissolved in 50 mM NaOH at 10 mg/mL. In a 384-wells 
microplate (Greiner) were added water, phosphate buffer pH 7 (50 mM), thioflavin-T (10 μM), metal 
complex (100 μM), ZnSO4 (50 μM) and Aβ1-28 (100 μM). Final ACN content was of 5%. 
Fluorescence intensity was recorded every 5 min for a total duration of 40 h using a Optima plate 
reader (BMG Labtech) set at 25 °C. Fluorescence parameters were set as follows: λexc = 440 nm, λem = 
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490 nm, gain = 1000, 200 rpm shaking for 12 s before each measurement. Aggregation curves were 
fitted using KaleidaGraph software. 
UV-Vis and Emission spectra of fibres samples 
See Experimental procedures for Chapter III. 
UV-Vis quantification of unbound metal complexes 
In the end of aggregation assay, wells containing fibres are gently sampled, gathering replicates. 
Samples are then centrifuged (10,000 g, 5 min) and the top fraction of supernatant is analysed by UV-
Vis spectrophotometry using a SpectroStar Nano reader (BMG Labtech). Negative controls (i.e. 
without peptide) are processed similarly, to consider potential precipitation or degradation issues. 
Quantification of metal complexes is achieved by comparing absorbance at complexes λmax versus 
negative controls.  
HPLC quantification of unbound Th-T 
In the end of aggregation assay, wells containing fibres are gently sampled, gathering replicates. 
Samples are then centrifuged (10,000 g, 5 min) and the top fraction of supernatant is analysed on 
Agilent 1200 HPLC fitted with a Nova-Pak C18 column, 4 mM, 3.9 mm x 75 mm (Waters). Elution 
method was set as follows: Isocratic elution for 1 min in 10% ACN in H2O+0.1% TFA, followed by a 
gradient from 10 to 100% ACN in 10 min, and isocratic elution in 100% ACN for 5 min. Elution is 
monitored at 220 nm and 250 nm. In these conditions, Th-T comes out around 6.9 min. Quantification 
is achieved by comparing integrations at 250 nm versus negative controls.  
NMR experiments: preparation of samples 
In a microtube are added D2O, phosphate buffer pH 7 in D2O (50 mM), metal complex in 
CD3CN (variable), and Aβ peptide solubilized in NaOD (variable). For control experiments in absence 
of complex, corresponding amount of CD3CN is added. The mixture is carefully transferred in an 
NMR tube and NMR spectra are promptly recorded on a 500 MHz NMR (Bruker).  
DOSY NMR: calculations of Kd 
This calculation is based on the idea that if a ligand is strongly bound to a protein, their 
diffusion coefficients become identical. Contrariwise, if the ligand does not bind the protein, its 
diffusion coefficient is unchanged. Considering this, a linear equation can be written, considering the 
fraction of ligand bound to the protein, noted . 
protein bound   free ligand unbound   bound ligand
protein bound   free ligand   bound   bound ligand
Upon simplification, we obtain: 
  

Annex I. Experimental procedures 

 
178 
 
bound  bound ligand   free ligandprotein   free ligand 
It is now possible to get the bound ligand concentration: 
   0 bound
Finally, a Kd can be calculated: 
    = 
  0    0  
  
Molecular Docking 
Docking was achieved using AutoDock 4 program. Protein and ligand files were prepared using 
AutoDock Tools software. Numbers of torsions were set to 2 for Th-T and to 4 for metal complexes.  
Grid bow parameters were set as follows: 
For 2LMN: 
Number of points in the x-dimension = 126 
Number of points in the y-dimension = 96 
Number of points in the z-dimension = 126 
Spacing = 0.65 Å 
 
For 2MXU: 
Number of points in the x-dimension = 126 
Number of points in the y-dimension = 126 
Number of points in the z-dimension = 126 
Spacing = 0.608 Å 
Centre of Grid Box was modulated according to the model used to encompass the whole fibre. 
 
Atomic map files were generated using the AutoGrid4 program. Docking was then run using the 
AutoDock4 program with Lamarckian Genetic Algorithm 4.2 parameters set as follows: 
Number of GA runs = 100 
Population size = 300 
Maximum number of evals = 2,500,000 (medium) 
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Maximum number of generations = 27,000 
Maximum number of top individuals that automatically survive = 1 
Rate of gene mutation = 0.02 
Rate of Crossover = 0.8 
GA Crossover mode: twopt 
Mean of Cauchy distribution for gene mutation = 0 
Variance of Cauchy distribution for gene mutation = 1 
Number of generations for picking worst individual = 10 
Solutions were analysed using AutoDock Tools, clustering solutions using a rmsd-tolerance of 
2.0 Å. Binding energies and Ki were automatically calculated by AutoDock Tools.  
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Experimental procedures for Chapter V 
General procedure: catalytic experiment 
In a 1.5 mL microcentrifuge tube were added ACN (550 μL), water (220 μL), aqueous solution 
of ammonium bicarbonate (100 mM, 80 μL), catalyst dissolved in ACN (1 mM, 40 μL), styrene 
diluted in ACN (400 mM, 10 μL), and finally Oxone dissolved in water (200 mM, 100 μL). Tube was 
placed in a Thermomixer and incubated at 25°C shaking at 1500 rpm for 4 h.  
At the end of the reaction, 100 μL of reaction medium are sampled and mixed with 2 mL of 
toluene (internal standard). Samples were analysed by GC, using a method sets as follows: 50°C for 2 
min, temperature gradient going from 50 to 300°C over 10 min, then 300°C for 1 min.  
Retention times and attribution methods for each product described appear in the following 
table. 
Compound Retention time (min) Attribution 
Toluene 4.4 Commercial reference 
Styrene 5.5 Commercial reference 
Benzaldehyde 6.0 Commercial reference 
Phenyl acetaldehyde 6.6 Commercial reference 
Epoxide 6.8 Commercial reference 
2-hydroxy 1-phenyl ethanone 7.9 Detected by GC-MS 
Diol 8.3 Synthesized and isolated 
 
General procedure: catalytic experiment on fibres 
Fibres were obtained by aggregation of 200 μM Aβ1-40 in the presence of 200 μM Fe(L1)2. In 
the end of aggregation, wells containing fibres were combined and centrifuged (10,000 g, 5 min). 
Supernatant was carefully sampled and submitted to UV-Vis titration to determine the amount of 
Fe(L1)2 inserted into fibres. Complex content in fibres was determined to be 6.3 e-8 mol. To the fibre 
pellet were added ACN (590 μL), water (220 μL), aqueous solution of ammonium bicarbonate (100 
mM, 80 μL), styrene diluted in ACN (400 mM, 10 μL), and finally Oxone dissolved in water (200 
mM, 100 μL). Catalytic loading is of 1.6 mol%. Corresponding controls were modified accordingly. 
Tubes were placed in a Thermomixer and incubated at 25°C shaking at 1500 rpm for 4 h.  
GC monitoring of the reaction was completed similarly as in absence of fibres (see above).
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4-p-aminophenyl-2,6- (2’,2’’-pyridyl)pyridine (L1) 
1H NMR (300 MHz, DMSO-d6) δ (ppm) = 8.75 (ddd, J = 4.8, 1.7, 0.9 Hz, 2H, H6 + H6’’), 8.64 (m, 2H, H3 + 
H3’’), 8.62 (s, 2H, H3’ + H5’), 8.02 (ddd, J = 7.9, 7.7, 1.8 Hz, 2H, H4 + H4’’), 7.66 (d, Jortho = 8.5 Hz, 2H, H9 + 
H9’), 7.51 (ddd, J = 7.7, 4.8, 1.2 Hz, 2H, H5 + H5’’), 6.74 (d, Jortho = 8.5 Hz, 2H, H8 + H8’), 5.60 (s, 2H, H11). 
(cf MH-1-24) 
13C NMR (300 MHz, DMSO-d6) δ (ppm) = 155.38 (C2’ + C2’’), 155.35 (C2 + C6), 150.54 (C10), 149.61 (C4), 
149.30 (C6’ + C6’’), 137.42 (C4’ + C4’’), 127.63 (C8 + C8’), 124.37 (C5’ + C5’’), 123.75 (C7), 120.87 (C3’ + 
C3’’), 116.16 (C3 + C5), 114.30 (C9 + C9’). (cf MH-1-24) 
MS (ESI+): calculated for C21H16N4 : 324.14, found: 325.18 ([M+H]+). 
IR (ν in cm-1): 3482 (N-H asymmetrical stretching), 3387 (N-H symmetrical stretching), 1583 (N-H 
bending), 1183 (C-N stretching). 
 
4-p-carboxyphenyl—2,6 (2’,2’’-pyridyl)pyridine (L2) 
1H NMR (300 MHz, DMSO-d6): δ (ppm) = 8.78 (ddd, J = 4.8, 1.8, 0.8 Hz, 2H, H6 + H6’’), 8.74 (s, 
2H, H3’ + H5’), 8.69 (dt, J = 8.0, 1.2 Hz, 2H, H3’ + H3’’), 8.04 (m, 4H, H9 + H9’ + H4 + H4’’), 7.80 
(dt, J = 8.0, 1.1 Hz, 2H, H8 + H8’), 7.54 (ddd, J = 7.6, 4.7, 1.2 Hz, 2H, H5 + H5’’). 
13C NMR (300 MHz, DMSO-d6): δ (ppm) = 168.57, 156.07, 155.45, 152.29, 150.10, 149.83, 137.94, 
137.45, 130.45, 126.09, 124.98, 121.38, 118.32. 
MS (ESI+): calculated for C22H15N3O2: 353.12, found: 353.9 ([M+H]+). 
IR: ν (cm-1) =3201, 1585, 1553, 1385, 777. 
 
4-(p-nitrophenyl)- 2,6- (2’,2’’-pyridyl)pyridine (L3) 
1H NMR (400 MHz, CDCl3): δ (ppm) = 8.76 (s, 2H, H3’ + H5’), 8.74 (ddd, J = 4.8, 1.8, 0.9 Hz, 2H, 
H6 + H6’’), 8.69 (m, 2H, H3 + H3’’), 8.37 (d, J = 8.7 Hz, 2H, H9 + H9’), 8.05 (d, J = 8.7 Hz, 2H, H8 
+ H8’), 7.91 (td, J = 8.0, 7.6, 1.8 Hz, 2H, H4 + H4’’), 7.39 (ddd, J = 7.6, 4.8, 1.2 Hz, 2H, H5 + H5’’).  
13C NMR (300 MHz, CDCl3) δ (ppm) = 156.40 (C2 + C2”), 155.68 (C2’ + C6’), 149.21 (C10), 137.02 
(C4 + C4”), 128.31 (C8 + C8’), 124.20 (C5 + C5’’), 124.18 (C7), 121.41 (C3 + C3’’), 118.94 (C6 + 
C6”).  
MS (ESI+): [M + H]+ calculated for C21H15N4O2, 355.12; found, 355.18.  
IR (ν in cm-1): 3080 (aromatic C-H stretching), 1510 (N=O asymmetrical stretching), 1350 (N=O 
symmetrical stretching), 855 (C-N stretching). 
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4-furyl-2,6 (2’,2’’-pyridyl)pyridine (L4) 
1H NMR (300 MHz, DMSO-d6): δ (ppm) = 8.78 (ddd, J = 4.8, 1.8, 0.9 Hz, 2H, H6 + H6’’), 8.71 
(s, 2H, H3’ + H5’), 8.66 (ddd, J = 8.0, 1.2, 0.9 Hz, 2H, H3 + H3’’), 8.05 (ddd, J = 8.0, 7.5, 1.8 Hz, 2H, 
H4 + H4’’), 7.99 (dd, J = 1.7, 0.7 Hz, 2H, H10), 7.55 (ddd, J = 7.5, 4.8, 1.2 Hz, 2H, H5 + H5’’), 7.50 
(dd, J = 3.6, 0.7 Hz, 2H, H8), 6.76 (dd, J = 3.5, 1.8 Hz, 2H, H9). 
13C NMR (400 MHz, DMSO-d6): δ (ppm) = 155.67, 154.76, 150.71, 149.29, 145.05, 138.97, 
137.41, 124.56, 120.82, 114.08, 112.75, 110.31. 
MS (ESI+): calculated for C19H13N3O: 299.11, found: 300.6 ([M+H]+). 
IR: ν (cm-1) = 1607, 1587, 1544, 1466, 789, 730. 
 
4-p-bromophenyl-2,6 (2’,2’’-pyridyl)pyridine (L5) 
1H NMR (300 MHz, DMSO-d6): δ (ppm) = 8.73 (ddd, J = 4.8, 1.7, 0.9 Hz, 2H, H6 + H6’’), 8.71 
(s, 2H, H3’ + H5’), 8.64 (ddd, J = 8.0, 1.2, 0.9 Hz, 2H, H3’ + H3’’), 8.01 (ddd, J = 8.0, 7.5, 1.8 Hz, 
2H, H4 + H4’’), 7.87 (d, J = 8.5 Hz, 2H, H9 + H9’), 7.75 (d, J = 8.5 Hz, 2H, H8 + H8’), 7.50 (ddd, J = 
7.5, 4.8, 1.2 Hz, 2H, H5 + H5’’) 
13C NMR (300 MHz, DMSO-d6): δ (ppm) = 155.80, 154.83, 149.38, 148.30, 137.53, 136.68, 
132.34, 129.08, 124.65, 123.12, 121.00, 117.79. 
 
Cu(L1)2(PF6)2 
MS (ESI+): calculated for [C42H32CuN8]2+: 355.60; 356.60, found: 355.60 ([M]2+), 356.60 ([M+H]2+). 
IR: ν (cm-1) = 3639, 3569 (N-H asymmetrical stretching), 3397 (N-H symmetrical stretching), 1597 
(N-H bending), 1189 (C-N stretching), 826 (PF6), 555 (PF6). 
UV-Visible: λ = 397 nm (MLCT), ε = 8454 L.mol-1.cm-1  
X-rays: 
Empirical formula                  C42 H32 Cu N8, 2(F6 P) 
    Formula weight                     1002.25 
      Temperature                        180(2) K 
      Wavelength                         0.71073 A 
      Crystal system, space group       orthorhombic,  P 21 21 21 
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      Unit cell dimensions             a = 9.0216(5) A   alpha = 90 deg. 
                                        b = 13.5996(8) A    beta = 90 deg. 
                                        c = 32.9658(19) A   gamma = 90 deg. 
      Volume                             4044.6(4) A^3 
Z, Calculated density              4,  1.646 Mg/m^3 
Absorption coefficient             0.720 mm^-1 
F(000)                              2028 
Crystal size                      0.20 x 0.06 x 0.02 mm 
Theta range for data collection    2.57 to 25.33 deg. 
Limiting indices                   -10<=h<=10, -16<=k<=15,  -37<=l<=39 
 
Cu(L2)2(PF6)2 
MS (ESI+): calculated for [C42H32CuN8]2+: 768.1546, found: 768.1573 ([M+H]+); 384.5812, found 
384.5828 ([M+2H]2+). 
IR: ν (cm-1) = 3271 (O-H stretching), 1594, 1557, 1366. 
Cu(salophen) 
IR: ν (cm-1) = 3053, 3011, 1603, 1574, 1518, 742. 
UV-Visible: λ = 420 nm (MLCT), ε = 14340 L.mol-1.cm-1 
X-Rays:  
     Empirical formula                  C20 H14 Cu N2 O2  
      Formula weight                     377.88 
      Temperature                         180(2) K 
      Wavelength                          0.71073 A 
      Crystal system, space group        orthorhombic,  P 21 21 21 
      Unit cell dimensions            a = 9.1051(4) A   alpha = 90 deg. 
                                        b = 17.9213(8) A    beta = 90 deg. 
                                        c = 18.8494(9) A   gamma = 90 deg. 
      Volume                              3075.8(2) A^3 
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      Z, Calculated density              8,  1.632 Mg/m^3 
      Absorption coefficient             1.437 mm^-1 
      F(000)                              1544 
      Crystal size                        0.60 x 0.08 x 0.02 mm 
      Theta range for data collection    1.57 to 26.59 deg. 
      Limiting indices                    -10<=h<=11, -22<=k<=22, -23<=l<=23 
  
 
Fe(L1)2(PF6)2  
1H NMR: (300 MHz, DMSO-d6): δ (ppm) = 9.49 (s, 4H), 9.01 (dd, J = 7.9, 1.3 Hz, 4H), 8.34 (d, J = 
8.6 Hz, 4H), 8.00 (ddd, J = 7.9, 7.5, 1.5 Hz, 4H), 7.25 (dd, J = 5.7, 1.5 Hz, 4H), 7.17 (ddd, J = 7.5, 5.7, 
1.3 Hz, 4H), 6.91 (d, J = 8.6 Hz, 4H), 5.98 (s, 4H).  
13C NMR: (400 MHz, DMSO-d6): δ (ppm) = 159.40, 158.25, 152.71, 151.80, 149.43, 138.50, 128.93, 
127.36, 123.72, 122.00, 118.83, 114.07.  
MS (ESI+): calculated for [C42H32FeN8]
2+
: 352.10, 352.61; found: 352.1049, 352.6065 ([M]
2+
), 
calculated for [C42H32FeN8PF6]
+
: 849.1742, 850.1770, found: 849.1750, 850.1770 ([M]
+
).  
IR: ν (cm-1) = 3650 (N-H asymmetrical stretching), 3386 (N-H symmetrical stretching), 1595 (N-H 
bending), 1191 (C-N stretching), 820 (PF6), 554 (PF6).  
UV-Visible: λ = 576 nm (MLCT), ε = 32,700 L.mol-1.cm-1 in ACN. 
X-rays:  
Empirical formula                  C42 H32 Fe N8, 2(F6 P) 
Formula weight                     994.55 
Temperature                        180(2) K 
Wavelength                         0.71073 A 
Crystal system, space group        orthorhombic,  P 21 21 21 
Unit cell dimensions            a = 8.8873(3) A   alpha = 90 deg. 
                                       b = 13.3727(4) A    beta = 90 deg. 
                                       c = 32.9736(11) A   gamma = 90 deg. 
Volume                             3918.8(2) A^3 
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Z, Calculated density              4,  1.686 Mg/m^3 
Absorption coefficient             0.570 mm^-1 
F(000)                              2016 
Crystal size                        0.16 x 0.12 x 0.04 mm 
Theta range for data collection    2.40 to 28.53 deg. 
Limiting indices                   -11<=h<=11, -16<=k<=17, -44<=l<=44 
 
Fe(L2)2(PF6)2  
1H NMR: (300 MHz, DMSO-d6): δ (ppm) = 9.71 (s, 4H), 9.11 (dd, J = Hz, 4H), 8.56 (d, J = Hz, 4H), 
8.28 (dd, J = Hz, 4H), 8.05 (dd, J = Hz, 4H), 7.30 (, J = Hz, 4H), 7.20 (, J = Hz, 4H).  
MS (ESI+): calculated for [C44H30FeN6O4]2+: 381.0840, 381.5854; found: 381.0842, 381.5857 
([M]2+).  
IR: ν (cm-1) = 3358 (O-H stretching), 1341 (NO3), 1159 (C-N stretching), 781 (NO3).  
UV-Visible: λ = 568 nm (MLCT), ε = 24,400 L.mol-1.cm-1 in ACN. 
 
Fe(L3)2(PF6)2  
1H NMR: (300 MHz, ACN-d3): δ (ppm) = 9.24 (s, 4H), 8.65 (m, 4H), 8.63 (m, 4H), 8.51 (d, J = 8.9 
Hz, 4H), 7.93 (ddd, J = 7.9, 7.6, 1.5 Hz, 4H), 7.19 (d, J = 5.1 Hz, 4H), 7.10 (m, 4H). 
13C NMR: (400 MHz, ACN-d3): δ (ppm) = 161.50, 158.70, 154.03, 139.89, 130.18, 128.44, 125.72, 
125.03, 123.01. 
MS (ESI+): calculated for [C42H28FeN8O4]2+: 382.08; found: 382.56 ([M]2+).  
UV-Visible: λ = 574 nm (MLCT), ε = 34,700 L.mol-1.cm-1 in ACN. 
 
Fe(L4)2(PF6)2 
1H NMR: (400 MHz, DMSO-d6): d (ppm) = 9.49 (s, 4H), 8.96 (d, 4H), 8.25 (d, J = 1.9 Hz, 2H), 8.01 
(ddd, 4H), 7.96 (d, J = 3.5 Hz, 2H), 7.30 (d, 4H), 7.17 (ddd, 4H), 7.03 (dd, J = 3.5, 1.9 Hz, 2H). 
13C NMR: (400 MHz, ACN-d3): δ (ppm) = 161.21, 158.79, 154.06, 147.20, 139.68, 128.28, 124.75, 
114.52, 113.75. 
IR: ν (cm-1) = 1707, 1614, 1483, 826, 556. 
MS (ESI): Calculated for C38H26FeN6O22+: 327.07, found: 327.1 ([M]2+) 
UV-Visible: λ = 576 nm (MLCT), ε = 32,000 L.mol-1.cm-1 in ACN. 
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Fe(L5)2(NO3)2 
1H NMR: (400 MHz, ACN-d3): δ (ppm) = 9.17 (s, 4H, H3’+H5’), 8.60 (d, J = 8.1 Hz, 4H, H9+H9’), 
8.23 (d, J = 8.1 Hz, 4H, H8+H8’), 7.99 (d, J = 8.2 Hz, 4H, H3+H3’’), 7.91 (ddd, J = 8.2, 7.4 Hz, 4H, 
H4+H4’’), 7.17 (d, J = 5.6 Hz, 4H, H6+H6’’), 7.09 (d, J = 7.4, 5.6 Hz, 4H, H5+H5’’). 
13C NMR: (400 MHz, ACN-d3): δ (ppm) = 153.96, 139.70, 133.74, 130.63, 128.24, 124.79, 122.38. 
IR: ν (cm-1) = 1707, 1614, 1483, 826, 556. 
MS (ESI): Calculated for C42H28Br2FeN62+: 830.01, found: ([M]2+) 
UV-Visible: λ = 567 nm (MLCT), ε = 21,830 L.mol-1.cm-1 in ACN. 
 
Fe(bpy)3(PF6)2  
1H NMR: (300 MHz, ACN-d3): δ (ppm) = 8.50 (dt, J = 8.3, 1.0 Hz, 3H), 8.10 (m, 3H), 7.38 (m, 6H). 
13C NMR: (300 MHz, ACN-d3): δ (ppm) = 160.10, 155.14, 139.61, 128.38, 124.88. 
MS (ESI+): calculated for [C30H24FeN6]2+: 262.07 ([M]2+); found: 262.1.  
UV-Visible: λ = 520 nm (MLCT), ε = 9,400 L.mol-1.cm-1 in ACN. 
 
Fe(tpy)2(PF6)2  
1H NMR: (300 MHz, ACN-d3): δ (ppm) = 8.86 (d, J = 8.0 Hz, 4H), 8.64 (t, J = 8.0 Hz, 2H), 8.43 (d, J 
= 8.0 Hz, 4H), 7.85 (dd, J = 8.0, 4.4 Hz, 4H), 7.03 (d, J = 4.4 Hz, 8H). 
13C NMR: (400 MHz, ACN-d3): δ (ppm) = 161.17, 158.72, 154.00, 139.66, 138.90, 128.26, 124.67, 
124.59. 
MS (ESI+): calculated for [C30H22FeN6]2+: 261.06; found: 261.08 ([M]2+).  
UV-Visible: λ = 551 nm (MLCT), ε = 7,620 L.mol-1.cm-1 in ACN. 
 
Fe(phen)3(PF6)2  
1H NMR: (300 MHz, ACN-d3): δ (ppm) = 8.59 (d, J = 8.0 Hz, 6H), 8.23 (s, 6H), 7.59 (m, 12 H). 
13C NMR: (400 MHz, ACN-d3): δ (ppm) = 157.01, 150.65, 138.21, 131.40, 128.94, 126.78. 
MS (ESI+): calculated for [C36H24FeN6]2+: 298.07 ([M]2+), 741.10 ([M](PF6)+); found: 298.08, 
740.58.  
UV-Visible: λ = 509 nm (MLCT), ε = 9,820 L.mol-1.cm-1 in ACN. 
Ru(L1)2(PF6)2  
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1H NMR: (300 MHz, DMSO-d6): δ (ppm) = 9.31 (s, 4H), 9.07 (d, J = 8.1 Hz, 4H), 8.23 (d, J = 
8.6 Hz, 4H), 8.04 (ddd, J = 7.9, 1.5 Hz, 4H), 7.51 (d, J = 5.5 Hz, 4H), 7.25 (ddd, J = 7.6, 5.6, 1.3 Hz, 
4H), 6.87 (d, j = 8.6 Hz, 4H), 5.88 (s, 4H). 
13C NMR: (400 MHz, ACN-d3): δ (ppm) = 159.46, 156.14, 153.29, 151.77, 149.38, 138.75, 129.76, 
128.17, 125.33, 125.16, 120.75, 115.73. 
MS (ESI+): calculated for [C42H32RuN8]
2+
: 375.09; found: 375.42 ([M]2+)  
UV-Visible: λ = 502 nm (MLCT), ε = 24,100 L.mol-1.cm-1 in ACN. 
 
Ru(L2)2(PF6)2  
1H NMR: (300 MHz, ACN-d3): δ (ppm) = 9.07 (S, 4H), 8.68 (dd, J = 8.3, 1.3 Hz, 4H), 8.39 (d, J = 8.3 
Hz, 4H), 8.33 (d, J = 8.3 Hz, 4H), 8.00 (ddd, J = 8.3, 7.6, 1.4 Hz, 4H), 7.49 (dd, J = 5.6, 1.4 Hz, 4H), 
7.24 (ddd, J = 7.6, 5.6, 1,3 Hz, 4H).  
13C NMR: (400 MHz, DMSO-d6): δ (ppm) = 158.99 (Cq), 156.50 (Cq), 153.43, 139.10, 131.70, 
129.01, 128.51, 125.61, 122.90. 
MS (ESI+): calculated for [C44H30RuN6O4]2+: 404.07 ([M]2+); found: 404.0.  
UV-Visible: λ = 492 nm (MLCT), ε = 24,700 L.mol-1.cm-1  
 
Ru(L3)2(PF6)2  
1H NMR: (300 MHz, ACN-d3): δ (ppm) = 9.03 (s, 4H), 8.63 (ddd, J = 8.1, 1.4, 0.7 Hz, 4H), 8.56 (d, J 
= 8.8 Hz, 4H), 8.37 (d, J = 8.8 Hz, 4H), 7.94 (ddd, J = 8.1, 7.8, 1.5 Hz, 4H), 7.40 (ddd, J = 5.6, 1.5, 
0.7 Hz, 4H), 7.17 (ddd, J = 7.8, 5.6, 1.3 Hz, 4H). 
13C NMR: (400 MHz, DMSO-d6): δ (ppm) = 153.45, 139.19, 130.02, 128.58, 125.67, 125.61, 123.09. 
MS (ESI+): calculated for [C42H28RuN8O4]2+: 405.06; found: 405.36 ([M]2+).  
UV-Visible: λ = 494 nm (MLCT), ε = 25,100 L.mol-1.cm-1 in ACN. 
 
Ru(bpy)3(PF6)2  
1H NMR: (400 MHz, ACN-d3): δ (ppm) = 8.48 (ddd, J = 8.2, 1.2, 0.8 Hz, 6H), 8.04 (ddd, J = 8.2, 7.6, 
1.5 Hz, 6H), 7.71 (ddd, J = 5.6, 1.5, 0.8 Hz, 6H), 7.37 (ddd, J = 7.6, 5.6, 1.2, 6H). 
13C NMR: (400 MHz, DMSO-d6): δ (ppm) = 157.93, 152.63, 138.74, 128.51, 125.20. 
MS (ESI+): calculated for [C30H24FeN6]2+: 285.05 ([M]2+), 715.07 ([M](PF6)+); found: 284.98, 715.0. 
UV-Visible: λ = 451 nm (MLCT), ε = 15,575 L.mol-1.cm-1 in ACN. 
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Ru(tpy)2(PF6)2  
1H NMR: (300 MHz, ACN-d3): δ (ppm) = 8.72 (d, J = 8.1 Hz, 4H), 8.46 (d, J = 8.1 Hz, 4H), 8.38 (t, J 
= 8.2 Hz, 2H), 7.89 (dd, J = 8.1, 7.8 Hz, 4H), 7.31 (d, J = 5.2 Hz, 4H), 7.13 (dd, J = 7.8, 5.4 Hz, 4H). 
13C NMR: (300 MHz, ACN-d3): δ (ppm) = 158.02 (Cq), 156.10 (Cq), 152.44, 138.05, 137.52, 127.43, 
124.38, 123,69.  
MS (ESI+): calculated for [C30H22RuN6]2+ : 284.05 ([M]2+), 713.06 ([M](PF6)+); found: 284.15, 
713.03.  
UV-Visible: λ = 474 nm (MLCT), ε = 14,980 L.mol-1.cm-1 in ACN. 
 
Ru(phen)3(PF6)2  
1H NMR: (300 MHz, ACN-d3): δ (ppm) = 8.57 (dd, J = 8.3, 3.1 Hz, 6H), 8.23 (s, 6H), 8.00 (dd, J = 
5.3, 3.1 Hz, 6H), 7.60 (dd, J = 8.3, 5.3 Hz, 6H). 
13C NMR: (400 MHz, ACN-d3): δ (ppm) = 152.96, 148.94, 136.74, 131.94, 128.02, 125.84. 
MS (ESI+): calculated for [C36H24RuN6]2+: 321.05 ([M]2+), 787.07 ([M](PF6)+); found: 321.17, 
786.92.  
UV-Visible: λ = 444 nm (MLCT), ε = 15,280 L.mol-1.cm-1 in ACN. 
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a  b  s  t r  a c t
Artiﬁcial  metalloenzymes, with their  high selectivity and speciﬁcity combined with  a  wide scope of  reac-
tivity  and substrates,  constitute  an  original  approach  for catalyst  development. Different strategies have
been  proposed  for  their  elaboration,  proceeding from modiﬁcation of natural enzymes using bioengi-
neering  methods to  de novo protein design. Another  bio-inspired methodology for the development of
hybrid  catalysts consists  in the incorporation of coordination complexes into biomolecules, with the
aim  to  upgrade their  catalytic  abilities. In  these systems, the reaction performed  by  the naked catalyst
is  modulated by  the  well-deﬁned  structure of the host  biomolecule.  This conveys added value to  the
catalyst,  such as enantioselectivity or chemoselectivity. DNA, apo-enzymes, proteins and peptides  have
been  engaged in this approach, affording  a wide diversity of  reactivities and substrates.  The resulting
systems  can then be improved by  combined  chemical  and bioengineering optimization, allowing access
to  powerful catalysts. Because this approach can virtually be applied to any biomolecule or coordination
complex,  the elaboration of bio-based  hybrid catalysts seems promising for advance in catalysis.
©  2015 Elsevier  B.V. All rights reserved.
1. Introduction
Over the last 15 years, the three Nobel Prizes associated with
organic synthesis have been awarded to Knowles, Noyori and
Sharpless for metal-catalyzed asymmetric hydrogenation and oxi-
dation  in 2001, Chauvin, Grubbs and Schrock for the work on oleﬁn
metathesis, based on the use of ruthenium, molybdenum and tung-
sten  complexes as catalysts, and in 2005 Heck, Negishi and Suzuki
for  palladium catalysed cross coupling in  2010.
This  exempliﬁes the importance of coordination complexes
(noted as such in  the present review to deﬁne a  metallic centre
bound to synthetic ligands) in organic synthesis. From a general
view, coordination catalysis utilises a large selection of metallic
ions, ligands and substrates to achieve a large set  of reactivities.
The  reactivity of a coordination complex is mainly based on
the tuning of its redox properties, substrate accessibility and/or
Lewis acidity of its metallic centre. This is achieved by  modulat-
ing the donor/acceptor character of the ligands, and by controlling
their geometry and arrangement around the  metallic centre. For
instance,  steric hindrance can be used to induce substrate selec-
tivity. Chemists excel at  developing very sophisticated ligands that
confer to  the  complexes the desired properties. But  this has several
bottlenecks, among which the multi-step synthesis of the targeted
ligands which potentially represents a  signiﬁcant economical con-
cern  and might hamper its accessibility.
By observing metalloenzymes, it  appears that the ﬁrst, sec-
ond and outer coordination spheres play a  crucial role in  tuning
the reactivity of the metallic centre. Indeed within enzymes, the
reactivity is not only driven by  steric  control of the  metal site
by the ligands (proteic and/or non-proteic) but also via remote
interactions (H bonding, electrostatic, stacking etc.) that guide the
substrate into the active site, position it to ease the  reaction, and
help the  release of the products.
In  other words, the strength of enzymes resides in the com-
bination of inner and outer sphere effects, which confers rate
enhancement, speciﬁcity and selectivity to  the enzyme. Moreover
the mobility, dynamics and/or conformational changes of the pro-
teic  chain can help to adopt the  most suitable geometry for the
active site. All of this makes enzymes very powerful catalysts, but
only  considering a single reactivity and substrate. Chemists thus
developed synthetic analogues of enzymes active sites, to better
understand the structure-properties relationships. The ultimate
goal would be to select the crucial parameters for powerful cataly-
sis,  getting rid of the less pertinent ones. Such mimics (structural,
functional or both) were thus developed for hydrogenases [1–4],
superoxide dismutases [5–9], photosynthetic system [10,11], oxy-
genases [12] etc. These systems go from the simplest, using very
usual metallic ions and ligands [13] to the  most sophisticated ones
[14–16].  Even though models of metalloenzymes are very helpful
for investigation purposes, these models are often poor catalysts
(with respect to their loadings).
To  overcome these two drawbacks, namely the cost and time
consuming production of the ligands involved in the  coordina-
tion catalysts while achieving the very high selectivity of enzymes,
chemists have recently developed two convergent strategies: (i)
Protein  re-design, based on their knowledge of the natural systems
and  (ii) de novo design of biomolecules, seeking for perfectly deﬁned
metal ion environment. In the  ﬁrst approach, shown in  Fig. 1 artiﬁ-
cial metalloenzymes are re-designed by modiﬁcation of the native
metal ion (panel B) or of the ligands (panel C) using bioengineer-
ing. In the second approach, depicted in the  panel D  of Fig. 1, host
cavities are rationally formed from scratch.
This review covers an  alternative approach, which cannot be
classiﬁed into those previously deﬁned categories. It relies on the
insertion of a  simple coordination catalyst into a  host biomolecule
(Fig. 1, panel A). The guest coordination complex already pos-
sesses its own reactivity, which is modulated by the environment
provided by the  host biomolecule. The appealing nature of this
approach is that it truly takes advantage of the knowledge of the
two ﬁelds (biochemistry and coordination chemistry driven catal-
ysis).  The coordination complex can be chosen among the wide
library of catalysts, according to the  desired reactivity, and can
be tuned easily. Obviously the  chosen system should be able to
operate under condition compatible with biomolecules (i.e. solvent
and  temperature compatibility). On the other hand, biomolecules
can be engineered to  host the complex in  the most suitable way.
This  strategy is exempliﬁed by a  Cu(bipy) complex, into a host
biomolecule, namely DNA, proteins and peptides, which is antic-
ipated to confer selectivity properties to  the  guest complex.
Therefore,  this review will focus on highlighting how a  coordi-
nation complex could have its activity upgraded by its interaction
with a  biomolecule. Using selected examples, we are trying to
exemplify this concept and to  highlight the different methodolo-
gies used. We may try to  foresee the  opened perspectives and future
development of this approach.
2.  The  artiﬁcial metalloenzyme approach
Before covering the main topic of this review, i.e. incorporation
of coordination complexes into biomolecules (Panel A Fig. 1),  we
will  give a concise overview of the other approaches (Panels B–D).
They all share the same ultimate goal: development of systems able
to  catalyse synthetically relevant reactions with the exquisite rates
and  selectivities of enzymes, and with an  extended set  of substrates.
This goal seems very  ambitious, and the path to  this target appears
still long and tough. Still, huge progresses have been made in the
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Fig. 1. Strategies to develop bio-supported catalysts based either on  the insertion of a  simple catalyst into a  biomolecule (panel A)  or  to the elaboration of artiﬁcial metal-
loenzymes (panels B–D), including modiﬁcation of  the natural metallic ion  of  an enzyme (panel B); the modiﬁcation of the natural active site of  an enzyme, generally by
mutagenesis (panel C); and the elaboration of  new  metallic ion coordinating biomolecules (panel D).
development of such systems, both in terms of methodology and
results.
Over  the years, different approaches have been explored to
develop such artiﬁcial enzymes, and these methods have been
widely reviewed [17–26]. As a  consequence, we will only summa-
rize  the most prominent and latest results in the following (sections
2.1 to  2.4).
2.1.  Replacement of  the native metallic ion
The replacement of the native metallic ion of an enzyme rep-
resents a  ﬁrst strategy, relatively easy to  develop. It consists in
replacing the native metallic ion of an enzyme by another. Kaiser
and  co-workers ﬁrst  exempliﬁed this approach in 1976. By chang-
ing  Zn(II) with Cu(II) in carboxypeptidase A, they showed that the
native  activity was completely inhibited, and substituted by oxi-
dizing properties [27]. Subsequent studies from Soumillion and
colleagues showed that Mn(II)-substituted carbonic anhydrase was
active  in epoxidation reactions [28]. In parallel, Kazlauskas et al.
showed  that replacing Zn(II) by Mn(II) could also afford a new per-
oxidase activity [29]. Fig. 2  shows the X-ray structure of the active
site of a Mn(II)-substituted human carbonic anhydrase. It appears
that the same amino acids are involved in  the coordination of Zn(II)
and  of Mn(II) (i.e. His 94, His 96, and His 119), showing that the  over-
all organization of the  active site is not distorted by the substitution
of the metallic ion. Some mutagenesis studies showed that several
other amino acids within the catalytic pocket (white circles in Fig. 2)
inﬂuence catalysis, further conﬁrming the crucial importance of the
whole  environment.
Another step forward was the  replacement of Zn(II) with a
metallic ion of low natural abundance. This was achieved by
Fig. 2. X-ray crystal structure of Mn(II) replacing Zn(II) in human carbonic anhy-
drase II.  The amino acids involved in metallic ion coordination (His 94, His 96 and His
119) are the same for  Mn and Zn. The circled amino acids affect catalysis efﬁciency
and  selectivity. Reprinted with permission from [29].
incorporating Rh(I) into human carbonic anhydrase. This system
catalyzed oleﬁn hydrogenation and styrene hydroformylation with
moderate to good yields and selectivities [30,31].
This  constitutes a typical illustration of how a  simple swap of
metallic ion in an enzyme can dramatically modify its reactivity.
Unfortunately, this strategy can only be applied to  a few, rather
exceptional, enzymes, and in  most cases, more signiﬁcant modiﬁ-
cations are required.
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Fig. 3. Left panel: Native active site of myoglobin (PDB 1JP6), right panel: Engineered
active site of myoglobin, showing the mutated residues (pink) and the Fe centres
in  red. The  resulting enzyme displays NO reductase activity [32,33]. Reprinted with
permission from [33].
2.2. Mutations of the amino-acid involved in the active site
Another  strategy aiming at modifying the native function of
enzymes was to facilitate some amino-acid mutations in order to
alter  their reactivity. This  approach usually beneﬁts from the sup-
port  of molecular modelling. Mutations, for instance, can impact
either the coordination of the  metallic centre or remote amino
acids in order to favour active site access towards a  wider range
of  substrates.
A  representative example, which encompasses these two
aspects, is the engineering of cytochrome P450, an iron hemo-
protein which catalyzes mono-oxygenation of substrates using
molecular dioxygen. By  performing some mutations on its active
site,  either site-directed or random, it  is possible to  enlarge the set
of  substrates of cytochrome P450, keeping its good oxidizing prop-
erties [34]. The Cys apical ligand of the  heme centre of cytochrome
P450 was replaced by Ser, removing the  “thiolate push”, and thus
preventing the native monooxygenase activity (i.e. C O bond for-
mation). Combination with other mutations was  also needed to
reach  speciﬁc reactivities, such as  intramolecular amination (C N
bond  formation) [35,36] and carbene transfer to  oleﬁns [37,38],
showing good yields and  selectivities.
Another possibility is the creation of a host site for a metallic ion
from scratch. For instance, Lu and co-workers gave WT-myoglobin
(Fig. 3, left panel) a  nitric oxide reductase activity, by mutating
three residues of the natural active site and thus inducing the
coordination of a second Fe ion (Fig. 3, right panel) [32,33]. The
mutated amino acids appear in pink in Fig. 3, right  panel (mutations
L29H, F43H, and V68E) and the  Fe(II) ions in red. Similarly, WT-
myoglobin was  implemented to  coordinate Cu ion, thus displaying
a 4-electrons dioxygen reductase activity [39].
A  ﬁnal opportunity would be to induce a  new reactivity in the
enzyme by modifying the peptidic ligands of the metallic cen-
tre.  Although this straightforward approach is  frequently used to
decipher the essential residues bound to the catalytic ion, or to
modulate the native reactivity of enzymes [40], there is to  the best
of  our knowledge, no report on mutations to induce a non-native
reactivity.
The use of bioengineering to  form artiﬁcial metalloenzymes,
although very interesting, can become highly laborious, and
requires an exceptional combination of advanced knowledge in
molecular and structural biology, molecular modelling and chem-
istry.
Fig. 4. The  three stranded coiled coils coordinating Zn, developed by  Pecoraro’s
group  reproduced by courtesy of V. Pecoraro [41].
2.3. De novo design of artiﬁcial metalloenzymes
De novo protein design, which consists in the rational design of
new proteins to  get a  speciﬁc 3D structure is of central interest for
artiﬁcial enzymes elaboration [42]. A typical example is the triple
helix bundle developed by the Pecoraro’s group (Fig. 4), formed by
hydrophobic interactions between amphiphilic helices. These sys-
tems,  ﬁrst developed to  study the  binding of toxic heavy metals
[43], have required huge effort to  control the geometry of the bind-
ing site [44]. These systems were then transposed for Cu [45,46] and
Zn  coordination [41,47] showing promising results as artiﬁcial met-
alloenzymes [48–50] such as nitrite reductase [46] and hydrolase
[47] or hydratase [41].
2.4.  Conclusions
All of this shows the abundant and diverse ways to generate arti-
ﬁcial enzymes, both in terms of approaches and techniques. The
coordination complex incorporation approach caught our atten-
tion, as it combines the use of inorganic and organic chemistry as
well  as biology.
In  the following sections, we will focus on this approach, which
consists in the insertion of a guest catalyst into a host biomolecule.
This will be split into three subsections depending on the nature
of the biomolecule: DNA, 3D-structured proteins, antibodies and
ﬂexible  peptides.
3.  Incorporation of coordination complexes into DNA
3.1.  Anchoring strategies
With  their structure in  double helix, nucleic acids are one of
the  most elegant natural examples of chirality. The  DNA double
helix constitutes a  rare example of switch from central molecular
chirality to  helical supramolecular chirality. Nature only uses RNA
for  metal-driven catalysis in ribozymes, but its known low stability
so far prevented its use for catalytic applications. DNA was  thus
logically a  privileged scaffold for asymmetric catalysis.
Fig.  5 depicts the different strategies reported in literature to
anchor a catalyst to  a DNA molecule. Three main possibilities have
been  investigated: (a) weak but additive interactions (stacking,
electrostatic, hydrogen bonds) with DNA, (b) covalent linkage with
a  base form synthetic DNA and  (c) covalent linkage to  a  known
intercalant of DNA.
In  the  former case, the  coordination complex is thus in close
vicinity to  the DNA chiral environment, although no experimen-
tal structural investigations on the exact mode of binding has
been reported to  date (Fig. 5a). In the latter case, the linkage to a
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Fig. 5. The three strategies to anchor coordination complexes on  DNA double helix.
Additive weak interactions anchoring (a), covalent binding to an oligonucleotide
followed  by  hybridization with another DNA strand (b) and DNA intercalant linked
to a  coordination complex (c).
DNA-intercalant, decreases the impact of the  chiral environ-
ment on the  catalytic centre due  to the increased distance
between the host molecule and the guest coordination complex
(Fig. 5c). Finally, it is  also possible to  covalently bioconju-
gate coordination complexes to  oligonucleotides, then re-forming
the  helix (second case). This strategy is less straightforward,
requiring oligonucleotide synthesis, but it allows a  better ratio-
nalization of the  effect of the oligonucleotide sequence in the
vicinity of the anchoring site, as more detailed in Section 3.3
(Fig. 5b).
These  three strategies were successfully applied, either using
natural or synthetic DNA. Some examples, considered as rep-
resentative, are further detailed in this review, and appear in
Table 1.
3.2. Intercalation of coordination complexes into natural
double-strand  DNA
In  their seminal paper, Roelfes and  Feringa presented the ﬁrst
example of a direct transfer of chirality from natural DNA  to  a Cu(II)
complex involved in Diels–Alder reaction [51]. It was promoted by
stacking  interactions between DNA and a  DNA-intercalant linked to
an  achiral Cu(II) complexes (Scheme 1, ligand amino pyridine and
Fig.  5c). When tested for catalytic Diels–Alder reaction, these sys-
tems  showed a strong predominance for the expected endo product
(entry  1a, Table 1 and Scheme 2  (i)). The enantiomeric compo-
sition was  dependent on linker length, and, moreover, when the
linker becomes too long, ee values dropped dramatically. Later
on, the same authors showed that this strategy is less efﬁcient
with respect to the cyclopropanation reaction than when simple
Cu(II) complexes interact directly with the DNA (entries 1b and
2a  in Table 1) via stacking with aromatic ligands (Scheme 1, lig-
ands  bipy, terpy, phen, and phenazine) [52]. This second anchoring
approach (Fig. 5a) was thus  used in subsequent studies, where
these Cu(II) complexes afforded ee’s up to 99% when involved in
Diels–Alder reaction, Friedel–Crafts, syn-Hydratation of enones or
Michael additions (entry 2b, Table 1) [53–55]. Interestingly, they
showed that in  the Friedel–Crafts and Diels–Alder reactions, the
replacement of a bipyridine by  a terpyridine causes a swap of enan-
tiopreference [55]. The Cu(II) to  ligand ratio was  also investigated
with respect to the cyclopropanation reaction and increasing the
Cu(II):L  ratio to  1:1 from 1:2 leads to an  improvement in the ee
values. In the meantime, Wang et al. showed the  crucial role of the
helix  chirality by studying L- and D-DNA interacting with a  Cu(II)
bipyridine complex [56]. The L- and D-hybrid systems, tested on
Friedel–Crafts and Michael addition, showed “mirror” selectivities,
the switch from L  to  D  inducing a  switch of chiral induction (entry
3,  Table 1).
Lastly,  Park and colleagues demonstrated the  dramatic inﬂuence
of the  oligonucleotide sequence: the  ee values strongly depend on
Scheme 1. Typical intercalating ligands used in DNA-based hybrid catalysts.
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Table 1
Some representative examples of DNA-based hybrid catalysts.
Entry Biomolecule Ligand type Metallic ion  LLink type
according to Fig.  5
Reaction Conv. max (%)  ee max (%) Ref.
1a St-DNA (aminomethyl)-
Pyridine
Cu(II) c Diels–Alder  80 82 [51]
1b  Cyclopropanation 42 0
2a Bipyridine
Terpyridine
Phenanthroline
Phenazine
Cu(II) a Cyclopropanation  100 84 [52]
2b  Michael addition,
Syn-hydratation of enones
Diels–Alder
Friedel–Crafts
100  99 [53–55]
3  Artiﬁcial L- and D-DNA Bipyridine Cu(II) a  Friedel–Crafts
Michael Addition
89  99 [56]
4  Artiﬁcial DNA Bipyridines
Phenanthrolines
Cu(II)  b Friedel–Crafts 91 82 [57]
5  Functionalized DNA Bipyridine Cu(II) b Diels–Alder 76 93 [58]
6  Functionalized DNA Diene Ir(I) b Allylic Amination
Kinetic  resolution of  phenyl
allyl  acetate
92  28 [59]
7  Functionalized DNA Bipyridine Cu(II) b Friedel–Crafts 80 86 [60]
Fig. 6. A binding model proposed by Park et  al. for coordination complex interca-
lation  into  double-helix DNA. The product of the reaction is also present. Reprinted
with  permission from [57].
the nucleotide GC or TA content and whether the A, T or G, C bases
are  alternated (entry 4, Table 1). The oligonucleotide length is also
signiﬁcant [57]. They also propose a  model of the catalyst binding
together with the product of the  reaction buried in the DNA helix
(Fig. 6)  [57,61].
This  case study highlights the  fundamental importance of both
the chiral environment of the host molecule and the nature of
ligand in  the guest catalysts, each  of them inﬂuencing selectivity.
The results obtained here are remarkably clear-cut since it is pos-
sible to  commute from one enantiomer to  the other by  changing
either the chirality of the DNA [56] or the  ligand used [55]. The
simplicity  of this system enables a thorough evaluation of key
parameters although no deep investigation on the exact nature of
the  catalytic entities has been performed yet. This would have fos-
tered  a  rapid and rational improvement of key features. The use
of solid-phase supported DNA was  recently reported, allowing the
development of such catalysis at synthetically relevant scale and
enabling recycling of the catalyst [62,63].
3.3. Covalently-functionalized oligonucleotides
Another strategy proposed by  Roelfes’ group was to covalently
functionalize an oligonucleotide with a  ligand. Upon hybridization
with a DNA template and coordination of the Cu(II) ion, a helix
DNA  duplex is formed with the  coordination complex in its vicinity
(Fig.  5b). This approach is convenient, allowing the screening of dif-
ferent  nucleotides, linkers and  ligands. When tested for Diels–Alder
cycloaddition, the  different systems displayed ee’s up to  93% (entry
5, Table 1).  Expectedly this effect is substantially dependent on
the nucleotides surrounding the anchoring position [58]. Similar
studies were conducted on synthetic DNA functionalized with a
diene–Ir(I) complex (entry 6, Table 1).  The resulting catalysts only
yielded 28% ee in kinetic resolution of phenyl allyl acetate [59].
Finally, Sugiyama and colleagues proposed to graft DNA strands on
two  points of a  bipyridine (Table 1, entry 7 and Scheme 3, middle).
Upon metallation and hybridization, the  resulting catalyst showed
86% ee for Friedel–Crafts alkylation [60]. The high reaction–speciﬁc
nature of this strategy is clearly highlighted by  the signiﬁcant dif-
ferences of enantioselectivities. Despite the variable efﬁciency of
these  catalysts, they constitute the  ﬁrst examples of covalently
functionalized DNA operating catalysis. The wholeness of this kind
of hybrid systems should be more easily preserved than those
where the coordination catalyst is bound to DNA by non-covalent
interactions.
3.4. Conclusions
All these examples conﬁrm the  value of DNA as host biomolecule
for asymmetric catalysis. According to  these results, all anchoring
strategies seem to afford good to excellent efﬁciencies. On the one
hand,  covalent linkage of catalysts to DNA allows one to  drive the
position of the complex relative to the DNA sequence, depending
on the  linker length. It is thus  anticipated an  easier rationaliza-
tion of different parameters. However, production of these systems
requires delicate solid phase synthesis. On the  other hand, the  use
of  non-covalent anchoring has the advantage to  be very  easy to  set
up,  enabling one to  test various ligands, but the lack of insight on  the
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Scheme 2. Typical reactions operated by  hybrid catalysts. (i) Diels–Alder, (ii) Michael addition (Friedel–Craft reaction corresponds to Michael addition with Nu = indole), (iii)
cyclopropanation, (iv) sulfoxidation, (v) epoxidation, (vi) hydrogenation, (vii) Ring-closing metathesis, (viii) Ring opening metathesis polymerization.
Scheme 3. Typical covalently linked ligands used in DNA-based hybrid catalysts (X = linker).
exact position and interactions in the system is still to  be explored.
Roelfes’ group proposed an intermediate strategy, using a  cisplatin
link  to  anchor the catalyst to  DNA, but here again the  positioning
remains unclear [64]. The choice of the anchoring strategy must be
considered according to  the  targeted reaction.
4.  Incorporation of coordination complexes into proteins
Virtually  any of the 35,000 known proteins might exhibit some
level of interaction with a coordination complex, thus becoming
a potential catalyst. Nevertheless in order to  signiﬁcantly enhance
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Fig. 7. The three existing strategies for the incorporation of a coordination complex inside a  protein.
the catalytic activity of the  coordination complex, this interaction
has to be optimized. Therefore the ﬁrst  criterion for selection of
an  appropriate host candidate is the  presence of a  large enough
vacant space buried inside the  protein. This could serve as a  reaction
pocket, conferring selectivity and even speciﬁcity to substrates.
As  for the DNA host biomolecule, three anchoring methods are
possible, as  depicted in Fig. 7.
(a) Non-covalent anchoring, taking advantage of weak but additive
interactions  between proteins and the  coordination complex
(electrostatic, hydrophobic, H-bonding. .  .).  This method is  very
convenient,  but requires investigating the location of the com-
plex.
(b) Covalent attachment of the coordination complex in the pocket
of  a protein. This strategy is more time-demanding and consists
in  the covalent attachment of the complex by bioconjugation,
using  natural or synthetic amino-acids.
(c)  Functionalization of a  natural guest of a protein with a coordi-
nation  complex.
Each of these strategies has been successfully explored, depend-
ing to  the targeted protein and will be exempliﬁed in  more detail
below.
4.1. Incorporation of a  coordination complex into an apo-protein
4.1.1.  Insertion of planar coordination complexes
A  straightforward strategy for the elaboration of hybrid cata-
lysts is the insertion of a synthetic catalyst into a  protein from
which the native Fe hemic group (entries 1a–1d, Table 2) or Ni(II)
metallophore (entry 2a, in Table 2) has been removed, thus taking
advantage of the cavity left vacant.
The ﬁrst example is the incorporation of coordination com-
plexes into apo-myoglobin, which naturally hosts an iron
porphyrin. Because of their planar structure and their high catalytic
efﬁciency, Schiff base complexes were considered as  good candi-
dates to replace the hemic group. The ﬁrst approach was envisaged
by Carey et al. consisting in  the covalent dual anchoring of func-
tionalized Mn(III) or Cr(III) salen complexes (Scheme 4) into the
hydrophobic pocket of apo-myoglobin. To do so, a  covalent link
was made by  the creation of two disulﬁde bridges using methane
thio-sulfonate salen derivatives and Cys mutations, which positions
were determined by molecular modelling. The corresponding Cys
mutants were expressed, produced and puriﬁed, then bioconju-
gated to  the Schiff base complex. Modelling studies showed that
the complex was positioned in the active site exactly at the  same
place as the hemic group in the wild type myoglobin, as depicted
in Fig. 8.
The interest of the double anchoring of the coordination catalyst
has  been established by  comparison with a  single-point attached
counterpart in  the  sulfoxidation of thioanisole: both the ee  val-
ues  and the rate have been improved (entries 1a and 1b, Table 2).
This  is  fully consistent with a  better immobilisation of the  complex
Fig. 8. Modelling of  the myoglobin active centre with Mn(salen)-type complex
covalently  attached on  the two L72C and Y103C mutated positions. The position
of  the hemic group in  wild-type myoglobin is shown in blue showing the correct
positioning  of  the coordination complex. Reprinted with permission from [65].
inside the  cavity, taking thus full  advantage of a better deﬁned envi-
ronment [65]. These systems could now be further improved by
directed  evolution, or  applied to  a  wider set of reactivities, but the
overall  process might represent a  rather time-consuming approach.
Another possibility, potentially easier but also probably less
topologically deﬁned, consists in anchoring the complex via non-
covalent interactions (Fig. 7a). The direct incorporation of Schiff
base complexes into apo-myoglobin mutants was  tried because
incorporation into wild-type myoglobin was  less successful [66].
The crystal structures obtained showed that the complexes were
positioned in pertinent mutants at the  exact same place as the
hemic group in the wild-type myoglobin. Even if the rate was
improved by optimising the ligand, the ee  obtained for thioanisole
sulfoxidation did not  exceed 33% (entry 1c, Table 2).
Comparison with the previous example leads to the observation
of three general remarks (although drawing trends with only two
examples is  uncertain): (i) Imposing a  ﬁxed position using covalent
anchorage may  precludes the most suitable location of the catalysts
for catalytic enhancement, whereas more freedom is given to the
system in  non-covalent anchoring, (ii) in contrast, regarding the ee
values  a  much more dynamic interaction leads to  a loss of inﬂuence
of the proteic environment and thus to a lower chiral induction,
(iii) combining the two approaches, i.e., mutations to  covalently
anchor the catalyst and to optimize the binding pocket could be
more  appropriate.
In  this context, Lewis and co-workers found a good compro-
mise: allowing the  complex to choose its best position, and then
covalently grafting it in situ [67]. To do so, they functionalized
their Mn-terpyridine complex with a  maleimide group. The result-
ing  coordination complex was  incubated with cysteine mutants of
nitrobindin. Once the complex is set at its most suitable place inside
the protein, the  formation of a  carbon-sulfur covalent bond allows
the immobilization of the  complex. The mutants displaying the
most efﬁcient bioconjugation were considered as the most appro-
priate, and were tested for several catalytic oxidation reactions
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Scheme 4. Typical ligands used in  protein-based hybrid catalysts.
(entry 1d, Table 2). In the best case, the product was obtained with
99%  yield. Yet the ee’s obtained remain low (7%) indicating that the
most  suitable positioning of the metallic complex in the protein
may  not efﬁciently transfer the chiral information from the envi-
ronment to  the reaction product. The topology of the  ediﬁce still
needs to  be improved for example allowing the metallic cofactor
to  choose its most favourable position inside the  protein. The reac-
tivity of the maleimide allows its permanent binding at the right
position, limiting dynamic exchanges; but the precise positioning
into a  chiral pocket might require a thorough screening to allow a
signiﬁcant chiral induction to be achieved.
4.1.2.  Insertion of non-planar coordination complexes
4.1.2.1.  Metallic complexes transport proteins. Non-planar coordi-
nation complexes can be inserted into proteins involved in  the
transport of metallic complexes. They have the  advantage to
exist natively in  the apo-form and are able to bind coordination
complexes easily. Thus, Fe(II) complexes of the diamino-pyridine
BPMEN and BPMCN ligands were incorporated into the apo-form
of the  periplasmic nickel-binding protein NikA (where NikA binds
Ni(II)  in form of a  coordination complex). They display sulfoxida-
tion activity with good to  moderate yields (entry 2a, Table 2).  In that
case,  suitable substrates were determined by docking studies [68].
Table 2
Some representative examples of hybrid catalysts made by incorporation of a coordination complex in  the active site  of  an apo-protein.
Entry  Biomolecule Ligand Metallic ion  Link type
according to
Fig.  7.
Reaction Conv. max (%)  ee max (%)  Ref.
1a Apo-Myoglobin Schiff base  Mn(III), Cr(III) b Asymmetric
sulfoxidation
0.4 TO/min 51 [65]
1b  0.05 TO/min 12
1c  a 2.7 TO/min 33 [66]
1d  Apo-
nitrobindin
Terpy Mn(II) b Benzylic oxygenation,
Oleﬁn  epoxidation
89
99
7  [67]
2a  Periplasmic
nickel-binding
protein
BPMEN BPMCN Fe(III)  a Selective sulfoxidation 85 Sel. 100 [68]
2b  FhuA Hoveyda–Grubbs
catalyst
Ru(III) b ROMP 98 Cis 70% [69]
2c  Apo-
nitrobindin
Cp Rh(I) b Polymerization of
phenylacetylene
Cis  95%  [70]
2d  Apo-ferritin Norbornadiene Rh(I) b Polymerization of
phenylacetylene
[71]
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Fig. 9. Crystal structure of the FeL complex [L  = 5  N-benzyl-N′-(2-hydroxybenzyl)-
N,N′-ethylenediaminediacetic acid] incorporated into  periplasmic nickel-binding
protein  (NikA) and electron density map  of FeL. Reprinted with permission from
[72].
To illustrate this, Fig. 9  shows the  crystal structure obtained for the
incorporation of an analogous Fe(II) complex into NikA, which was
involved in arene dihydroxylation of the ligand itself [72].
The  other example is FhuA that incorporates the
Hoveyda–Grubbs catalyst (entry 2b, Table 2).  This system showed
efﬁcient polymerization with a  preference for the cis form [69].
This was assigned to  the cavity effect of FhuA, which has a  -
barrel structure and hence a  conﬁned space. Similar results, i.e.
efﬁcient polymerization and preference for the  cis  form, were
also reported for another hybrid system namely the -barrel
protein aponitrobindin functionalized with CpRh(I) (entry 2c,
Table 2). These examples nicely illustrate the fundamental effect
of  the  conﬁnement to  force the reaction even to  its less favoured
stereochemical outcome.
4.1.2.2.  Ferritin. An even more pronounced conﬁnement can be
obtained with apo-ferritin, a hollow protein with several rela-
tively small access-channels. A Rh(I)-norbornadiene complex was
inserted  in the cavity of apo-ferritin, where it  reacted to  form a
covalent bond with a  cysteine. The Rh complex catalyzes the poly-
merization of phenyl acetylene with restricted molecular weight
and  a  narrow molecular weight distribution due  to  the cavity effect
(entry 2d, Table 2) [71].
From  these examples, one can conclude that the  native pocket
of  an  apo-enzyme can efﬁciently host a  coordination complex, thus
displaying new catalytic activities. The conversion rates obtained
are mostly high, but the selectivity/speciﬁcity ﬂuctuate depending
on the  reactions tested, potentially requiring some optimization.
Another potential approach is to  consider naturally non-metallic
proteins.
4.2. Incorporation of a  coordination complex into a non-metallic
protein
A  more chancy strategy is to  consider proteins which do not
natively host metallic complex but possess cavities, for instance
for the transport of organic molecules. Different proteins were
considered, as summarized in Table 3. Even though cavities are
not  naturally used for catalysis, they remain an asymmetric
environment, allowing stereoselectivity to  be expected. When
the cavity is sufﬁciently small, using of non-covalent anchoring
approach was preferred.
A  very  simple strategy to form hybrid catalyst was introduced
by Ward and co-workers, who incorporated vanadium oxide [78]
or  osmium oxide [79] into streptavidin. The resulting systems
displayed selectivities up to  95% ee for oleﬁns dihydroxylation.
However, these examples exceed the  scope of this review, in so
far as metallic oxides may  not  be considered as  true coordination
complexes. Anyway, they are neat illustrations of how a catalytic
moiety can be upgraded by a proteic environment.
4.2.1. The host cavity is  made by a  monomeric protein
An  elegant biomimetic oxidation system was  developed by
incorporating a  corrole metallic complex into albumins. The  com-
plex  was  buried inside the protein via interaction with the  sulfonato
and pentaﬂuorophenyl groups that decorated the  corrole central
group. The system was  tested for thioanisole sulfoxidation using
hydrogen peroxide, showing efﬁcient reactivity and promising ee’s
(Entry  1a, Table 3) [70].
Another  example, using the same strategy, was the incorpora-
tion of manganese complexes into xylanase (entry 1b, Table 3),
a  protein displaying afﬁnity for synthetic Fe(II) porphyrins [80].
When tested for styrene oxidation, the system displayed moderate
yields, but good selectivities (up to 80%) [74].
4.2.2. The host cavity is  made by supramolecular interaction of
proteins
In  a recent study, Roelfes and  co-workers showed that the
hydrophobic interface formed upon dimerization of proteins could
also  be used as an active site. Copper complexes grafted onto
dimerized Lactococcal multidrug resistance regulator were used
to  catalyse Diels–Alder cycloaddition with excellent efﬁciency and
selectivity (entry 2a, Table 3) [75].
In a similar way, Hilvert developed a system based on a small
heat shock protein, able to form spherical capsids, functionalized
with Grubbs–Hoveyda catalyst. This system demonstrated good
properties for oleﬁn metathesis (entry 2b, Table 3) [76].
These  two studies represent good examples of reconversion of
protein activity. This methodology could beneﬁcially be extended
to other proteins.
4.2.3. Grafting of coordination complex outside a  cavity
An  hybrid system with coordination complexes, namely a bipy-
Sc(III) species, in which the ligand is covalently anchored onto the
surface  of proteins has been developed. The species exhibit mod-
erate results both in terms of conversion and ee values (entry 3,
Table 3). Although this strategy seems less convincing compared
with the previously detailed ones and to  the  corresponding DNA
covalent functionalization (Section 3.3), this proof of concept study
shows that there is some ability for induction of asymmetry. This
should stimulate further studies along this approach [77].
4.2.4.  Concluding remarks
The  previously described results provide evidence for the
expected importance of the  cavity effect. If this strategy is at this
point of limited extent, it could at least conceptually be applied
to a  wide range of hollow proteins; yet the optimization required
to  achieve an efﬁcient catalysis remains the main source of uncer-
tainty, and might require signiﬁcant screening capabilities.
4.3.  Functionalization of a  natural cofactor of a protein
4.3.1.  (Strept)avidin/biotin system
In an effort to simplify the  elaboration of hybrid catalysts,
some groups proposed to attach the  coordination complex onto
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Table  3
Some representative examples of hybrid catalysts prepared by incorporation of  a  coordination complex into  non-enzymatic proteins.
Entry  Biomolecule Ligand Metal Link type according
to  Fig. 7
Reaction Conv. max  (%) ee max (%)  Ref.
1a Serum albumins Corrole Fe(III), Mn(III) a  Asymmetric sulfoxidation 98 74 [73]
1b  Xylanase A Salen,
porphyrin
Mn  a  Asymmetric epoxidation 23 80 [74]
2a  Lactococcal
multidrug
resistance
Regulator (LmrR)
Bipyridine,
phenanthroline
Cu(II)  b  Asymmetric Diels–Alder 100 97 [75]
2b  Small heat  shock
protein
Hoveyda–Grubbs
catalyst
Ru(III)  b  RCM TON  = 33 / [76]
3  Tubular protein Bipyridine Sc(III) b  Epoxide ring-opening 42 17 [77]
Table 4
Representative examples of hybrid catalysts formed by functionalization of natural cofactors of proteins.
Entry  Biomolecule Ligand Metal Link type
according to
Fig.  7
Reaction Conv. max (%) ee max (%) Ref.
1a Avidin,
streptavidin
Phosphines Rh(I) c Asymmetric
hydrogenation
100 96 [81,82]
1b  Streptavidin
(S112H)
Cp functionalized Rh(III) Asymmetric
transfer
hydrogenation
100 79 [83]
1c  Streptavidin
mutants
Asymmetric
C H activation
99 82 [84]
1d  Streptavidin
S112 mutants
Imine
reduction
100 96 [85]
1e  Streptavidin Salen Mn(III) Asymmetric
sulfoxidation
50 11 [86]
2a  Chymotrypsin Hoveyda–Grubbs
catalyst
Ru(III) Ring closing
metathesis
TN  = 20 (2 h) /  [87]
2b  Neocarzinostatin
mutant
Porphyrin Fe(III) Thioanisole
sulfoxidation
/  13 [88]
natural cofactors of proteins, taking advantage of the strong
host–guest interaction to incorporate the complex at  a  precise
place in the protein (Fig. 7c). The most common example is
the biotin-(strept)avidin couple, in which the  interaction is very
strong (KD ≈  10−15 M)  and fast (binding rate constant of biotin-
streptavidin is in a range of 3.0 × 106–4.5 × 107 M−1 s−1) [89].
Conjugation of catalysts onto biotin, followed by  interaction with
avidin or streptavidin, affords highly reliable systems [90]. This also
permits one to  get rid of the complicated step of bioconjugation
with a protein (Fig. 7b). But  some other protein-cofactor systems
can  be used as well, as illustrated in Table 4.
In  2003, Ward and co-workers developed a  phosphine function-
alized biotin which upon metallation with Rh(I) and incorporation
into avidin and streptavidin was able to catalyse asymmetric hydro-
genation with 96% ee  after 15 h  (entry 1a,  Table 4). Interestingly,
avidin and streptavidin offered opposite enantiopreference [81].
Much effort was made in subsequent studies to  improve this sys-
tem, considering different optimization parameters. Chemically,
different anchoring positions, metallic ions and ligands were tested.
Different mutants of the host protein were also considered. Finally,
a  library of substrates was tested. This  “chemogenetic” optimiza-
tion allowed determination of a system with good to very good
selectivity. After the chemogenetic selection, a  careful study of crys-
tal  structures allowed one to  point out other mutations of interest,
further improving the  catalysts [82]. This constitutes a  very elegant
example of combined chemical and genetic optimization, showing
the  full potential of this yet simple system.
In subsequent studies, Ward and colleagues showed that a
unique mutated position (112 or 121) into histidine allowed a dual
anchoring, both by  biotin/streptavidin interaction and by Rh coor-
dination by histidine, as shown on Fig. 10. This appeared highly
beneﬁcial to  the system: conversion is increased from 60 to  100%,
and  ee  values from 0  to 79% for transfer hydrogenation of a  prochiral
imine  compared with the wild type protein (entry 1b, Table 4) [83].
This  study only considered the transfer hydrogenation, but other
reactivities were also demonstrated. As such, biotinylated Rh(III)
complexes were efﬁcient for C H activation (entry 1c, Table 4)
[84] and imine reduction (entry 1d, Table 4) [85,91]. In a  very com-
prehensive study, the  same group investigated several parameters
with respect to  the hydrogen transfer reaction, including the nature
of  the coordination complex and the inﬂuence of the mutants at
position 112. Interestingly, the nature of the complex impacted
strongly the  transfer of chirality, with the two  enantiomers being
detected depending on the catalysts used. Also, with a given cata-
lyst,  the two enantiomers can be obtained depending on the  nature
of  the  mutants at position 112 [92]. More recently, Cp-Ir(III) com-
plexes were also successfully used for NAD+ reduction [93].
Mn salen complexes were also tested for asymmetric sulfoxi-
dation, displaying somewhat low yields and selectivities (entry 1e,
Table  4),  therefore illustrating that this strategy cannot be system-
atically generalized, and requires cautious optimization [86].
4.3.2.  Other host–guest systems
Still within this context, an original example is  the use of a
natural protein inhibitor to constitute hybrid catalysts proposed
by  Matsuo and co-workers. They functionalized an  inhibitor of
chymotrypsin with a  linker and a  catalytic entity. The inhibitor
goes into the active site of the  enzyme and the coordination com-
plex is thus positioned inside the  hydrophobic pocket, and can
intercept the incoming substrates. In the present case, the function-
alized Grubbs–Hoveyda complex was  able to catalyze ring-closing
metathesis with good rates (entry 2a, Table 4) [87].
Finally  Mahy and co-workers used neocarzinostatin, a  cyto-
toxic protein known to  recognize speciﬁcally enediyne derivatives.
Since these compounds are of limited stability, the authors used
a  formerly established mutant that binds tightly testosterone. An
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Fig. 10. Docking studies of Rh-functionalized biotin into WT-streptavidin (left), S112H (middle) and K121H streptavidin (right). The  double anchoring of the coordination
complex improves the catalytic properties of the system. Reprinted with permission from [83].
Fig. 11. Schematic representation of  antibody–coordination complex recognition
(a)  and antibody–antigen recognition, where the antigen is linked to the coordina-
tion  complex. (b).
iron–porphyrin complex was then decorated with a  testosterone
moiety and inserted into the cavity. The resulting system was sub-
sequently tested for thioanisole sulfoxidation, but showed only low
enantioselectivity (entry 2b, Table 4) [88].
4.3.3. Concluding remarks
These  examples show the high convenience of this approach,
which affords efﬁcient catalysts with a  single bioconjugation step.
Directed evolution enables one to  further improve the  systems,
virtually both in  terms of rate and selectivity. This represents a
powerful example of combining chemical and biological methods
for hybrid catalysts development and optimization.
5. Incorporation of  a  coordination complex into an
antibody
An  original example of hybrid catalyst development is  the use
the antibody–antigen recognition. The presence of exogeneous
species in a body leads to the  production of antibodies directed
against it, forming a  very stable duplex. In the case of an exoge-
neous metallic complex, the association with an antibody would
modify the environment of the  metallic centre in an asymmetric
manner (Fig. 11a).
For  example, Mahy’s group aimed at developing cytochrome
P450 mimics by  raising antibodies against natural or synthetic por-
phyrins [94]. In this precise case, the proteic environment also
serves as a  protection against heme oxidative degradation.
A  ﬁrst example using Fe(III)–porphyrin and the corresponding
antibody showed good peroxidase activity, using a  large scope of
peroxide sources and substrates [95]. Looking for a  system bearing
an axial ligand on the metallic centre, antibodies were then directed
against Microperoxidase 8. The resulting scaffold was  tested for
peroxidase activity [96], nitration of phenol [97] and thioanisole
sulfoxidation [98]. This study constitutes a  proof of concept for
the use of antibody–metal complex system as hydrid catalysts.
But despite the clear improvement due to the  presence of an axial
ligand, these systems remain much less efﬁcient than natural heme
peroxidases. A way  to  further improve the  system, could be the
use of monoclonal antibodies, combined with site directed muta-
genesis and structural analysis. Yet, this would represent a  tough
approach.
Nevertheless, an  attempt was made using the so-called “Trojan
horse strategy”. The porphyrin group was attached to an estra-
diol molecule which allowed binding to  an  anti-estradiol antibody
(Fig.  11b). The catalytic rates were thus improved, but the ee’s
remained low, witnessing the  low inﬂuence of the proteic envi-
ronment [99]. This seems to show the limitations of this antibody
strategy, at least for heme complexes.
6. Incorporation of coordination complexes into peptides
Because  of their shorter length, and hence the  possibility to
produce them by chemical synthesis, peptides were ﬁrst consid-
ered as a more convenient opportunity for elaboration of hybrid
catalysts. Efforts of synthesis and functionalization are less sub-
stantial than for proteins and their handling is less sensitive. But
their conformational dynamic makes the  chiral environment less
deﬁned, diminishing the  effect on the  metallic centre. Predictions
are also more difﬁcult to make, which contrasts with the de  novo
approach used for proteins and  presented in Section 2.3. In a  ﬁrst
trial to  design a  catalyst-peptide hybrid, Lewis et al. developed
tetrapeptides bearing Pd or Ir metallacycle on their N-terminal end
(Fig.  12a, Scheme 5). These constructions conserved the  reactivity of
the  free complexes, but unfortunately no selectivity was  observed.
The authors proposed that in its favoured conformation, the peptide
scaffold is too far from the  metallic centre to  inﬂuence its reactivity
(entry 1, Table 5) [100].
To  get a  stronger inﬂuence, the coordination complex was
grafted along the peptidic chain, using a  non-natural amino acid
as  the  anchor. Christensen and colleagues proposed to  position the
ligands either in the middle (Fig. 12b) or on  each side (Fig. 12c) of
the  peptide backbone. In this way, peptidic environment surrounds
the  coordination complexes. A ﬁrst attempt with phosphine ligands
displayed high yields but mild selectivities [101]. Interestingly, the
doubly coordinated complex (Fig. 12e) showed better yields and
selectivity than its single-point attachment analogue (Fig. 12d).
This  is  consistent with an increasing burying of the catalytic centre
in  the  peptidic scaffold. In a  subsequent work, a  second generation
of [P,S] ligands enabled the remarkable improvement of selectivi-
ties. Although not discussed in the publication, a  reason for the
improvement could be the closer proximity of the chiral centre
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Scheme 5. [Pd] and [Ir]-peptide hybrid catalysts.
Table 5
Some examples of peptides bearing a  catalytically active coordination complex detailed in this review.
Entry  Biomolecule Ligand Metal Link type
according to
Fig.  12
Reaction Conv.max (%) ee max (%)  Ref.
1  Tetra-peptide Metallacycle Pd(II), Ir (II) a Transfer hydrogenation
Imidate  rearrangement
70 0  [100]
2  Peptide Phosphines Pd  (II) b–c Asymmetric allylic
substitution
98 60 [101,102]
2  -Turn peptide Phosphines Pd  (II) c Asymmetric addition 99 85 [103]
Fig. 12. Top: Schematic representations of the different types of coordination com-
plex decorated peptides. The  complexes can be either in the terminal end (a), or
along the peptidic chain, either by single (b)  or double-point attachment (c). Bot-
tom: the corresponding molecular dynamics modelling obtained by  Christensen
et  al. (d and e). Reprinted with permission from [101].
of the amino acids and the fact that the  backbone is part of the
metallacycle, which is expected to increase the rigidity. They also
demonstrated that inverting the  stereochemistry of the amino acids
induces  an inversion of the stereochemistry of the products [102].
The  use of three-dimensionally ordered peptides was  also pro-
posed, in order to reduce the  dynamic issue. In a  paper of Gilbertson,
a library of -turn peptides was decorated with phosphine lig-
ands. The corresponding Pd  complex turned efﬁcient for Michael
addition, with ee’s up to  85% [103].
A ﬁnal strategy is the coordination of Rh catalysts to  carboxyl-
ate groups from side chains of amino-acids of host peptides [104].
However, this is at  the edge of the  central approach described in
this  review (i.e. a combination of a coordination complex with a
host  biomolecule), since the  host peptide itself participates in the
metal  centre binding.
Table 5 summarizes the results obtained for these different
examples. It appears that conversion rates are excellent, showing
that good results can still be expected from peptide-based cata-
lysts.  Enantiomeric excesses vary a  lot according to  the systems,
highlighting a  new issue: here, there is no risk of steric hindrance,
contrariwise it seems that the  peptidic backbone should surround
the catalytic moiety as much as possible. The somewhat easy
development of libraries should strongly help to  improve the sys-
tems, even though the  results may  be not fully predictable.
7.  Conclusion and outlooks
7.1.  SWOT analysis
All  these examples highlight the wide diversity of applications
that can  arise from this area of hybrid catalysts prepared from coor-
dination  complexes host in  biomolecules: chiral scaffolds can be
constituted from a large scope of biomolecules and used to  target
a  wide range of reactivities. The  simple change of ligands or metals
usually constitutes the ﬁrst optimization step, affording moderate
efﬁciencies. For protein-based systems, genetic optimization might
be  performed for further improvement. In all cases, the help of
molecular modelling and  the  resolution of crystal (or NMR) struc-
tures are crucial for the determination of relevant mutations. This
overall process affords catalysts with high selectivity. The rates
are still remaining more difﬁcult to improve, sometimes requiring
several optimization cycles.
Even  if at this point, none of these systems can compete with
naturally occurring enzymes in terms of speed rates (all the  pro-
cesses presented above being complete in a  few hours to a few
days). Their main interest is that they clearly establish that the cat-
alytic  properties of a  coordination complex can be highly enriched
by the stereochemical induction brought by biomolecules.
Compared with standard coordination catalysts they offer inter-
esting alternative as they can  induce enantioselectivity without
requiring production of sophisticated ligands, which is expen-
sive and generates waste. In contrast, the use of biosynthesized
biomolecules further increases the sustainability factor brought by
catalysis.
Further development of the ﬁeld can be expected and would
take advantage of the methodological improvement. First of all,
control experiments should never be omitted (in particular, com-
parison with the catalyst in absence of the host biomolecule). In
addition, although having a  unique reaction as universal control is
hardly  achievable, having a  set  of test reactions depending on the
nature  of the catalysts appears reasonable.
Similarly, the metrics used to assess catalytic efﬁciency (yield,
conversion, speed rates, TON. .  .)  might also be standardized [105].
These would bring a  more convenient comparison of the  differ-
ent  approaches. A relation between the  catalytic efﬁciency (kcat)
and  the catalyst stability under the  reaction conditions (TON
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usually used in catalysis based on transition metals) would also
be  beneﬁcial.
Related to  this, one can also regret that mainly highly efﬁcient
strategies are reported. Indeed poorly efﬁcient systems, when prop-
erly  characterized, represent important and interesting results,
which can shed light on unexpected effects of the biomolecule
when interacting with the  coordination complex. This  can help to
understand the rational behind these systems, and to  develop new
optimization strategies.
Still,  the development of hybrid catalysts seems to  have a
bright future. First, because it  relies on a  truly multidisciplinary
approach, it  can take advantage of the  technological developments
from the two ﬁelds, enabling a  faster advance. The constantly
increasing understanding of protein-substrate interactions should
help  to move towards a more rational method for proteins opti-
mization. Among the efforts made to  facilitate the elaboration of
the  systems, one can especially consider the  improvement of the
anchoring methods [106–108]. Thanks to  the  support of compu-
tational modelling and directed evolution [40], virtually all of the
existing systems can be further optimized.
7.2. Perspectives: Other bio- or bioinspired molecules as potential
host
Finally,  it  appears that many biomolecules are still to  be
explored. This includes:
(i)  Auto-assembling structures: Some promising examples involv-
ing  auto-assembling proteins, including ﬁbres, needles, disc
and  rod structures obtained with amphiphilic proteins and
peptides  recently appeared in literature, showing interest-
ing  extension of this research ﬁeld to heterogeneous catalysis
[109,110]. This approach using amyloid type ﬁbres has been
recently  developed for hydrolytic purpose [111]. It is currently
under  investigation in our group for application to more syn-
thetically  relevant catalytic reactions.
(ii)  Foldamers: The  emerging use of foldamers, i.e. artiﬁcial folded
molecular  architectures inspired by the structures and func-
tions  of biopolymers (glycoproteins [112,113] and peptide
analogues  [114]), is  also of great potential [115]. Foldamers are
already  being used for organocatalysis [116–118], and can coor-
dinate  metallic ions [119], or form cavities [120]. Yet, to  the best
of  our knowledge, no example was described for chemistry-
based  catalysis hosted by foldamer scaffolds, but this is likely
to  appear in  a  very close future. Another direction of research is
also  consisting in the  generation of catalysts inside cells, which
gives  a new dimension to  the ﬁeld [36].
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Abstract
An improved production and purification method for Alzheimer’s disease related methio-
nine-modified amyloid-β 1–40 and 1–42 peptides is proposed, taking advantage of the for-
mation of inclusion body in Escherichia coli. A Thioflavin-S assay was set-up to evaluate
inclusion body formation during growth and optimize culture conditions for amyloid-β pep-
tides production. A simple and fast purification protocol including first the isolation of the
inclusion bodies and second, two cycles of high pH denaturation/ neutralization combined
with an ultrafiltration step on 30-kDa cut-off membrane was established. Special attention
was paid to purity monitoring based on a rational combination of UV spectrophotometry and
SDS-PAGE analyses at the various stages of the process. It revealed that this chromatogra-
phy-free protocol affords good yield of high quality peptides in term of purity. The resulting
peptides were fully characterized and are appropriate models for highly reproducible in vitro
aggregation studies.
Introduction
With a worldwide incidence of millions people, Alzheimer’s disease is considered as a major
health issue, and much research effort is currently being devoted to better understand the
causes and mechanisms of the disease. Diverse therapeutic approaches are being explored,
including hormonotherapy [1], immunotherapy [2], genetics [3] or pharmaceutics [4].
Although their implication in the disease remains unclear, the presence of amyloid plaques
and oligomers in the synaptic cleft is widely considered as one of the hallmarks of Alzheimer’s
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disease, and were found to be highly deleterious for neuron plasticity [5]. These aggregates are
mainly constituted of amyloid-β (Aβ) peptides, namely Aβ1–40 and Aβ1–42, resulting from the
abnormal proteolytic cleavage of the amyloid precursor protein. Understanding the mecha-
nism of formation and the behavior of these aggregates could pave the way to new therapeutic
approaches against Alzheimer’s disease, promoting multiple investigations on Aβ peptide
aggregation process [6].
For in vitro experimentation, disposing of Aβ samples displaying reproducible behaviours is
a key issue. Indeed, aggregation was shown to be highly sensitive to many factors, such as tem-
perature, concentration, agitation, but also storage or sample preparation [7,8]. But most
importantly, the presence of both contaminants and pre-aggregated forms of the peptide were
shown to strongly alter the course of aggregation, either inhibiting it or yielding no fibrillary
material. In this regard, the easy access to pure and homogeneous Aβ samples is still challeng-
ing and essential for in vitro experimentation.
Most investigations are usually performed with chemically synthesized peptides. Although
convenient and easily accessible, solid phase peptide synthesis can be complex in terms of puri-
fication. Indeed, the presence of peptides with altered sequence caused by non-quantitative
synthetic steps or of racemized peptides is observed, which can hardly be removed, even by up-
to-date purification methods. Traces of salts or metal ions were also reported [9]. Finally, pres-
ence of pre-formed aggregates due to storage conditions is frequent. All of this induce signifi-
cant variations of aggregation properties from batch to batch. This has been recently
exemplified in a study, which showed that the recombinant peptide is more aggregation-prone
and more neurotoxic than its synthetic analogue, demonstrating a deleterious effect of syn-
thetic procedures on peptide properties [10]. This has encouraged the exploration of various
biological routes to access recombinant Aβ, getting rid of such issues.
Aβ peptide recombinant production was attempted in yeast [11] or by combining recombi-
nant and synthetic procedures [12] but, to date, the most common expression system remains
Escherichia coli. Most often, peptides are appended to a fusion protein that enhance their solu-
bility and ease their isolation and purification using affinity chromatography. However, such
strategies raised several issues. First of all, despite the increased solubility of the fusion proteins,
a significant amount of the peptide frequently remains insoluble, thus requiring an extra dena-
turation step to achieve full recovery [13,14]. Moreover, a cleavage site has to be installed, its
position being critical; indeed if not carefully chosen, upon cleavage amino-acids will be intro-
duced at the terminal end of the peptide, potentially modifying its aggregation and metal-bind-
ing properties [15,16]. The same drawback is also observed with smaller affinity tags [17,18].
This problem has been solved through the use of proteolytic enzymes whose cleavage sites
enable the formation of native Aβ (Factor Xa, Enterokinase. . .) [19,20]. Still such methods are
time-consuming and require many purification steps, including long affinity chromatography
purification procedures that induce in a loss of peptide. A representative example was
described by Zhang and co-workers, showing that only 24% of Glutathione S-transferase-
tagged peptide is recovered in the soluble fraction after cell lysis. This yield is weakly affected
by affinity chromatography (21%), but drops to 5.1% after thrombin cleavage. To overcome
this drawback, it was proposed to express Aβ in its native form in E. coli [21,22]. Notably, Aβ
forms insoluble inclusion bodies (IBs) when expressed in E. coli in their native form. This was
exploited by Walsh and co-workers to isolate pure recombinant methionine-modified Aβ pep-
tides MAβ1–40 and MAβ1–42 in five purification steps [21].
We describe here an alternative and straightforward procedure of recombinant MAβ1–40
and MAβ1–42 production and purification. First, expression conditions were optimized using
Thioflavin-S (Th-S), a known fluorescent probe for in vivo imaging of IBs. We subsequently
established a rapid purification process based on inclusion body treatment with NaOH followed
Robust Purification Procedure of Recombinant Alzheimer's Disease Methionine-Amyloid-Beta Peptides
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by an ultrafiltration step that has proven remarkably efficient to remove protein and nucleic acid
contaminants. Finally, a detailed monitoring of the purification process was conducted, showing
that only a combination of characterization techniques can ensure sample reliability.
Materials and Methods
All chemicals were purchased from Sigma-Aldrich (St. Louis, USA). pET28a plasmid was pur-
chased from Novagen (Darmstadt, Germany). NcoI, XhoI and BamHI restriction enzymes
Antarctic phosphatase and T4 DNA Ligase were purchased from New England Biolabs (Ips-
wich, USA) and used with the provided buffer according to supplier’s recommendations.
pET28a_His-Thromb-Aβ1–42 plasmid was synthesized by Genecust (Dudelange, Luxembourg).
E. coli TOP10 cells and E. coli BL21 (DE3) cells were obtained from Invitrogen (Carlsbad,
USA). QIAprep spin MiniPrep kit was purchased from Qiagen (Hilden, Germany). Sequence
analyses of the constructions were performed by GATC Biotech (Constance, Germany).
Vectors construction and cloning procedure
The commercial pET28a plasmid was digested by NcoI and XhoI restriction enzymes, dephos-
phorylated using Antarctic phosphatase, and gel purified on an agarose 0.8% Tris acetate
EDTA (TAE) gel. The pET28a_His-Thromb-Aβ1–42 plasmid was used as template for PCR
amplification of the Aβ1–42 coding sequence using pR_pET28_Ab42: AGCGGTGGCAGCAG
CCAACTCAGCT and pF_pET28_Ab42: GACCTACCCATGGACGCTGAATTTCGCCAC
GACTCCGGCTAT as primers. The PCR product was digested by NcoI and XhoI, gel purified
on an agarose 1.2% TAE gel and ligated in the NcoI/XhoI digested pET28a yielding the desired
pET28a_MAβ1–42 plasmid. The construction was used to transform chimiocompetent E.coli
TOP10 cells that were grown on solid Luria-Bertani (LB) medium (10 g/L tryptone, 10 g/L
NaCl, 5 g/L yeast extract) containing 50 mg/L kanamycin (1X). One colony was used to inocu-
late 5 mL LB kanamycin 1X at 37°C. Cells were grown overnight, harvested before plasmid
extraction using a MiniPrep kit.
The pET28a_MAβ1–40 was obtained from pET28a_MAβ1–42 using a similar procedure
except that the sequence coding for Aβ1–40 was PCR-amplified with pR_pet28_Ab40: AATGG
ATCCTAATTAAACAACGCCGCCAACCATCAGACCGATG and pF_pet28_Ab40: AATT
GTGAGCGGATAACAATTCCCCTCTAG as primers. The PCR-product was digested using
NcoI and BamHI, and ligated into NcoI/BamHI digested and dephosphorylated pET28a.
Expression of MAβ1–40 and MAβ1–42 and inclusion body isolation
Chemically competent E. coli BL21 (DE3) cells transformed with pET28a_MAβ1–40 or
pET28a_MAβ1–42 plasmids were used for peptide production. One single colony was used to
inoculate 10 mL LB kanamycin 1X medium. The cells were grown for 16 h. 100 mL of LB
medium containing kanamycin 1X were inoculated to an OD600 of 0.05 with an overnight pre-
culture performed from one single clone in 10 mL LB-Kana medium. Cells were grown at 37°C
under agitation to an OD600 of 0.8. Expression was induced with 0.5 mM Isopropyl β-D-1-thio-
galactopyranoside (IPTG) during for 4 additional hours of culture at 37°C. Cells were harvested
by centrifugation (8,000 g, 10 min) and re-suspended to an OD600 of 80 in lysis buffer (50 mM
Tris-HCl, 100 mMNaCl, pH 8) containing 1% Tergitol-type NP40 detergent. Cells were then
lysed by 30s sonication on ice and the lysate was centrifuged (12,000 g, 10 min). The insoluble
fraction was re-suspended in 1 mL lysis buffer, containing phenylmethanesulfonyl fluoride (15
mM) and lysozyme (300 μg/mL), and incubated for 1 h at room temperature. IBs were har-
vested by centrifugation (12,000 g, 10 min), washed with Triton X100 0.5% and twice with
phosphate saline buffer (PBS) 1X pH 8. IBs were finally resuspended in PBS buffer and
Robust Purification Procedure of Recombinant Alzheimer's Disease Methionine-Amyloid-Beta Peptides
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submitted to 10 cycles of 10 s sonication followed by centrifugation to remove nucleic acid con-
taminants contained in the supernatant and that could be stacked on their surface, according
to a previously reported procedure [23].
Peptide purification
IBs were denatured by 2 h incubation in 500 μL of NaOH 50 mM under smooth shaking at
room temperature. The resulting mixture was centrifuged (12,000 g, 5 min), and the superna-
tant neutralized by addition of 500 mMHCl. The formation of a white precipitate was
observed. The mixture was centrifuged once again, and the supernatant was collected. To opti-
mize recovery, this denaturation/neutralisation cycle was applied twice. Supernatants were
passed through a 30-kDa Amicon-Ultra centrifugal device, to remove high molecular weight
contaminant proteins, and then concentrated on a 3-kDa Amicon-Ultra centrifugal device.
SDS-PAGE analysis
15 μL protein samples were mixed with 5 μL Laemli Sample buffer (Bio-Rad) containing 10%
β-mercaptoethanol, and denatured at 95°C for 10 min. Samples were then loaded on a Mini-
protean TGX Stain-Free Any Kd Precast Gel (Bio-Rad) and electrophoresis was run for 30 min
at 150 V in Tris/Glycine/SDS buffer (Bio-Rad). Gel was then stained using PageBlue Protein
Staining solution (Bio-Rad).
Thioflavin-S staining
Samples of Aβ peptide producing cells or purified IBs are centrifuged (12,000 g, 10 min) and
resuspended in 200 μL Thioflavin-S 125 μM in PBS 1X pH 8. After 15 min incubation, cells or
IBs were harvested by centrifugation, washed with 200 μL PBS, re-suspended in PBS, and sub-
mitted to fluorescence experiments.
Fluorescence microscopy
50 μL samples of Th-S stained cells or IBs were dispensed on a microscope glass slide and
imaged using a Leica microscope with a 63x lens with a DAPI filter (λexc = 340–380 nm,
dichroic = 400, λem = 425 nm).
Fluorescence spectrophotometry
1 mL samples of Th-S stained cells or IBs were placed in a quartz cuvette and their emission
spectra were recorded using a Jasco fluorimeter (λexc = 375 nm). Right after each measurement,
OD600 was measured, to normalize the signal.
1H NMR
Pure samples of peptides in water were diluted to 100 μM in phosphate buffer 50 mM pH 7 in
D2O.
1H NMR spectra were recorded on a 500 MHz NMR (Bruker) at 25°C using solvent as
reference. As a control, synthetic Aβ1–40 was dissolved in NaOD and diluted to 100 μM under
the same conditions.
LC-MS
Peptide samples were analysed by LC-MS on an Agilent 1200 HPLC fitted with a Macherey
Nagel Nucleodur 300–5 C4 ec 250 mm x 2 mm 5 μm at 30°C coupled with a Thermo Fisher
Scientific LCQ Fleet mass spectrometer fitted with an H-ESI II Probe.
Robust Purification Procedure of Recombinant Alzheimer's Disease Methionine-Amyloid-Beta Peptides
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Samples were eluted at 0.33 mL/min using a gradient of acetonitrile going from 5% to 90%
in aqueous formic acid 0.1% in 12 min. Multiply-charged peptides were detected by mass spec-
trometry (ESI +).
Thioflavin-T aggregation assay
To ensure of the homogeneity of the starting sample, monomeric peptides were isolated by ste-
ric exclusion chromatography (SEC). An Aktä Purifier system equipped with a Superdex 75
10/300 column was equilibrated with 2 column volumes of 15 mM NaOH. Peptide samples in
NaOH 50 mM were then eluted using NaOH 15 mM at 1 mL/min, with UV monitoring at 220
and 293 nm. Monomeric MAβ peptides display retention times around 9 min. Fractions con-
taining peptides were collected, centrifuged, and their concentration was assessed by UV-Vis at
pH 12 (λ = 293 nm, ε = 2400 L.mol-1.cm-1).
In a 384-wells microplate (Greiner) were added phosphate buffer (50 mM), Thioflavin-T
(10 μM) and freshly SEC-purified peptide (20 μM or 50 μM). Fluorescence intensity was
recorded every 5 min for a total duration of 4 days using a ClarioStar plate reader (BMG Lab-
tech) set at 37°C. Fluorescence parameters were set as follows: λexc = 440 nm, λem = 490 nm,
gain = 650, shaking at 200 rpm for 12 s before each measurement. Aggregation curves were fit-
ted using KaleidaGraph software.
Results and Discussion
Optimization of MAβ1–40 and MAβ1–42 expression
The genes encoding MAβ1–40 and MAβ1–42 were first cloned in pET28. They were then
expressed by growing E. coli BL21 (DE3) transformed with the recombinant plasmids on LB
broth supplemented with kanamycin. To determine optimal conditions for peptide expression,
we envisioned a procedure based on Th-S monitoring.
Indeed, Th-S is usually used for staining amyloid plaques but was also recently shown to
stain bacterial IBs formed by MAβ peptides, both in vivo and in vitro. Hence, Th-S was used to
detect protein aggregation in bacteria [22], or to screen in vivo aggregation inhibitors [24]. In
order to use Th-S staining as a tool for the optimization of peptide expression, the correlation
between IB content and the Th-S fluorescence level had to be established. For this purpose, cul-
tures expressing MAβ1–42 were stopped at different induction times. The cells were sampled,
incubated with Th-S, and their emission spectra were recorded. As shown in Fig 1A, the fluo-
rescence level increased during the first 4 hours of induction and then reached a plateau. The
corresponding cultures were lysed and peptide was purified and analysed by SDS-PAGE. A
good correlation was observed between the amount of purified peptide and the fluorescence
level (Fig 1B). Similar results were obtained with MAβ1–40, showing that Th-S staining is very
useful to estimate MAβ IB content in cells. Based on these results, a 4 h induction was consid-
ered as adapted and applied throughout the rest of the study.
Th-S monitoring was then used to screen for the optimal concentration of IPTG inducer.
No significant variations of IB production was observed with IPTG concentration comprised
between 0.5 and 1.5 mM (Fig 1C). Contrariwise, increased levels of protein contaminants were
observed when using 1 or 1.5 mM IPTG, which could be due to the overexpression of E. coli
chaperones [25]. Induction at 0.5 mM IPTG was thus found optimal. Finally, the optimal tem-
perature of cell growth was investigated. As shown in Fig 1D, the best temperature allowing the
formation of a maximal amount of IBs was 37°C.
This preliminary work allowed us to establish the optimal conditions of MAβ peptide
recombinant production as corresponding to recombinant cell cultures carried out at 37°C and
Robust Purification Procedure of Recombinant Alzheimer's Disease Methionine-Amyloid-Beta Peptides
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induced for 4 h with 0.5 mM IPTG. Under these conditions, both visible and fluorescence
microscopy confirmed the presence of IBs located at the poles of the cells (Fig 1E).
Purification of MAβ1–40 and MAβ1–42
As Aβ peptides were produced as IBs, the first step of the purification procedure consisted in
isolating and purifying IBs. The main challenge of this approach was to succeed in removing
proteins and nucleic acids that could be trapped in the IBs or stacked on their surface.
First, the previously reported “soni-removal” method, which consists in multiple sonication
and centrifugation cycles, was performed to roughly eliminate nucleic acids and proteins
stacked at the IB surface [23]. At this stage, Th-S fluorescence visualization of isolated IBs con-
firmed that their average size remained unchanged, showing no deterioration due to
sonication.
The protocol shown in Fig 2A was then applied. Aβ peptides are soluble at high pH, since
their isoelectric point is about 5–6. The IBs were thus first incubated with 50 mM sodium
hydroxide, to solubilize MAβ. Upon pH neutralization, a large amount of proteins is removed
by precipitation, while MAβ peptides remain in the supernatant (Fig 2B, lanes S1 and P2). The
high pH denaturation/neutralization cycle was applied twice to maximize MAβ recovery (Fig
2B, lane S2). Further completion of contaminant elimination was carried out by ultrafiltration
of the solubilized peptides followed by concentration, respectively on a 30-kDa and a 3-kDa
molecular weight cut-off membranes. As shown on the electrophoresis gel (Fig 2B, lane F), the
Fig 1. MAβ1–42 expressionmonitoring using Thioflavin-S. A. Variations of normalized fluorescence of Th-S-treated E. coli cells
expressing MAβ1–42 with culture induction time. B. SDS-PAGE of inclusion bodies formed during E. coli cultures expressing MAβ1–
42; lane 1: 10–250 kDa protein ladder, lane 2 to 5: samples taken at 0, 2, 4, and 6 hours of growth, respectively. C. Normalized
fluorescence intensity of Th-S-treated E. coli cells expressing MAβ1–42 as a function of IPTG concentration used for induction. D.
Normalized fluorescence intensity of Th-S-treated E. coli cells expressing MAβ1–42 during 4h at various temperatures. E.
Fluorescence microscopy of E. coli cells expressing MAβ1–42 as IBs after 4 h culture.
doi:10.1371/journal.pone.0161209.g001
Robust Purification Procedure of Recombinant Alzheimer's Disease Methionine-Amyloid-Beta Peptides
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ultrafiltration step allowed getting one single band around 5 kDa, the presence of any protein
contaminant being excluded.
In parallel, the MAβ1–42 IBs were also solubilized using 8M urea and then passed through a
DEAE Sepharose ion-exchange resin to remove NA traces. As seen in Fig 3, this protocol did
not allow the elimination of a 13 kDa protein contaminant, regardless of IPTG concentration
used for induction. Furthermore, this protein could not be eliminated by ultrafiltration indicat-
ing that the urea treatment did not allow breaking the interaction probably existing between
the 13 kDa protein and the peptide (Fig 3 lanes 4 and 5). This clearly showed the limitation of
the denaturation with urea and emphasizes the interest of the NaOH treatment with to elimi-
nate proteins and nucleic acids.
Fig 2. Purification monitoring of MAβ. A. Simplified scheme of the purification procedure. Circled letters correspond to samples
collected for either UV/Vis measurements or gel analysis. Supernatant S1 and S2, and pellet P1 and P2 correspond to the supernatant
and the precipitate obtained for the two cycles of denaturation/neutralisation. B. SDS-PAGE at different steps of purification, compared
with 10–250 kDa protein marker (lane M). C. UV-Vis spectra at pH 12 after IBs denaturation (D), after denaturation/neutralisation cycles
(S1+S2), after 30-kDa ultrafiltration (F), after concentration (C), and after size exclusion chromatography (SEC).
doi:10.1371/journal.pone.0161209.g002
Robust Purification Procedure of Recombinant Alzheimer's Disease Methionine-Amyloid-Beta Peptides
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At this point, one important issue was the monitoring of the sample purity at the various
stages of the purification procedure. The Bradford protein assay was eliminated because it does
not give any information on sample purity and only allows the determination of a global pro-
tein content. Combination of UV-Vis spectrophotometry with gel electrophoresis was clearly
preferred. Indeed, SDS-PAGE permits to visualize the presence of protein contaminants while
UV-Vis analyses inform on the predominant presence of either nucleic acids (λ = 260 nm) or
specific amino acids, namely tryptophan (λ = 280 nm), tyrosine/tyrosinate (λ = 274 nm/λ =
293 nm), phenylalanine (λ = 257 nm) [26]. Both methods were thus combined to assess the
purity level of the peptide samples depending on the purification steps as shown in Fig 2C.
After denaturation (Fig 2C, spectrum D), a lot of species are evidenced. The supernatant har-
vested after neutralization (Fig 2C, spectrum S1+S2), still contain proteins but is already devoid
of nucleic acids. After ultrafiltration, the sample was too diluted to give an informative UV
spectrum (Fig 2C, spectrum F). Finally, the concentration step yielded a pure sample showing a
UV signature with the typical UV band at λ = 293 nm corresponding to the tyrosinate form
(Fig 2C, spectrum C). This typical profile is conserved after size exclusion chromatography,
which was performed to isolate only monomeric peptide before aggregation assays (Fig 2C,
spectrum SEC). Overall, these analyses confirmed the high level of purity of the peptide
preparation.
Fig 3. Purification protocol of MAβ1–42 IBs dissolved in 8M urea. Lane 1: 10–250 kDa protein marker, lane 2: IBs after urea
denaturation, lane 3: after passing through DEAE resin, lane 4: after 30-kDa ultrafiltration, lane 5: after 3-kDa concentration.
doi:10.1371/journal.pone.0161209.g003
Robust Purification Procedure of Recombinant Alzheimer's Disease Methionine-Amyloid-Beta Peptides
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As the sample was devoid of any protein contaminants, the pH-dependent absorption of
Tyr was used to estimate the peptide yield. Absorption spectra of the peptides were thus
recorded at pH 12 (showing the absorption band of tyrosinate at 293 nm) and at pH 2 (display-
ing no tyrosinate band). The precise quantification of the tyrosine content of the sample was
performed by subtracting spectra. This enabled the estimation of the peptide yield as being
around 4 mg/L of culture, which is in the same range as those previously reported, comprised
between 3 and 7 mg/L [13,14,19,27,28].
Characterization of MAβ1–40 and MAβ1–42
To further characterize the peptides, LC-MS and NMR analyses were conducted right after the
concentration step on both peptides. MAβ1–40 displays a clean chromatographic trace with a
major peak at 10.8 min. The mass spectrum associated to this peak is in good agreement with
the expected masses (Fig 4A and 4C). MAβ1–42 chromatogram is less resolved, the main peak
being shouldered (Fig 4B and 4D). The masses detected for both the shoulder and the peak are
consistent with the calculated masses of MAβ1–42, indicating that oligomeric forms of MAβ1–42
could be present. This is consistent with the high propensity of Aβ1–42 to aggregate.
1H NMR spectra of both peptides were then recorded, and compared with commercially
available synthetic Aβ1–40 (Fig 5). They display the typical signals usually observed for Aβ1–40
peptide. In the aromatic region, signals corresponding to the Hδ and Hε of aromatic residues
are well defined. As such, Phe 19 and 20 (ca. 7.2 ppm and ca. 7.3 ppm) and Tyr 10 (ca.
7.95 ppm and ca. 6.8 ppm) can be distinguished. Slight shifts are observed for His 6, 13 and 14
Fig 4. LC-MS analysis of MAβ1–40 and MAβ1–42. A. LC trace of MAβ1–40 monitored by mass detection. B. LC trace of MAβ1–42 monitored
by mass detection.C.MS of MAβ1–40 displaying [M+5H]
5+, [M+4H]4+, and [M+3H]3+ peaks (expected values: 892.65, 1115.56, 1487.07).
D.MS of MAβ1–42 displaying [M+5H]
5+, [M+4H]4+, and [M+3H]3+ peaks (expected values: 929.47, 1162.17, 1548.44).
doi:10.1371/journal.pone.0161209.g004
Robust Purification Procedure of Recombinant Alzheimer's Disease Methionine-Amyloid-Beta Peptides
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(ca. 7.8 ppm and ca. 7.1 ppm), which can be attributed to pH variations. The absence of signal
ca. 7.5 ppm confirms the absence of Trp residue in the peptides. Expectedly, signals corre-
sponding to Hα (4.5–3.8 ppm) and Hβ (3.2–2.6 ppm and 2.3–1.5 ppm) are more difficult to
attribute in details. In the aliphatic region, signals corresponding to Lys 16 and 28 (1.4 ppm)
and to Val and Leu (1.0–0.7 ppm) are observed. Finally, the signal at 3.9 ppm reveals the pres-
ence of a methionine residue for the recombinant peptides as expected.
Because most in vitro studies on Aβ peptides consist in studying their aggregative properties
under various conditions, it was essential to ensure that the auto-assembling properties of the
peptides are conserved after this purification process. Prior to this, it was important to remove
traces of oligomeric species, to ensure a homogeneous aggregation process. The two peptides
were thus submitted to SEC. To assess the apparent molecular weight of targeted peptides, a
calibration curve was established using other unstructured peptides. It confirmed that the
apparent molecular weight of the two peptides was about 4 kDa (S1 Fig). Fractions correspond-
ing to monomeric peptides were then submitted to Th-T fibrillization assay. In 26 h, both pep-
tides afford a characteristic sigmoidal aggregation curve, with aggregation half-times around
15 h (Fig 6). The MAβ peptides obtained through our purification procedure thus conserved
their auto-assembling properties. The same results were obtained with peptide batches from
different cultures, showing the high robustness of the purification procedure in terms of repro-
ducibility. This purification protocol could thus be applied for routine lab-scale MAβ produc-
tion. This also confirms that the presence of a N-ter Met residue does not affect the aggregation
properties of MAβ peptides as previously reported [16]. Removing Met residue could be benefi-
cial for specific studies such as metal coordination, but does not seem mandatory for classical
aggregation assays.
Conclusion
We have here reported a rapid, straightforward and highly reproducible recombinant produc-
tion and purification of MAβ1–40 and MAβ1–42. First, we showed that Th-S staining was reliable
to monitor IB production during cell growth. Purification monitoring provided evidence that
only the combination of UV-Vis spectrophotometry and gel electrophoresis analyses could
properly allow the assessment of the peptide purity along the purification process.
Fig 5. 1H NMR of MAβ1–40 and MAβ1–42 compared with Aβ1–40. Samples of MAβ in water are diluted to 100 μM in 100 mM phosphate buffer pH 7 in
D2O. Synthetic Aβ1–40 is dissolved in NaOD and diluted to 100 μM under the same conditions. Signals at 4.75 ppm correspond to H2O, and signals at
3.25 ppm and 1.25 ppm correspond to traces of ethanol.
doi:10.1371/journal.pone.0161209.g005
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In addition, we established that pH treatment of IBs is an efficient way to get rid of most
nucleic acid and protein contaminants, contrasting with commonly used chaotropic agents.
Additional purification steps consisting in simple ultrafiltrations, providing clean peptide prep-
arations, as revealed by UV-Vis spectrophotometry, SDS-PAGE, LC-MS and 1H NMR. With
this protocol, up to 4 mg of peptides are produced within 2 days. In addition, the preparations
are suitable for aggregation assays, which were highly reproducible from batch to batch,
accounting for a robust purification procedure. Supplementary investigation might now be
engaged to remove the N-ter methionine residue, in order to obtain the native Aβ, as already
proposed by Walsh and co-workers and further improve the peptide yield [21].
Supporting Information
S1 Fig. SEC calibration curve with unstructured peptides. The different peptides were dis-
solved in NaOH 50 mM to 10 mg/mL and injected on a Superdex 75 10/300 GL. Samples were
eluted with NaOH 15 mM at 1 mL/min monitoring at 220 nm and 293 nm. The arrows indi-
cate the elution volume found for synthetic Aβ1–40 and the two recombinant MAβ1–40 and
MAβ1–42 peptides.
(TIFF)
Fig 6. Normalized aggregation curves of MAβ1–40 and MAβ1–42. Two different batches of MAβ1–40 (A and B) and
MAβ1–42 (C and D) (20 μM) aggregate in the presence of Th-T (10 μM) in phosphate buffer (50 mM, pH 7). Assay was
run at 37°C with gentle shaking. Each experiment was run in triplicates.
doi:10.1371/journal.pone.0161209.g006
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Résumé en français 
Introduction 
C’est annoncé, le vingt-et-unième siècle sera celui de l’écologie. Dans le domaine de la chimie, 
cela se traduit par la mise en place des principes de la Chimie Verte, ayant pour but de rendre les 
procédés chimiques moins destructeurs pour la Planète. Cela inclut notamment l’utilisation de 
catalyseurs, dont l’utilisation en faibles quantités permet de convertir efficacement de grandes 
quantités de substrat. Cependant, même utilisés à l’état de traces, les métaux lourds et les ligands issus 
de nombreuses étapes de synthèse employés dans les catalyseurs sont à eux seuls une source de 
pollution. Les efforts de recherche sont donc dirigés vers l’élaboration de catalyseurs plus éco-
compatibles. 
Pour cela, la Recherche s’est intéressée aux catalyseurs existant dans la nature : les enzymes. 
Cela a inspiré différentes approches, qui incluent le développement de complexes mimant les sites 
actifs d’enzymes, la modification d’enzymes existantes pour modifier leur réactivité, et la création 
d’enzymes artificielles. Ce dernier domaine consiste à combiner l’efficacité des enzymes à variété et la 
versatilité de catalyseurs chimiques. L’utilisation de catalyseurs chimiques donne accès à une large 
gamme de réactivités et de substrats, tandis que la présence de la biomolécule confère à ces systèmes 
une accélération de la réaction, ainsi qu’une sélectivité et une spécificité. 
Dans ce contexte, nous nous sommes intéressés à l’élaboration de systèmes hybrides basés sur 
les fibres amyloïdes. Ces agrégats de protéines présentent des propriétés uniques de rigidité, de 
solidité, et de résistance à la chaleur et aux solvants, qui en font de bons candidats pour une utilisation 
en catalyse. De par leur caractère insoluble, les catalyseurs formés seraient également recyclables. 
Ce manuscrit présente les résultats obtenus pour l’élaboration de nouveaux catalyseurs bio-
inorganiques préparés par incorporation de complexes métalliques dans les fibres de peptides β-
amyloïdes. Dans ce contexte, un nouveau protocole d’expression et de purification des peptides β-
amyloïdes dans Escherichia coli a été mis en place, permettant l’accès rapide à des échantillons fiables 
de peptides (voir Chapter V.II). 
Une seconde partie du travail a consisté à développer une série de ligands capables de s’insérer 
de façon non-covalente dans les fibres amyloïdes. Inspirés par les différentes molécules intercalantes 
décrites dans la littérature, nous avons synthétisé une série de cinq ligands portant différents 
substituants. Les complexes métalliques correspondants ont été préparés, et caractérisés par différentes 
techniques (RMN, RPE, voltamétrie cyclique, Rayons X) (voir Chapter V.III). 
   
 

Résumé en français 

 
222 
 
L’interaction de ces différents complexes avec les fibres amyloïdes a ensuite été testée. Une 
étude spectrophotométrique a permis de discriminer les complexes capables de s’insérer dans les 
fibres. Des études ont ensuite été réalisées concernant la nature du site d’interaction, ainsi que le motif 
d’interaction sur les complexes. Ces premiers résultats ont été supportés par des études de Docking 
(voir Chapter V.IV).  
Enfin, des études préliminaires de catalyse ont permis d’ouvrir des pistes d’optimisation de nos 
systèmes hybrides, incluant des variations sur les complexes et sur le peptide (voir Chapter V.V). 
I. Contexte du projet 
I.1. Contexte du projet : les metalloenzymes artificielles 
Une alternative aux catalyseurs chimiques consiste à élaborer des enzymes artificielles. 
Différentes stratégies d’élaboration ont été développées : 
• Remplacer l’ion métallique d’une enzyme : le remplacement de l’ion métallique peut 
permettre de modifier sa réactivité. Cela a été réalisé avec succès avec la 
carboxypeptidase A [26] et l’anhydrase carbonique [27,28].  
• Réaliser des mutations sur le site actif d’une enzyme : une modification des résidus 
du site actif d’une enzyme peut permettre de modifier la gamme de substrats, voire de 
modifier sa réactivité. De nombreuses études de ce type ont été réalisées avec le 
cytochrome P450 [31,32,34,35]. 
• Elaborer une protéine De Novo : les progrès de la biologie moléculaire permettent de 
construire de nouveaux systèmes protéiques capables de coordiner des ions métalliques 
de manière parfaitement contrôlée. La réactivité de ces systèmes est elle aussi 
modulable [42,44]. 
• Insérer un complexe de coordination dans une biomolécule : l’objectif est alors 
d’ajouter à un catalyseur préexistant un environnement protéique capable de lui 
conférer des effets de sphère externe (accélération, sélectivité, spécificité...). On espère 
alors combiner l’efficacité des enzymes avec la modularité des catalyseurs chimiques. 
Cette stratégie a été utilisée avec de l’ADN [47], des protéines [73], des peptides [93] et 
des anticorps [89]. Selon les cas, il est possible de greffer le complexe de façon 
covalente, ou de tirer parti des interactions non-covalentes entre la biomolécule et le 
complexe. L’utilisation de cofacteurs naturels a également été proposée.  
Cette dernière approche a été sélectionnée pour l’élaboration de nos catalyseurs. Parmi les 
différentes biomolécules susceptibles d’accueillir des complexes métalliques, notre intérêt s’est porté 
sur les fibres amyloïdes. 
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I.2. Les fibres amyloïdes comme bio-nano-matériaux 
La définition des protéines amyloïdes est avant tout structurale: il s’agit de polypeptides qui, en 
plus de leur repliement natif, peuvent adopter un second repliement, très stable et structuré en un 
assemblage de feuillets β. 
Les protéines amyloïdes ont initialement été découvertes dans le cadre de maladies humaines : 
la maladie d’Alzheimer [138], le diabète de type II [102], ou les maladies à Prions [104] impliquent 
tous la formation d’agrégats amyloïdes. Mais des structures amyloïdes ont depuis été découvertes chez 
d’autres organismes, jouant un rôle non plus délétère, mais structural [242,243].  
Ces protéines sont très différentes en termes de taille et de séquence, mais partagent certaines 
caractéristiques : toutes sont capables de s’auto-assembler sous la forme de fibres de 6-12 nm de 
diamètres et de quelques μm de long, avec une structure cross-β caractéristique. Ces fibres sont très 
rigides et robustes, résistant à la chaleur et aux agents dénaturants.  
Du fait de ces propriétés uniques, les fibres amyloïdes ont été proposées pour différentes 
applications, les utilisant comme support de greffage [121], comme moule pour la formation de 
nanoparticules [117–119] ou pour la formation d’hydrogels [122]. 
I.3. Description moléculaire des fibres amyloïdes 
I.3.a. Peptide β-amyloïde 
Le peptide β-amyloïde existe dans le cerveau sous deux formes majoritaires, de 40 (Aβ1-40) et 
42 (Aβ1-42) acides aminés, respectivement. Leur séquence est constituée d’une partie dynamique et peu 
structurée en N-terminal (résidus 1 à 16), capable de coordiner les métaux [123,129,130]. Au 
contraire, la partie C-terminale est majoritairement constituée de résidus hydrophobes, qui sont à 
l’origine de la formation de la structure « cross-β » caractéristique des amyloïdes. Les résidus 17 à 20 
semblent particulièrement importants.  
Avec leurs nombreux résidus hydrophobes, les peptides β-amyloïdes sont faiblement solubles 
dans l’eau et s’auto-assemblent rapidement. Il est donc courant de les solubiliser à des pH extrêmes. 
H2N-DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA-COOH 
Metal coordination Aggregation 
β-strand β-strand β-turn 
	
	

	
		
Figure 58: Séquence de Aβ1-42 et structure secondaire correspondante. Les résidus hydrophobes apparaissent en gras. 
   
 

Résumé en français 

 
224 
 
Les peptides Aβ contiennent un résidu Tyr, qui est utilisé pour leur quantification par 
spectrophotométrie UV-Visible (ε = 2400 L.mol-1.cm-1 à 293 nm à pH >12) [128]. Il confère 
également au peptide de faibles propriétés de fluorescence (φ = 0,14 dans l’eau à 23 °C). 
I.3.b. Fibre β-amyloïde 
A température et pH physiologiques, les peptides amyloïdes s’auto-assemblent rapidement pour 
former les fibres amyloïdes. Bien qu’encore mal compris, le processus d’agrégation consiste 
généralement en trois phases : une phase de latence, suivi d’une phase d’élongation et d’un plateau 
(Schéma 39). Parmi les différentes méthodes existant pour suivre cette agrégation in vitro, la plus 
commune est de suivre la fluorescence de la Thioflavine-T (Th-T). Cette molécule, peu fluorescente 
en solution, subit une augmentation brutale de sa fluorescence lorsqu’elle s’insère dans les structures 
amyloïdes. Effectuer un suivi de la fluorescence de la Th-T permet donc de mettre en évidence la 
formation de fibres.  
Les fibres amyloïdes étant insolubles et non cristallines, peu de techniques physico-chimiques 
permettent de les caractériser. La RMN du solide a permis d’obtenir quelques structures [141,143–
145], mais nécessite trop d’échantillon pour être utilisée de façon routinière. Les microscopies AFM et 
TEM sont régulièrement utilisées, mais ne permettent d’avoir qu’une idée globale de la morphologie 
des fibres.  
Schéma 39: Courbe d’agrégation typique des amyloïdes. 
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II. Production recombinante des peptides β-amyloïdes 
II.1.  Différentes méthodes de production des peptides β-amyloïdes 
Le nombre d’études portant sur la maladie d’Alzheimer ayant considérablement augmenté ces 
dernières années, la question de la production de peptide β-amyloïde destiné aux études in vitro est 
devenu un problème clé.  
La synthèse de peptides sur phase solide est souvent utilisée, mais reste compliquée dans le cas 
de peptide hydrophobes, et la purification et le stockage sont encore mal gérés [136]. Une différence 
de comportement a également été notée entre les peptides de synthèse et les peptides recombinants 
[150]. Pour cela, les peptides issus de la production recombinante sont parfois considérés comme de 
meilleurs modèles, les peptides ne subissant aucun traitement chimique. Cependant d’autres 
inconvénients apparaissent parfois, comme l’usage d’étiquettes facilitant la purification, mais qui 
ajoutent des acides aminés supplémentaires à la séquence native des peptides [154,155,158,159]. 
Dans le cadre de ce projet, nous avons réalisé trois constructions plasmidiques, les séquences 
correspondances apparaissant en Figure 59. 
  
II.2. Production du 6xHis-Thromb-Aβ1-42 
 Dans un premier temps, nous nous sommes intéressés à la production de peptide Aβ1-42 portant 
un tag 6xHis séparé du peptide par un site de clivage à la Thrombine. Cette construction présente 
l’avantage de permettre une purification du peptide par chromatographie d’affinité.  
Des productions ont été réalisées dans E.coli, et le peptide a été purifié sur résine TALON. 
Cependant, les tentatives de clivage ont été incomplètes, nécéssitant d’autres étapes de purification. 
Construction 2: MAβ1-42 
 
MDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA 
Construction 1: His-tagged Aβ1-42 
 
MGSSHHHHHHSSGLVPRGSHMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA 
Construction 3: MAβ1-40 
 
MDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV 
Figure 59: Séquences peptidiques ciblées. La séquence native de Aβ apparait en noir (Aβ1-42 pour les constructions 1 et 2, 
Aβ1-40 pour la construction 3). Le tag 6xHis apparait en bleu, la séquence de reconnaissance de la Thrombine apparait en 
vert, les acides aminés supplémentaires apparaissent en gris. T indique le site de clivage à la Thrombine. 
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Cette stratégie ne nous a donc pas semblé adaptée, et nous nous sommes concentrés sur la production 
de peptides dépourvus d’étiquettes.  
II.3.  Production des peptides Met-β-amyloïde 1-40 et 1-42 
II.3.a. Observations préliminaires 
Lors des premières expériences d’expression des peptides MAβ, nous nous sommes aperçu que 
la totalité des peptides exprimés était contenue dans la fraction insoluble. Après observation au 
microscope, il est apparu que ces peptides formaient des corps d’inclusions (ou inclusion bodies, IB) 
dans les bactéries. Nous avons souhaité tirer parti de cette caractéristique, tentant d’isoler ces IB pour 
les purifier par la suite.  
II.3.b. Optimisation des paramètres d’expression 
Une première étape a consisté à optimiser les paramètres d’expression des peptides dans E. coli. 
Pour cela, nous nous sommes servis de la capacité de fluorescence de la Thioflavine-S (Th-S) 
lorsqu’elle est insérée dans les IB bactériens (Figure 60) [163,165]. Différentes cultures de E.coli 
exprimant MAβ1-42 ont donc été incubées à des températures différentes, pendant des durées 
différentes, et ont été induites avec différentes quantités d’inducteur. 
Cela a permis d’établir les conditions optimales comme étant une expression à 37 °C pendant 4 
h en induisant avec 0,5 mM d’inducteur.  
II.3.c. Purification 
Une fois les conditions optimales d’expression trouvées, nous nous sommes intéressés à la 
purification des peptides MAβ. Les corps d’inclusions ont été isolés des débris bactériens suivant une 
procédure préalablement décrite [162]. Cependant à la place de l’habituelle solubilisation des IB dans 
des solutions concentrées d’agents dénaturants (urée, chlorure de guanidinium…), nous avons proposé 
de les solubiliser en milieu basique. Une étape de neutralisation permet ensuite de faire précipiter les 
Figure 60: Visualisation des corps d’inclusion bactériens formés par MAβ1-42. A. Cellules E. coli exprimant MAβ1-42 et 
incubés dans la Th-S observés par microscopie de fluorescence. B. Superposition des images de microscopie visible et de 
fluorescence. Conditions expérimentales: λexc = 340-380 nm, dichroic = 400, λem = 425 nm, grossissement 63x. 
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protéines contaminantes, alors que le peptide reste en solution. Afin d’optimiser les rendements, cette 
étape de solubilisation/neutralisation est réalisée deux fois. Une étape de filtration sur membrane 30 
kDa, suivie d’une étape de concentration sur membrane 3 kDa permettent d’obtenir un échantillon pur 
de peptide. Une représentation schématique de ce protocole apparaît en Figure 61.A.  
Afin d’évaluer le degré de pureté de nos échantillons, nous proposons l’utilisation combinée de 
la spectrophotométrie UV-Vis et des gels SDS-PAGE. En effet, les peptides cibles ne contenant pas de 
Trp, la présence d’une bande à 280 nm sur le spectre UV-Vis est un bon témoin de la présence d’un 
contaminant protéique. De même, une bande à 260 nm serait significative de la présence d’acides 
nucléiques. Dans notre cas, le maximum d’absorbance se situe à 293 nm à pH 12, ce qui correspond au 
tyrosinate du peptide (Figure 61.C) [128]. Le gel SDS-PAGE confirme également l’absence de 
protéine contaminante à la fin du processus de purification (Figure 61.B).  
Figure 61: Suivi de purification de MAβ . A. Schéma simplifié du protocole de purification. Les lettres cerclées 
correspondent aux échantillons prélevés pour les analyses UV-Vis ou sur gel. Les surnageants S1 et S2, et les culots P1 et P2 
correspondent aux surnageants et aux culots obtenus pour les deux cycles de dénaturation/neutralisation. B. SDS-PAGE à 
différentes étapes de purification, comparé au marqueur 10-250 kDa (noté M). C. Spectre UV-Vis à pH 12 après 
dénaturation des IB (D), après les cycles de dénaturation/neutralisation (S1+S2), après ultrafiltration à 30-kDa (F), après 
concentration (C), et après chromatographie d’exclusion stérique (SEC). 
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II.3.d. Caractérisation 
Les deux peptides MAβ1-40 et MAβ1-42 ont été caractérisés par différentes techniques: 
• LC-MS: Les deux peptides ont été soumis à l’analyse LC-MS en milieu acide, montrant 
des temps de rétention similaires. Le spectre de masse correspondant montre les 
peptides protonnés trois, quatre et cinq fois, comme observé pour le peptide Aβ1-40 
synthétique. 
• RMN: Les spectres RMN 1H des deux peptides ont été enregistrés, montrant des 
signatures similaires à celle du peptide Aβ1-40 synthétique.  
• Agrégation: Les deux peptides ont été soumis à une expérience d’agrégation suivie à la 
Thioflavine-T. A 20 et 50 μM, les deux peptides agrègent en suivant une courbe 
sigmoïdale typique des peptides amyloïdes. 
 Tous ces résultats confirment la fiabilité et la robustesse de ce nouveau protocole de 
purification. Les rendements obtenus sont de 4 mg par litre de culture, ce qui correspond aux résultats 
décrits dans la littérature. Ce protocole présente l’avantage de ne comprendre aucune étape 
chromatographique, et peut être réalisé en deux jours.  
III. Elaboration des complexes de coordination 
III.1. Elaboration des ligands  
Différents points ont été pris en compte lors de l’élaboration des ligands: 
• Leur facilité de synthèse, afin de pouvoir obtenir une série d’analogues, 
• Leur coordination à différents ions métalliques, 
• Leur capacité à faire des liaisons non-covalentes, afin de pouvoir s’insérer dans les 
fibres amyloïdes, 
• Leur utilisation possible en catalyse. 
Lorsque l’on observe les structures des molécules reportées dans la littérature pour leur bonne 
intercalation dans les fibres, on remarque qu’elles comportent de nombreux (hétéro)cycles 
aromatiques, ainsi que des hétéroatomes capables de former des liaisons H.  
Parmi les différents ligands accessibles possédant ces caractéristiques, notre intérêt s’est porté 
sur les analogues de terpyridine. Ces ligands ont la propriété de coordiner différents ions métalliques 
[184,187,206], et ont été de nombreuses fois utilisés en catalyse [190,207,233]. Leur synthèse se fait 
en une étape à partir d’un aldéhyde et de 2-acetyl pyridine en milieu basique (Schéma 40) [192].  
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Afin d’augmenter la surface aromatique, les ligands ont été fonctionnalisés avec un groupement 
phényl sur la pyridine centrale, portant différents substituants en position para. Les différents ligands 
synthétisés apparaissent en Schéma 41. Les ligands commerciaux terpyridine, bipyridine, 
phénanthroline et salophen ont été ajoutés à cette série.  
III.2. Synthèse des complexes de coordination 
Une fois les différents ligands synthétisés, les complexes de Cu(II), Fe(II) et Ru(II) 
correspondants ont été préparés (Schéma 42). 
R H
O N
O
+ + KOH
Reflux
24 h
EtOH/NH4OH 1:1
2 6
N
N N
R
Schéma 40: Synthèse de la terpyridine suivant la méthode de Kröhnke. 
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Schéma 41: Ligands utilisés dans cette étude. Les ligands L1 à L5 ont été synthétisés, alors que Tpy, Bpy, Phen et Salophen 
sont commerciaux. 
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Les synthèses ont été réalisées au reflux du méthanol, à partir de sels de Cu(II), Fe(III) ou 
Ru(III), respectivement. Les complexes ont ensuite été isolés par précipitation suite à un échange 
d’anion avec l’hexafluorophosphate de sodium.  
Les différents complexes ont ensuite été caractérisés à l’aide de différentes techniques : 
• La diffraction des rayons X a permis de résoudre la structure de certains complexes. 
Cela a confirmé l’orthogonalité des terpyridine autour du cation métallique, ainsi que la 
légère rotation du groupement phényl.  
• La RMN a permis de mettre en évidence la formation des complexes de Fe(II) et 
Ru(II), celle-ci se traduit par le déblindage global des signaux. La comparaison des 
différents complexes a montré que la nature du groupement fonctionnel sur le phényl 
n’avait que très peu d’influence sur les propriétés électroniques du complexe. 
• La RPE des complexes de cuivre a confirmé une sphère de coordination de type 6N. 
Un effet Jahn-Teller dynamique a également été observé, caractéristique des complexes 
de terpyridine. 
• La voltamétrie cyclique nous a permis d’obtenir les potentiels d’oxydation et de 
réduction des complexes de cuivre et de ruthénium, apportant confirmation que la 
fonctionnalisation du ligand n’interférait pas avec les propriétés électroniques du centre 
métallique. 
• Les spectres UV-Visible et de fluorescence des différents complexes ont été 
enregistrés. Seuls les complexes de Ru(II) démontrent des propriétés de fluorescence.  
Les différents complexes ont ensuite été étudiés pour leur interaction avec les fibres 
amyloïdes. 
Schéma 42: Complexes métalliques synthétisés. 
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IV. Etude de l’interaction complexes de coordination-fibres amyloïdes 
IV.1. Preuves expérimentales de l’interaction  
IV.1.a. Validation de l’interaction 
Afin de déterminer si certains des complexes démontraient une interaction avec les fibres 
amyloïdes, ceux-ci ont été mis en présence de peptide Aβ1-40 monomérique que l’on a fait agréger. La 
présence de certains composés se traduit par une modification significative de la cinétique 
d’agrégation du peptide (Figure 62.A). En fin d’agrégation, les échantillons de fibres sont collectés et 
centrifugés. Certains culots de fibres apparaissent très colorés, témoignant d’une incorporation des 
complexes métalliques, alors que d’autres sont quasiment incolores (Figure 62.B). 
  
Un dosage soigneux des surnageants par spectrophotométrie UV-Visible a permis de quantifier 
la quantité de complexes insérée dans les fibres. Les résultats montrent une incorporation importante 
pour les ligands phényl-terpyridine, à l’exception du ligand L2. Cela peut s’expliquer par une répulsion 
entre les peptides et les carboxylates présents sur les ligands. Les complexes de bpy, tpy et phen 
semblent également ne pas interagir, probablement du fait de leur surface aromatique trop limitée.  
Table 27: Quantités de complexes insérées en fin d’agrégation du peptide Aβ1-40. 
Complexe % complexe inséré 
Ru(bpy)3 1 
Ru(phen)3 2 
Figure 62: Validation de l’interaction entre les fibres de Aβ1-40 et les complexes métalliques.  A. Effet des complexes 
métalliques sur la cinétique d’agrégation de Aβ1-40. L’agrégation a été réalisée avec Aβ1-40 seul (rouge) ou en présence de 
Ru(L1)2 (bleu), Ru(L2)2 (vert), Ru(L3)2 (noir), and Ru(bpy)3 (orange) Conditions: [Aβ1-40] = 50 μM, [Th-T] = 10 μM, [PB] = 
50 mM, [complexe] = 50 μM, pH = 7, ACN 5%. Chaque courbe est la moyenne de triplicats. B. Photographie du contenu 
des puits en fin d’agrégation avant et après centrifugation. 
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Ru(tpy)2 3 
Ru(L1)2 55 
Ru(L2)2 0 
Ru(L3)2 100 
Fe(bpy)3 10 
Fe(L1)2 81 
Fe(L2)2 0 
Fe(L3)2 99 
Fe(L4)2 67 
Fe(L5)2 93 
Les caractéristiques spectrophotométriques des complexes sont également modifiées lorsqu’ils 
sont insérés dans les fibres. La bande d’absorbance de Ru(L1)2 est légèrement décalée vers les hautes 
longueurs d’ondes (Figure 63.A), alors que sa fluorescence est amplifiée (Figure 63.B). Cela est 
cohérent avec un passage d’un milieu aqueux à un milieu hydrophobe [217]. 
IV.1.b. Etudes du site de liaison 
• Site de la Thioflavine-T 
Des investigations ont été menées afin de déterminer si les complexes métalliques pouvaient se 
lier sur le(s) même(s) site(s) que la Th-T. Pour cela, une expérience de compétition a été réalisée entre 
la Th-T et les complexes Ru(L1)2 et Ru(L3)2 présents en quantités croissantes. Les résultats montrent 
que même en présence d’un large excès de complexe, seule une petite quantité de Th-T est déplacée 
A B 
Figure 63: Effet de l’insertion dans les fibres sur les propriétés spectrophotométriques des complexes. A. Spectres UV-
Visible. B. Spectres d’émission de fluorescence. Conditions: [Aβ1-40] = 50 μM, [Th-T] = 10 μM, [PB] = 50 mM, [complexe] 
= variable, pH = 7, agrégation pendant 4 jours à 37°C.  
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vers le surnageant. Il semble donc que la Th-T et les complexes métalliques s’insèrent dans les fibres 
sur différents sites. 
• Etudes de peptides tronqués 
Afin de déterminer les résidus impliqués dans l’interaction fibres-complexes, une étude 
similaire a été menée sur les peptides β-amyloïdes tronqués Aβ1-28 et Aβ1-28 (Schéma 43). 
 
Les complexes Fe(L1)2, Fe(L3)2, Ru(L1)2 et Ru(L3)2 ont été ajouté au début de l’expérience 
d’agrégation. Une fois formées, les fibres sont collectées et centrifugées, et les surnageants sont dosés. 
Il s’avère qu’aucun des complexes ne semble s’insérer dans les fibres de peptides tronqués. Pour cela, 
deux explications sont envisagées : une interaction avec des acides aminés du segment 28-40, ou une 
différence de morphologie des fibres qui empêcherait l’interaction avec les fibres de peptides tronqués. 
IV.1.c. Etude du motif de reconnaissance 
Une étude a également été menée afin de connaître le motif minimal nécessaire à l’interaction. 
La comparaison entre les complexes de Fe(II) et de Ru(II) n’a montré aucun effet de la nature de l’ion 
métallique. Au contraire, l’interaction observée pour Fe(L1)2 et Fe(L3)2 est complètement perdue avec 
Fe(tpy)2 ; il semble donc que la présence du groupement phényl (et de ses substituants) soit 
primordiale à l’interaction. 
Aβ11-28             DAEFRHDSGY EVHHQKLVFFAEDVGSNKGAIIGLMVGGVV 
Aβ1-28               DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV 
Aβ1-40               DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV 
Schéma 43: Séquences des peptides Aβ11-28, Aβ1-28, and Aβ1-40. 
B 
Schéma 44: Motif d’interaction des complexes métalliques. A: motif minimal d’interaction proposé; B: Modèle proposé 
pour l’interaction fibre-complexe. La fibre est représentée par un rectangle gris, les deux ligands terpyridines sont 
représentés en bleu et en vert, les atomes ayant démontrés expérimentalement une interaction avec les fibres apparaissent en 
rouge. 
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Une expérience de RMN STD avec le peptide Aβ1-40 monomérique a permis de mettre en 
évidence l’interaction entre les protons des pyridines centrales et latérales avec le peptide [224]. Tout 
cela nous a permis de proposer un motif minimal d’interaction constitué d’une pyridine latérale, de la 
pyridine centrale, et du cycle phényl (Schéma 44.A). Un modèle d’interaction a également été 
envisagé, le complexe s’incorporant dans les sillons formés par les chaines latérales du peptide 
(Schéma 44.B). 
IV.2. Modélisation des systèmes hybrides 
IV.2.a. Fibres de Aβ1-40 
• Th-T 
La Th-T a été dockée dans la structure de fibres de Aβ1-40 (code PDB 2LMN) [141]. Les 
résultats montrent trois sites principaux : à l’interface entre les deux filaments, dans la boucle β, et à 
l’extrémité de la boucle. Dans les trois cas, la Th-T est enfouie dans les fibres, positionnée 
parallèlement à l’axe de la fibre (Figure 64, gauche). 
• Fe(L1)2 et Fe(L3)2 
Les complexes Fe(L1)2 et Fe(L3)2 ont également été dockés sur la structure 2LMN. Cependant, 
tous les résultats placent les complexes sur l’extrémité de la fibre (Figure 64, droite). Cela est peut-être 
dû à la longueur insuffisante de la fibre dans ce modèle. En effet, chaque filament n’est constitué que 
de six peptides, ce qui pourrait être insuffisant pour modéliser la fibre. 
 
 
Figure 64: Résultats de docking de la Th-T (gauche) et de Fe(L1)2 et Fe(L3)2 (droite) sur la structure 2LMN. 
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IV.2.b. Fibres de Aβ1-42 
• Th-T 
La structure de la Th-T a été dockée sur la structure des fibres de Aβ1-42 (Code PDB 2MXU) 
[145], montrant un site de liaison majoritaire le long du sillon entre Ile32 et Leu34 (Figure 65, haut). 
Là encore, la Th-T est positionnée parallèlement à l’axe de la fibre, à l’interface entre la partie rigide 
et la partie flexible. 
• Fe(L1)2 
Le docking de Fe(L1)2 a mis en évidence un site de liaison dans le sillon formé par les chaines 
latérales des Glu22 et Asp23 (Figure 65, gauche). Le groupement amine porté par le ligand forme 
deux liaisons H avec les carboxylates des chaines latérales. Ce résultat est cohérent avec l’observation 
expérimentale d’un site de liaison différent de la Th-T. 
• Fe(L3)2 
Fe(L3)2 a également été amarré sur la structure 2MXU. Contrairement à Fe(L3)2 aucun site n’a 
été mis en évidence à la surface de la fibre. Le résultat principal place le complexe en travers de 
l’ouverture de la fibre, empiétant en partie sur le site proposé pour la Th-T. Les résidus Glu11 et His14 
étant très flexible, cette position pourrait ne pas être favorable (Figure 65, droite). 
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Cette étude donne une idée préliminaire des différents sites d’interaction possibles sur ces deux 
structures de fibres. Cependant, des études dynamiques seront indispensables pour conclure sur la 
validité de ces sites.  
V. Vers des catalyseurs bio-inorganiques hybrides 
V.1. Etude des complexes Fe terpyridine en catalyse 
Peu d’études de catalyse ont été reportées utilisant les complexes de type Fe(II) bis terpyridine, 
d’autant moins dans des conditions biocompatibles. En 2008, le groupe de Che a développé des 
complexes de Fe(II) bis- 4,4’,4’’-trichloroterpyridine capables de catalyser l’époxydation de différents 
types d’alcènes à partir d’Oxone et de bicarbonate d’ammonium dans un milieu ACN/eau et à 
température ambiante (Schéma 45) [234].  
Figure 65: Résultats de docking de la Th-T (haut), de Fe(L1)2 (gauche) et de Fe(L3)2 (droite) obtenus sur la structure 
2MXU. 
Schéma 45: Réaction d’époxydation décrite par le groupe de Che. 
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Nous avons choisi de tester cette réaction avec nos complexes de Fe(II). Cependant, alors que 
Che décrivait la formation quasi-exclusive d’époxyde, un total de cinq produits ont été détectés dans 
notre cas : le benzaldéhyde (majoritaire), l’époxyde, le diol, l’hydroxy phényl éthanone, et le 
phényalacétaldehyde (Schéma 46).  
Notre objectif étant d’observer un transfert de chiralité de l’environnement peptidique au 
substrat lors de la catalyse. Nous avons donc fait varier les différents paramètres de la réaction de 
catalyse afin d’observer majoritairement la formation d’un produit prochiral. 
• Effet de l’oxydant 
Tout d’abord, différentes quantités d’Oxone ont été testées, allant de 1,25 à 15 éq. Il semble que 
5 éq soit la quantité nécessaire pour obtenir une conversion totale, formant majoritairement le 
benzaldéhyde. A partir de 10 éq, le produit majoritairement formé est le 2-hydroxy 1-phényl éthanone. 
Cependant, cela s’accompagne d’une dégradation du catalyseur. 
D’autres catalyseurs, comme le peroxyde d’hydrogène ou le tert-butyl hydropéroxyde, avec 
différents additifs. Cependant, les conversions obtenues avec ces oxydants sont restées très basses. 
• Rôle du bicarbonate d’ammonium 
Nous avons cherché à connaître le rôle du bicarbonate d’ammonium dans la réaction. Un essai 
préliminaire nous a montré que sa présence était essentielle à la faisabilité de la réaction. Il semble que 
la quantité optimale à utiliser soit de 1 éq, une quantité excessive entrainant une baisse de conversion. 
Quelque soit la quantité utilisée, le produit majoritaire reste le benzaldéhyde. 
• Charge catalytique 
Différentes charges catalytiques ont été testées, allant de 0,5 à 5 mol%. Dans cette gamme, la 
quantité de catalyseur ne semble pas influencer la conversion ou la nature du produit majoritaire 
formé. Lors des expériences avec nos catalyseurs hybrides, il sera donc possible de descendre jusqu’à 
0,5 mol% de catalyseur sans diminuer la conversion. 
 
O
OH
OH
O
O
O
Epoxide Diol
Benzaldehyde Phenyl acetaldehyde
Hydroxy phenyl ethanone
OH
Schéma 46: Différents produits observés par GC pour l’oxydation du styrène.  
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• Température 
La température de réaction a également été modifiée. Les résultats montrent qu’elle n’a que peu 
d’effet sur la réaction : un passage de 4 à 60°C ne permet d’augmenter la conversion que de 80 à 
100%, le produit majoritaire restant le benzaldéhyde. Une température de 25°C sera donc privilégiée, 
car moins susceptible d’entrainer une dégradation du catalyseur. 
• Ordre d’addition 
Au cours des expériences de catalyse, nous nous sommes aperçu que l’ordre d’addition des 
différents réactifs avait une importance pour la réaction. En effet, lorsque l’ajout de l’Oxone avait lieu 
avant l’ajout du substrat, cela donnait lieu à une dégradation du catalyseur, et à une chute des 
conversions. Lors des expériences suivantes, l’Oxone a donc été ajoutée en dernier. 
Cette étude a permis de déterminer les conditions optimales à utiliser pour nos systèmes Fe(II) 
bis-terpyridine, mais n’a pas permis d’identifier des conditions menant à la formation majoritaire d’un 
produit prochiral. Ces conditions ont donc été appliquées à nos systèmes hybrides, afin de démontrer 
la faisabilité de cette réaction en présence de fibres. 
V.2. Etude préliminaire: catalyse sur les systèmes hybrides 
Une étude préliminaire a été menée afin de valider que l’activité catalytique des complexes 
métalliques était maintenue en présence des fibres. Pour cela, des échantillons de fibres contenant des 
complexes ont été collectés et les fibres ont été isolées par centrifugation. La quantité de complexe 
insérée dans les fibres a été évaluée par différence avec la quantité restant dans le surnageant après 
centrifugation. L’expérience de catalyse a ensuite pu être lancée, en prenant soin de réaliser le contrôle 
en absence de fibres. Les résultats apparaissent en Table 28. 
Table 28: Résultats de catalyse en présence des catalyseurs hybrides. 
Catalyseur Oxone éq Conversion (%) Produit majoritaire 
Fe(L1)2 4 93 Benzaldéhyde 
Fe(L1)2 8 100 Benzaldéhyde 
Fibres + Fe(L1)2 4 15 Traces 
Fibres + Fe(L1)2 8 51 Benzaldéhyde 
Fibres + Fe(L1)2 + Th-T 4 0 / 
Fibres + Fe(L1)2 + Th-T 8 63 Benzaldéhyde 
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Il semble que pour une même charge catalytique, la quantité d’Oxone nécessaire pour réaliser la 
réaction soit supérieure en présence des fibres. Cela peut être dû à un enfouissement du catalyseur, ou 
à une oxydation du peptide. Il semble par contre que la présence de la Th-T n’interfère pas avec la 
réaction catalytique.  
Ce résultat, bien que préliminaire, constitue une preuve de concept : une réaction peut être 
catalysée par un système formé d’un complexe de coordination inséré dans des fibres amyloïdes. 
Malheureusement, aucune induction chirale n’a pu être démontrée, le produit majoritairement formé 
étant le benzaldéhyde. D’autres substrats pourront donc être testés, afin de rendre possible une 
induction chirale de la fibre amyloïde vers le produit de catalyse. 
V.3. Perspectives: évolution des systèmes hybrides 
V.3.a. Autres activités catalytiques 
Afin d’explorer toutes les possibilités offertes par nos systèmes catalytiques, d’autres réactivités 
devront être testées. Des études préliminaires des réactions d’aziridination [234] et de 
cyclopropanation [232] ont été réalisées, démontrant des conversions ne dépassant pas les 15%. Un 
test systématique des réactions de catalyse pourra être envisagé pour déterminer les réactivités les plus 
prometteuses.   
V.3.b. Changement d’ion métallique 
Les ligands choisis pour cette étude étant capables d’accommoder différents ions métalliques, 
un changement de métal pourrait également être envisagé. Par exemple, le complexe Mn(salophen) a 
démontré d’excellentes conversions pour la sulfoxydation du thioanisole [82]. Cependant les 
propriétés d’interaction des complexes de salophen avec les fibres s’étant montrées décevantes, une 
évolution de ce ligand devra être envisagée pour augmenter son intercalation. 
V.3.c. Evolution des ligands 
Restant sur la réaction d’oxydation des alcènes, différentes évolutions peuvent être imaginées 
pour nos ligands phényl-terpyridine. Que ce soit chez les enzymes ou parmi les catalyseurs chimiques, 
il semble que la majorité des sites actifs de fer contiennent quatre ligands et deux positions vacantes, 
qui permettent l’activation de l’oxydant. Des ligands tétradentes pourraient donc être envisagés, 
incluant des dérivés de quaterpyridine [244], de phénazine [208] ou de bases de Schiff (Schéma 47). 
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V.3.d. Modifications sur le peptide 
Afin d’augmenter l’interaction entre les complexes et les fibres, une autre possibilité consiste à 
réaliser une ou plusieurs mutations sur le peptide. Du fait du manque d’informations structurales, la 
mutagénèse aléatoire semble être la stratégie à privilégier. Bien que cela demanderait un lourd travail 
d’élaboration d’une méthode de criblage sur colonies, afin d’identifier les mutants d’intérêt, cela 
pourrait permettre d’augmenter significativement l’interaction. 
Les protéines/peptides amyloïdes étant nombreux, il serait également envisageable de cribler les 
systèmes catalytiques formés à partir de ces différents amyloïdes.  
  
Schéma 47: Proposition d’une seconde génération de ligands. 
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Conclusion 
Au cours de cette thèse, nous nous sommes intéressés à l’élaboration de catalyseurs bio-
inorganiques hybrides préparés par incorporation de complexes de coordination dans les fibres 
amyloïdes. Cela s’est fait en trois temps : la production de peptide amyloïde par voie recombinante, la 
synthèse de complexes métalliques, et l’étude de leur interaction, l’objectif final étant l’étude des 
propriétés catalytiques du système final.  
Pour cela, la production recombinante des peptides β-amyloïdes 1-40 et 1-42 a été réalisée dans 
Escherichia coli. Les conditions d’expression ont été optimisées, et un nouveau protocole de 
purification a été mis en place, exempté d’étapes chromatographiques. Les échantillons de peptides 
obtenus démontrent des caractéristiques physicochimiques similaires aux peptides β-amyloïdes 
commerciaux. 
Une série de ligands para phényl terpyridine ont été synthétisés, portant différents substituants. 
Les complexes de Cu(II), Fe(II), et Ru(II) ont été synthétisés et caractérisés par différentes techniques 
physicochimiques. 
Les complexes de Fe(II) et de Ru(II) ont été testés pour leur interaction avec les fibres de 
peptide Aβ1-40. Parmi la série synthétisée, trois ligands semblent se détacher, démontrant 
d’intéressantes propriétés d’intercalation. Cela se traduit également par une accélération de la 
cinétique d’agrégation du peptide en présence des complexes correspondants. 
Des études ont été réalisées afin de déterminer le motif de reconnaissance de ces ligands, 
montrant que l’enchainement pyridine-pyridine-phényl était essentiel à l’interaction. La nature de l’ion 
métallique semble quant à lui n’avoir aucune influence. Enfin, pour connaître la nature du site 
d’interaction, une étude a été réalisée avec des fibres de peptides tronqués, montrant une claire 
différence d’incorporation. Toutefois, le manque d’informations structurales ne permet pas de 
conclure quant à la nature précise du site de liaison. 
Pour obtenir plus d’informations sur ce point, des études de docking ont été menées sur des 
structures des fibres Aβ1-40 and Aβ1-42 obtenues par RMN du solide. Les résultats confirment que la Th-
T et les complexes métalliques ne se lient pas sur les mêmes sites de la fibre. L’amarrage de Fe(L1)2 
sur le modèle de fibre de Aβ1-42 propose la liaison du complexe dans les sillons formés par les chaines 
latérales à la surface des fibres, par le biais du groupement phényl et d’une pyridine latérale. 
La dernière étape pour conclure cette étude consistait à tester l’activité catalytique des 
catalyseurs hybrides fibre-complexe. Pour cela, nous avons choisi d’étudier la réaction d’époxydation 
du styrène, décrite avec des complexes de Fe(II) bis terpyridine. Etonnamment, nos complexes n’ont 
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permis de former que le benzaldéhyde. Des résultats préliminaires en présence des fibres ont validé 
que l’activité catalytique des complexes était maintenue après incorporation. 
Ces travaux valident le concept de catalyseurs hybrides préparés à partir de fibres amyloïdes. 
Bien que ces systèmes présentent déjà des avantages, comme leur production rapide et leur 
biocompatibilité, ils devront être améliorés pour être à la hauteur des systèmes existants. Pour cela, 
une optimisation chimio-génétique, combinant des études structurales plus poussées, la mutagénèse du 
peptide avec l’évolution des complexes de coordination, pourra être envisagée. 
Résumé 
Le développement d’alternatives durables aux catalyseurs actuels est un sujet clé de la chimie 
verte. Parmi les différentes approches proposées, l’élaboration de métalloenzymes artificielles 
permet de combiner l’efficacité des enzymes avec la versatilité des catalyseurs chimiques. Dans ce 
contexte, nous nous sommes intéressés à l’élaboration de nouveaux catalyseurs hybrides bio-
inorganiques, préparés par incorporation de complexes métalliques dans les fibres amyloïdes. Ces 
agrégats de protéines démontrent des propriétés mécaniques exceptionnelles en biologie, qui en font 
des candidats de choix pour une application en catalyse. 
Une première partie de ce travail a consisté à surexprimer les peptides β-amyloïdes dans 
Escherichia coli. Une nouvelle méthode de purification des peptides a ensuite été établie permettant 
d’obtenir des échantillons de haute qualité en seulement quelques étapes. Une série de ligands 
organiques a également été synthétisée, ainsi que les complexes de Cu(II), Fe(II) et Ru(II) 
correspondants.  
L’interaction entre ces complexes et les fibres amyloïdes a été évaluée à l’aide de 
différentes techniques (UV-Visible, fluorescence, RMN…) et étudiée par modélisation moléculaire 
pour donner accès à de nouvelles informations concernant les sites potentiels d’interaction.  
Enfin, des études de catalyse ont été menées sur les complexes de Fe(II), démontrant des 
conversions élevées pour la réaction d’oxydation du styrène.  Des résultats préliminaires sur les 
systèmes hybrides montrent que cette activité est maintenue en présence de fibres, validant le concept 
de catalyseurs hybrides préparés à partir de fibres amyloïdes. 
 
 
 
Abstract 
Developing sustainable alternatives to catalytic systems developed to date is a key point of the 
Green Chemistry Principles. Among the different existing approaches, the artificial metalloenzyme 
strategy aims at combining the efficiency of enzymes with the versatility of chemical catalysts. In this 
context, we turned our interest in developing a new type of bioinorganic hybrid catalysts through 
incorporation of coordination complexes in amyloid fibres. These protein aggregates display 
unique mechanical properties that make them good candidates for applications in catalysis. 
In a first part, our work consisted in overexpressing amyloid-β  peptides in Escherichia coli. 
A new purification procedure was set up that allowed to obtain peptides in a few steps. A series of 
organic ligands was synthesized, as well as the corresponding Cu(II), Fe(II) and Ru(II) complexes.  
The interaction between amyloid fibres and metal complexes was assessed, using a set of 
techniques (UV-Visible, Fluorescence, NMR…). Docking studies were also conducted by molecular 
modelling to acquire further insights in the interaction. 
Finally, catalytic experiments were performed with Fe(II) complexes, showing high 
conversion rates for styrene oxidation reaction. Preliminary results on the final hybrid systems show 
that the catalytic activity of metal complexes is maintained upon incorporation within fibres. This 
constitutes a proof of concept for the elaboration of hybrid catalysts based on amyloid fibres. 
